英文論文

2009年以降に当研究室より発表された英文論文をご紹介いたします。

2022年度

  1. Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. ;21(5):103056,2022.
  2. Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O’Callaghan AS, Nikiphorou E, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Cagnotto G, Nune A, Distler O, Chinoy H, Aggarwal V, Aggarwal R; COVAD Study Group. COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatol Int.42(1):pp.23-29,2022
  3. Sasaki T, Akiyama M, Kaneko Y, Takeuchi T. Immunoglobulin G4-related disease and idiopathic multicentric Castleman’s disease: confusable immune-mediated disorders. Rheumatology (Oxford). 2;61(2):pp.490-501,2022.
  4. Akiyama M, Kaneko Y, Takeuchi T. T follicular helper cells mediate local production of allergen-specific IgE and IgG4. J Allergy Clin Immunol. 16:S0091-6749(22) pp. 00662-5,2022.
  5. Kaneko Y. Interluekin-6 inhibitors for the treatment of adult-onset Still’s disease. Mod Rheumatol. 5;32(1): pp.12-15,2022.
  6. Kondo Y, Oyama M, Nakamura Y, Matsubara S, Tanikawa A, Kaneko Y. Dermatomyositis-like rash and inflammatory myopathy after mRNA-1273 vaccination. Rheumatology (Oxford). 6;61(7):pp.e171-e173,2022.
  7. Sobue Y, Kojima T, Ito H, Nishida K, Matsushita I, Kaneko Y, Kishimoto M, Kohno M, Sugihara T, Seto Y, Tanaka E, Nakayama T, Hirata S, Murashima A, Morinobu A, Mori M, Kojima M, Kawahito Y, Harigai M. Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 5;32(1):pp.96-104,2022.
  8. Akiyama M, Kaneko Y, Takeuchi T. Interleukin-4 as an emerging therapeutic target for IgG4-related disease. Ann Rheum Dis.;81(2):e28,2022.
  9. Taylor PC, Alten R, Álvaro Gracia JM, Kaneko Y, Walls C, Quebe A, Jia B, Bello N, Terres JR, Fleischmann R. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 8(1):e001994,2022.
  10. Fazal ZZ, Sen P, Joshi M, Ravichandran N, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Selva-O’Callaghan A, Nune A, Knitza J, Kuwana M, Gutiérrez CT, Caballero-Uribe CV, Dey D, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatol Int.42(12):pp.2151-2158,2022.
  11. Matsumoto K, Suzuki K, Yoshida H, Magi M, Kaneko Y, Takeuchi T. Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis. Autoimmun Rev. 21(10):103160,2022.
  12. Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review. Mod Rheumatol. 5;32(1):pp.231-237,2022.
  13. Uchiyama S, Takanashi S, Takeno M, Gono T, Kaneko Y, Takeuchi T, Kuwana M. Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society? Mod Rheumatol. 28;32(2):pp.323-329,2022.
  14. Kaneko Y, Takeuchi T. Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease. Expert Opin Biol Ther. 22(1):pp.79-85,2022.
  15. Tanemura S, Seki N, Tsujimoto H, Saito S, Kikuchi J, Sugahara K, Yoshimoto K, Suzuki K, Kaneko Y, Chiba K, Takeuchi T. Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells. Int Immunol. 9;34(10):pp.533-544,2022.
  16. Ito H, Murata K, Sobue Y, Kojima T, Nishida K, Matsushita I, Kawahito Y, Kojima M, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Mori M, Morinobu A, Murashima A, Seto Y, Sugihara T, Tanaka E, Nakayama T, Harigai M. Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 28;32(2):pp.296-306,2022.
  17. Tanemura S, Tsujimoto H, Seki N, Kojima S, Miyoshi F, Sugahara K, Yoshimoto K, Suzuki K, Kaneko Y, Chiba K, Takeuchi T. Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells.Int Immunol. 9;34(10):pp.519-532,2022.
  18. Akiyama M, Kaneko Y, Takeuchi T. Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease. Ann Rheum Dis. 81(7):e120,2022.
  19. Akiyama M, Yoshimoto K, Ishigaki S, Suzuki K, Takeuchi T, Kaneko Y. Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiplesignalling pathways in spondyloarthritis. Rheumatology (Oxford). 62(3):pp.1296-1305,2023.
  20. Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimar et al. Ann Rheum Dis. 81(10):e204,2022.
  21. Ono K, Kishimoto M, Deshpande GA, Fukui S, Kawaai S, Sawada H, Matsuura M, Rodriguez VR, Proft F, Tada K, Tamura N, Taniguchi Y, Hirata A, Kameda H, Tsuji S, Kaneko Y, Dobashi H, Okano T, Haji Y, Morita A, Okada M, Komagata Y, Medina CL, Molto A, Dougados M, Hisamatsu T, Tomita T, Kaname S. Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis. Rheumatol Int. 42(10):pp.1751-1766,2022.
  22. Sen P, R N, Nune A, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O’Callaghan AS, Nikiphorou E, Chatterjee T, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology (Oxford). 17:keac305,2022.
  23. Kaneko Y, Ota T, Shibata K. Erratum to “Relationship between chopstick manipulation and cross-sectional shape in the developmental stages from infancy to early school age” [Appl. Ergon. 97 (2021) 103507]. Appl Ergon. 101:103696,2022.
  24. Dey M, Naveen R, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, Kardes S, Day J, Milchert M, Joshi M, Gheita T, Salim B, Velikova T, Edgar Gracia-Ramos A, Parodis I, O’Callaghan AS, Kim M, Chatterjee T, Tan AL, Makol A, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Barman B, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manoj M M, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pande AR, Chandwar K, Pauling JD, Wincup C, Üsküdar Cansu D, Zamora Tehozol EA, Rojas Serrano J, La Torre IG, Del Papa N, Sambataro G, Atzeni F, Govoni M, Parisi S, Bocci EB, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Traboco LS, Hoff LS, Kusumo Wibowo SA, Tomaras S, Langguth D, Limaye V, Needham M, Srivastav N, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Loarce-Martos J, Prieto-González S, Gil-Vila A, Gonzalez RA, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study. Rheumatology (Oxford). 25:keac603,2022.
  25. Takeshita M, Nishina N, Moriyama S, Takahashi Y, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T; Keio Donner Project. Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. Clin Immunol. 238:108999,2022.
  26. Tanaka E, Kawahito Y, Kohno M, Hirata S, Kishimoto M, Kaneko Y, Tamai H, Seto Y, Morinobu A, Sugihara T, Murashima A, Kojima M, Mori M, Ito H, Kojima T, Sobue Y, Nishida K, Matsushita I, Nakayama T, Yamanaka H, Harigai M. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 5;32(1):pp.74-86,2022.
  27. Kawahito Y, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M, Seto Y, Sugihara T, Tanaka E, Ito H, Kojima T, Matsushita I, Nishida K, Mori M, Murashima A, Yamanaka H, Nakayama T, Kojima M, Harigai M. Drug Treatment Algorithm and Recommendations from the 2020 update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis-Secondary Publication. Mod Rheumatol. 16:roac017,2022.
  28. Hanaoka H, Kikuchi J, Hiramoto K, Saito S, Kondo Y, Kaneko Y. Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. Clin Kidney J. 31;15(7):pp.1373-1378,2022.
  29. Kuramoto N, Saito S, Fujii T, Kaneko Y, Saito R, Tanaka M, Takada H, Nakano K, Saito K, Sugimoto N, Sasaki S, Harigai M, Suzuki Y. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case-control study. Mod Rheumatol. 5;32(1):pp.24-31,2022.
  30. Kaneko Y, Sakurai M, Snijder R, Kokubo S, Kato D. A Retrospective, Longitudinal Study of Rheumatoid Arthritis Treatment Patterns with Janus Kinase Inhibitors and Other Disease-Modifying Antirheumatic Drugs in Japan. Mod Rheumatol. 27:roac046,2022.
  31. Kojima M, Hasegawa M, Hirata S, Ito H, Kaneko Y, Kishimoto M, Kohno M, Kojima T, Matsushita I, Mori M, Morinobu A, Murashima A, Nishida K, Seto Y, Sobue Y, Sugihara T, Tanaka E, Nakayama T, Kawahito Y, Harigai M. Patients’ perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines.Mod Rheumatol. 28;32(2):pp.307-312,2022.
  32. Sobue Y, Kojima M, Kojima T, Ito H, Nishida K, Matsushita I, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Murashima A, Morinobu A, Mori M, Nakayama T, Sugihara T, Seto Y, Tanaka E, Hasegawa M, Kawahito Y, Harigai M. Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. Mod Rheumatol. 5;32(1):pp.121-126,2022.
  33. Tanaka Y, Yamaguchi A, Miyamoto T, Tanimura K, Iwai H, Kaneko Y, Takeuchi T, Amano K, Iwamoto N, Kawakami A, Murakami M, Nishimoto N, Atsumi T, Sumida T, Ohmura K, Mimori T, Yamanaka H, Fujio K, Fujino Y, Saito K, Nakano K, Hirata S, Nakayamada S. Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology (Oxford). 8:keac075,2022.
  34. Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Kaneko Y, Takeuchi T. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. Rheumatology (Oxford). 30;61(9):pp.3777-3791,2022.
  35. Ito H, Nishida K, Kojima T, Matsushita I, Kojima M, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Mori M, Morinobu A, Murashima A, Seto Y, Sugihara T, Tanaka E, Nakayama T, Yamanaka H, Kawahito Y, Harigai M.Non-Drug and Surgical Treatment Algorithm and Recommendations for the 2020 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis – Secondary Publication. Mod Rheumatol. 16:roac019,2022.
  36. Tsuboi H, Toko H, Honda F, Abe S, Takahashi H, Yagishita M, Hagiwara S, Ohyama A, Kondo Y, Nakano K, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Fujieda Y, Atsumi T, Suzuki Y, Kawano M, Nishina N, Kaneko Y, Takeuchi T, Kobayashi H, Takei M, Ogasawara M, Tamura N, Takasaki Y, Yokota K, Akiyama Y, Mimura T, Murakami K, Mimori T, Ohshima S, Azuma N, Sano H, Nishiyama S, Matsumoto I, Sumida T. Abatacept Ameliorates Both Glandular and Extraglandular Involvements in Patients With Sjögren’s Syndrome Associated with Rheumatoid Arthritis: Findings from an Open-Label, Multicenter, 1-Year, Prospective Study: the ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren’s Syndrome Endocrinopathy) and ROSE II trials. Mod Rheumatol. 4:roac011,2022.
  37. Sugihara T, Kawahito Y, Morinobu A, Kaneko Y, Seto Y, Kojima T, Ito H, Kohno M, Nakayama T, Sobue Y, Nishida K, Matsushita I, Murashima A, Mori M, Tanaka E, Hirata S, Kishimoto M, Yamanaka H, Kojima M, Harigai M. Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 28;32(2):pp.313-322,2022.
  38. Tamai H, Nishina N, Kikuchi J, Izumi K, Otomo K, Yoshimoto K, Yamaoka K, Takeuchi T, Kaneko Y. Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs. Clin Rheumatol.42(3):pp.721-730,2023
  39. Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, Suzuki Y. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Mod Rheumatol. 5;32(1):pp.41-49,2022.
  40. Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-center, randomized controlled trial. Rheumatology (Oxford). 18:keac101,2022.
  41. Takada H, Kaneko Y, Nakano K, Tanaka M, Fujii T, Saito K, Sugimoto N, Sasaki S, Saito S, Saito R, Kuramoto N, Harigai M, Suzuki Y. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study. Mod Rheumatol. 5;32(1):pp.32-40,2022.
  42. Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S, Kaneko Y, Nakano K, Saito K, Takada H, Sugimoto N, Sasaki S, Harigai M, Suzuki Y. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study. Mod Rheumatol. 5;32(1):pp.50-58,2022.
  43. Imai Y, Kondo Y, Ishigaki S, Nishina N, Ota Y, Hanaoka H, Kaneko Y, Takeuchi T. A case of eosinophilic granulomatosis with polyangiitis after prolonged intervals of an anti-interleukin-6 receptor antibody for rheumatoid arthritis. Mod Rheumatol Case Rep. 7;6(1):pp.83-86,2022.
  44. Tsuboi H, Kaneko Y, Ikeda K, Aranishi T, Cai Z, Ishizuka T. Current status of shared decision making for rheumatoid arthritis treatment in Japan: a web-based survey on physicians and patients. Curr Med Res Opin. 38(5):pp.853-861,2022.
  45. Tanaka H, Asakura T, Kikuchi J, Ishii M, Namkoong H, Kaneko Y, Fukunaga K, Hasegawa N. Development of Rheumatoid Arthritis in Cavitary Mycobacterium avium Pulmonary Disease: A Case Report of Successful Treatment with CTLA4-Ig (Abatacept). Infect Drug Resist. 11;15:pp.91-97,2022.
  46. R N, Parodis I, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Nune A, Shinjo SK, Salim B, Ziade N, Velikova T, Edgar Gracia-Ramos A, Saavedra MA, Day J, Makol A, Distler O, Chinoy H; COVAD Study Group, Agarwal V, Aggarwal R, Gupta L, Nikiphorou E. COVID-19 vaccination in autoimmune diseases (COVAD) Study: vaccine safety and tolerance in rheumatoid arthritis. Rheumatology (Oxford). 31:keac624,2022.
  47. Matsumoto K, Suzuki K, Yasuoka H, Hirahashi J, Yoshida H, Magi M, Noguchi-Sasaki M, Kaneko Y, Takeuchi T. Longitudinal monitoring of circulating immune cell phenotypes in anti-neutrophil cytoplasmic antibody-associated vasculitis. Autoimmun Rev.22(3):103271,2023.
  48. Matsumoto K, Suzuki K, Yoshida H, Magi M, Matsumoto Y, Noguchi-Sasaki M,Yoshimoto K, Takeuchi T, Kaneko Y. Distinct gene signatures of monocytes and Bcells in patients with giant cell arteritis: a longitudinal transcriptomeanalysis. Arthritis Res Ther. 3;25(1):1,2023.
  49. Takeshita M, Fukuyama H, Kamada K, Matsumoto T, Makino-Okamura C, Uchikubo-Kamo T, Tomabechi Y, Hanada K, Moriyama S, Takahashi Y, Ishigaki H, Nakayama M,Nguyen CT, Kitagawa Y, Itoh Y, Imai M, Maemura T, Furusawa Y, Ueki H, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Kawaoka Y, Shirouzu M, Ishii M, Saya H, Kondo Y,Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T. Potent SARS-CoV-2 neutralizingantibodies with therapeutic effects in two animal models. iScience. 25(12):105596,2022.
  50. Murata O, Suzuki K, Takeuchi T. Thymus variants on imaging of patients withprimary Sjögren’s syndrome and polymyositis/dermatomyositis: clinical andimmunological significance. Immunol Med. 46(1):pp.25-31.2023.
  51. Takei H, Nishina N, Namkoong H, Suzuki K, Uwamino Y, Hasegawa N, Takeuchi T. Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: a retrospective, single-centre cohort study. Mod Rheumatol.32(3):pp.534-540. doi: 10.1093/mr/roab032. PMID: 34910202,2022.
  52. Mecoli CA, Yoshida A, Paik JJ, Lin CT, Danoff S, Hanaoka H, Rosen A, Christopher-Stine L, Kuwana M, Casciola-Rosen L. Presence and Implications of Anti-Angiotensin Converting Enzyme-2 Immunoglobulin M Antibodies in Anti-Melanoma-Differentiation-Associated 5 Dermatomyositis. ACR Open Rheumatol. pp. 457-463
  53. Higashida-Konishi M, Akiyama M, Shimada T, Hama S, Oshige T, Izumi k, Oshima H, Okano Y. Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy. Rheumatology International. 43(3) pp.545-549,2023.
  54. Higashida-Konishi M, Izumi K, Shimada T, Hama S, Oshige T, Oshima H, Okano Y. Allergic disorders and their risk factors in primary Sjögren’s syndrome. The World Allergy Organization journal. 16(2) pp.100745-100745,2023.
  55. Hama S, Akiyama M, Higashida-Konishi M, Oshige T, Takei H, Izumi K, Oshima H, Okano Y. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis. Modern Rheumatology Case Reports. 7(1) pp.92-95,2023.
  56. Izumi K, Suzuki K, Hashimoto M, Endoh T, Doi K, Iwai Y, Jinzaki M, Ko S, Takeuchi T, Kaneko Y. Detecting hand joint ankylosis and subluxation in radiographic images using deep learning: A step in the development of an automatic radiographic scoring system for joint destruction. PloS one. 18(2) e0281088,2023.
  57. Higashida-Konishi M, Akiyama M, Shimada T, Hama S, Oshige T, Izumi K, Oshima H, Okano Y. Aseptic meningitis as an initial manifestation of primary Sjögren’s syndrome. Modern Rheumatology Case Reports..7(2) pp.388-393,2022.
  58. Shimada T, Higashida-Konishi M, Izumi K, Hama S, Oshige T, Oshima H, Okano Y. Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study. Scientific Reports .12(1) pp.20926-20926,2022.
  59. Shimada T, Higashida-Konishi M, Akiyama M, Hama S, Izumi K, Matsubara S, et al. Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins. Immunol Med. 45:pp.175-179,2022.
  60. Shimada T, Higashida-Konishi M, Akiyama M, Hama S, Takei H, Izumi K, Oshima H, Okano Y. Dropped head in systemic sclerosis: a case based review. Rheumatol Int. 42:pp.1483-1489,2022.
  61. Higashida-Konishi M, Akiyama M, Shimada T, Hama S, Takei H, Izumi K, Oshima H, Okano Y. Acute encephalitis in primary Sjögren’s syndrome: A case report and literature review. Modern Rheumatology Case Reports. 6(2) pp.209–216,2022.
  62. Hama S, Higashida-Konishi M, Akiyama M, Shimada T, Takei H, Izumi K, Oshima H, Okano Y. Dermatomyositis Which Was Double Positive for Anti-MDA5 and Anti-ARS Antibodies That Was Successfully Treated by Intensive Immunosuppressive Therapy. Intern Med. 61:pp.1085-1091,2022.
  63. Shiga K, Izumi K, Minato K, Yoshimura M, Kitazawa M, Hanashiro S, Cortright K, Kurokawa S, Momota Y, Sado M, Maeno T, Takebayashi T, Mimura T, Kishimoto T. Association of work environment with stress and depression among Japanese workers. Work. 72(4)pp.1321-1335,2022.
  64. Kandane-Rathnayake R , Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, Cho J, Lateef A, Hamijoyo L, Navarra SV, Zamora L, Sockalingam S, An Y, Li Z, Katsumata Y, Harigai M, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Basnayake BMDB, Chan M, Ng KPL, Tugnet N, Kumar S, Oon S, Goldblatt F, O’Neill S, Gibson KA, Ohkubo N, Tanaka Y, Bae SC, Lau CS, Nikpour M, Golder V, Morand EF; Asia-Pacific Lupus Collaboration. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther. 24: 70,2022.
  65. Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Takeuchi T, Kaneko Y. Deep remission within 12 months prevents renal flare and damage accrual in lupus nephritis. Clin Exp Rheumatol. doi: 10.55563/clinexprheumatol/7yv1dz. Epub ahead of print,2023.
  66. Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra S, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake B, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O’Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Yu DY, Karyekar C, Lau CS, Monk JA, Nikpour M, Hoi A, Morand EF, Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study, Lancet Rheumatol. e822-e830,2022.
  67. Connelly K, Kandane-Rathnayake R, Hoi A, Louthrenoo W, Hamijoyo L, Cho J, Lateef A, Luo SF, Wu YJ, Li Z, Navarra S, Zamora L, Sockalingam S, Hao Y, Zhang Z, Katsumata Y, Harigai M, Oon S, Chan M, Chen YH, Bae SC, O’Neill S, Goldblatt F, Kikuchi J, Takeuchi T, Ng KPL, Tugnet N, Basnayake B, Ohkubo N, Tanaka Y, Lau CS, Nikpour M, Golder V, Morand EF. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study. Lancet Rheumatol. e831-841,2022.
  68. Connelly K, Kandane-Rathnayake R, Hoi A, Louthrenoo W, Hamijoyo L, Luo SF, Wu YJ, Cho J, Lateef A, Lau CS, Chen YH, Navarra S, Zamora L, Li Z, An Y, Sockalingam S, Hao Y, Zhang Z, Chan M, Katsumata Y, Harigai M, Oon S, Bae SC, O’Neill S, Gibson KA, Basnayake B, Kikuchi J, Takeuchi T, Ng KPL, Tugnet N, Kumar S, Goldblatt F, Law A, Tee M, Tee C, Tanaka Y, Ohkubo N, Tan JY, Karyekar CS, Nikpour M, Golder V, Morand EF. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment and Long-Term Clinical Outcomes: A Five-Year Prospective Study. Arthritis Rheumatol. 75: pp.401-410,2023.
  69. Morimoto S, Saeki K, Takeshita M, Hirano K, Shirakawa M, Yamada Y, Nakamura S, Ozawa F, Okano H. Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model. Genes Cells. 28(1):pp.29-41,2022.
  70. Mise-Omata S, Ikeda M, Takeshita M, Uwamino Y, Wakui M, Arai T, Yoshifuji A, Murano K, Siomi H, Nakagawara K, Ohyagi M, Ando M, Hasegawa N, Saya H, Murata M, Fukunaga K, Namkoong H, Lu X, Yamasaki S, Yoshimura A. Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant. J Immunol. 209(11):pp.2104-2113,2022.
  71. Saito S, Suzuki K, Yoshimoto K, Kondo Y, Kikuchi J, Hanaoka H, Kaneko Y, Takeuchi T. Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients. Clin Exp Rheumatol..doi:10.55563/clinexprheumatol/k0ctlf,2022.
  72. Ishigaki S, Akiyama M. Clinical Images: Dacryoadenitis in eosinophilic granulomatosis with polyangiitis mimicking immunoglobulin G4-related disease. ACR Open Rheumatol. 4:1030,2022.
  73. Waki D, Tamai H, Yokochi R, Kido T, Yagyu Y, Yanai R, Sada KE. Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study.PLoS One. 22;17(7):e0271921,2022.
  74. Matsumoto K, Suzuki K, Yoshida H, Magi M, Matsumoto Y, Noguchi-Sasaki M, Yoshimoto K, Takeuchi T, Kaneko Y. Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis. Arthritis Res Ther.25(1):1,2023.
  75. Kojima M, Kawahito Y, Sugihara T, Kojima T, Harada R, Hirata S, Hashimoto M, Hidaka T, Ishikawa H, Ito H, Kishimoto M, Kaneko Y, Matsui K, Matsui T, Matsushita I, Morinobu A, Nishida K, Tanaka E, Abe A, Ishitoku M, Asai S, Kida T, Onishi A, Takanashi S, Harigai M. Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design. BMC Rheumatol.;6(1):9,2022.
  76. Takahashi S, Kato A, Hashimoto K, Takehara T, Ishioka K, Takanashi S. A case of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung diseases developed after administration of COVID-19 vaccine and subsequent pneumococcal vaccine. Respirol Case Rep.10(12):e01064,2022.
  77. Takanashi S, Takeuchi T, Kaneko Y. Effects of Aging on Rheumatoid Factor and Anticyclic Citrullinated Peptide Antibody Positivity in Patients With Rheumatoid Arthritis. J Rheumatol.50(3):pp.330-334.,2023.
  78. Takanashi S. Correspondence on ‘Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis’. Ann Rheum Dis. 82(3):e61,2023.
  79. Honda N, Shigehara R, Furuhashi K, Nagai Y, Yokogawa N. Anti-glomerular basement membrane diseases and thrombotic microangiopathy treated with rituximab. Mod Rheumatol Case Rep.7(2):pp.422-425,2022.
  80. Nagayama Y, Edamoto M, Komine Y, Nakai H, Ichikura-Iida A, Inoue T, Ono K, Otani M, Iwasaki S. Streptococcal Infection-related Glomerulonephritis in an Elderly Diabetic Patient Complicated by Hemophagocytic Syndrome and Cytomegalovirus Nephritis.InternMed. 62(2):pp.261-267. doi: 10.2169/internalmedicine.9314-21,2022.
  81. Suzuki K, Akiyama M, Ishigaki S, Kondo Y, Saito S, Kikuchi J, et al. A severe cerebral infarction associated with giant cell arteritis which developed during tocilizumab therapy and was successfully treated with intravenous cyclophosphamide. Mod Rheumatol Case Rep. doi:10.1093/mrcr/rxad009,2023.
  82. Suzuki K, Akiyama M, Kondo Y, Saito S, Kikuchi J, Hanaoka H, et al. Rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis triggered by a 23-valent pneumococcal polysaccharide vaccine. Autoimmun Rev. 22: 103307,2023.
  83. Oshima Y, Wakino S, Kanda T, Tajima T, Itoh T, Uchiyama K, Yoshimoto K, Sasabe J, Yasui M, Itoh H. Sodium benzoate attenuates 2,8-dihydroxyadenine nephropathy by inhibiting monocyte/macrophage TNF-α expression. Sci Rep. 13: 3331,2023.
  84. Nagasaka K, Amano K, Dobashi H, Nagafuchi H, Sada K-E, Komagata Y, Yamamura M, Kato M, Endo T, Nakaya I, Takeuchi T, Murakawa Y, Sugihara T, Saito M, Hayashi T, Furuta S, Tamura N, Karasawa K, Banno S, Endo S, Majima M, Kaname S, Arimura Y, and Harigai M. Nation-wide Cohort Study of Remission Induction Therapy using Rituximab in Japanese patients with ANCA-Associated Vasculitis: effectiveness and safety in the first six months. Mod Rheum. online ,2022.
  85. Sepriano A, Kerschbaumer A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards JC, Verschueren P, de Souza S, Pope J, Takeuchi T, Hyrich KL, Winthrop K, Aletaha D, Stamm T, Schoones JW, and Landewe R. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis. 82:pp.107-118,2023.
  86. Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards JC, Verschueren P, de Souza S, Pope J, Takeuchi T, Hyrich KL, Winthrop K, Schoones JW, Stamm T, Aletaha D, and Landewe R. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis. 82:pp.95-106, 2023.
  87. Bergstra SA, Sepriano A, Kerschbaumer A, van der Heijde D, Caporali R, Edwards JC, Verschueren P, de Souza S, Pope J, Takeuchi T, Hyrich KL, Winthrop K, Aletaha D, Stamm T, Schoones JW, Smolen JS, and Landewe R. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis. 82:pp.81-94,2023.
  88. Smolen JS, Landewe R, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich KL, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J,15 Buch MH, Burmester G,1 Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, Aoufy KE, Finckh A, Fonseca J, Gottenberg J-E, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poor G, Rubbert-Roth A, Rivellese F, Ristic GG, Stoilov N, Schulze-Koops H, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vlieland TV, Westhovens R, and van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2022 update. Ann Rheum Dis. 82:pp.3-18, 2023.
  89. Tanaka Y, Atsumi T, Aletaha D, Bartok B, Prechonkina A, Han L, Emoto K, Kano S, Rajendran A, and Takeuchi T. Benefit of filgotinib, a JAK1 prefernetial inhibitor, in rheumatoid arthritis patients with previous rapid radiographic progression: post hoc analysis of two trials. Rheumatol Ther. 10:pp.161-85, 2023.
  90. Tanaka Y, Kawanishi M, Nakanishi M, Yamasaki M, and Takeuchi T. Efficacy and safety of anti-TNF multivalent compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Mod Rheum online. 2022.
  91. Tanaka Y, Kawanishi M, Nakanishi M, Yamasaki M, and Takeuchi T. Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial). Mod Rheum. online, 2022.
  92. Sugihara T, Uchida HA, Yoshifuji H, Maejima Y, Naniwa T, Katsumata Y, Okazaki T, Ishizaki J, Murakawa Y, Ogawa N, Dobashi H, Horita T, Tanaka Y, Furuta S, Takeuchi T, Komagata Y, Nakaoka Y, Harigai M, and Japan Research Committee of the Ministry of Health, Labour, and Welfate for Intractable Vasculitis (JPVAS). Associations between the patterns of large-vessel lesions and treatment outcomes in patients with large-vessel giant cell arteritis. Mod Rheum .online, 2022.
  93. Tanaka Y, Okuda K, Takeuchi Y, Katayama K, Haji Y, Yamanashi Y, Tribanek M, Guimbal-Schmolck C, and Takeuchi T. Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population. Mod Rheum.online , 2022.
  94. Kastrati K, Kerschbaumer A, Chwala E, Dejaco C, Dougados M, McInnes I, Ravelli A, Sattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, SmolenJ, and Aletaha D. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs. RMD open . 8:e002359, 2022.
  95. Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes I, Nattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, Ravelli A, Betteridge N, Burmester GR, Bijlsma J, Bykerk V, Caporali R, Choy E, Codreanu C, Combe B, Crow MK, de Wit M, Emery P, Fleischmann R, Gabay C, Hetland ML, Hyrich K, Iagnocco A, Isaacs J, Kremer J, Mariette X, Merkel P, Mysler E, Nash P, Nurmohamed MT, Pavelka K, Poor G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, and Smolen S. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis . online, 2022.
  96. Takagi M, Atsumi T, Matsuno H, Tamura N, Fujii T, Okamoto N, Takahashi N, Nakajima A, Tsujimoto N, Nishikawa A, Ishii T, Takeuchi T, and Kuwana M. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Mod Rheum .online, 2022.
  97. Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae S-C, Keystone EC, Nash P, Genovese M, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Gong Q, Tasset C, and Takeuchi T. Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results, Mod Rheum . online, 2022.
  98. Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Genovese M, Bartok B, Pechonkina A, Kondo A, Yin Z, Gong Q, Tasset C, and Takeuchi T. Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3). Mod Rheum . online, 2022.
  99. Tanemura S, Tsujimoto H, Seki N, Kojima S, Miyoshi F, Sugahara K, Yoshimoto K, Suzuki K, Kaneko Y, Chiba K, and Takeuchi T. Role of interferons (IFNs) in differentiation of T peripheral helper cells (Tph) cells. 2: IFNαand IFNλcooperatively contribute to the expansion of Tph cells in systemic lupus erythematosus. Int Immunol . 34:pp.533-44, 2022.
  100. Takeuchi T, Kawanishi M, Nakanishi M, Yamasaki H, and Tanaka Y. Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial). Arthritis and Rheum .74:pp.1176-85, 2022.
  101. Bae S-C, Bang S-Y, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng R-X, Otomo N, Kwon Y-C, Sheng Y, Sugano N, Hwang M Y, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung W T, Huang H, Takahashi D, Lee S-S, Wang M, Karino K, Zheng X, Miyamura T, Kang Y M, Ye D, Nakamura J, Suh C-H, Tang Y, Motomura G, Park Y-B, Ding H, Kuroda T, Choe J-Y, Li C, Niiro H, Park Y, Shen C, Miyamoto T, Ahn G-Y, Fei W, Takeuchi T, Shin J-M, Li K, Kawaguchi Y, Lee Y-K, Wang Y, Amano K, Park D J, yanggwl, Tada Y, Lau YL, Yamaji K, Zhu Z, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y, Tomizuka K, Seki T, Tanaka Y, Kubo T, Hisada R, Yoshioka T, Yamazaki M, Kabata T, Amasaki Y, Ohta Y, Okawa T, Naito Y, Kaneuji A, Yasunaga Y, Ohzono K, Yamamoto K, Ohmura K, Kim T-H, Yang S, Yamamoto T, Kim B-J, Shen N, Ikegawa S, Lee H-S, and Zhang X. Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study. Ann Rheum Dis .81:pp.1273-80, 2022.
  102. Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, Matsumura R, Hayashi N, Abreu G, Tummla R, Morland EF, and Takeuchi T. The Efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis. Mod Rheum . 33:pp.134-44, 2023.
  103. Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, Rokuda M, and van der Heijde D. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Mod Rheum . 33:pp.73-80, 2023.
  104. Ishiguro N, Tanaka Y, Matsubara T, Atsumi T, Amano K, Sugiyama E, Yamaoka K, Winthrop K, Kivitz A, Burmester GR, Gottenberg J-E, Genovese MC, Matzkies F, Guo Y, Jiang D, Bartok B, Pechonkina A, Kondo A, Besuyen R, and Takeuchi T. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. Mod Rheum .33:pp.64-72, 2023.
  105. Suematsu H, Kim K, Yamamoto T, Bang S-Y, Sakamoto Y, Shin J-M, Sugano N, Kim JS, Mukai M, Lee Y-K, Ohmura K, Park DJ, Takahashi D, Ahn G-Y, Karino K, Kwon Y-C, Miyamura T, Kim J, Nakamura J, Motomura G, Kuroda T, Niiro H, Miyamoto T, Takeuchi T, Ikari K, Amano K, Tada Y, Yamaji K, Shimizu M, Atsumi T, Seki T, Tanaka Y, Kubo T, Hisada R, Yoshioka T, Yamazaki M, Kabata T, Kajino T, Ohta Y, Okawa T, Naito Y, Kaneuji A, Yasunaga Y, Ohzono K, Tomizuka K, Koido M, Matsuda K, Okada Y, Suzuki A, Kin B-J, Kochi Y, Lee H-Y, Ikegawa S, Bae S-C, and Terao C. Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. Human Mol Genetics.31:pp.1082-95, 2022.
  106. Winthrop K, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese M, Jiang D, Chen K, Bartok B, Jahreis K, Besuyen R, Burmester G-R, and Gottenberg J-E. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis .81:pp.184-92, 2022.
  107. Taylor P, Takeuchi T, Burmester G, Duretz P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, and Winthrop K. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: Final results from long-term extension study and integrated database. Ann Rheum Dis .81:pp.335-43, 2022.
  108. Takeuchi T, Hashimoto H, and Matsumoto M. The long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan. Mod Rheum .32:pp.746-54, 2022.
  109. Takeuchi T, Nishikawa K, Yamada F, Ohshima S, Inoue M, Yoshioka Y, and Yamanaka H. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics. Mod Rheum . 32:pp.718-27, 2022.
  110. Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, and Rokuda M. A pooled analysis of severe infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Mod Rheum . 32:pp.708-17, 2022.
  111. Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, and Miyake D. Impact of age on the of efficacy and safety offor the treatment of rheumatoid arthritis. Mod Rheum.32:pp.696-707, 2022.
  112. Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Bartok B, Pechonkina A, Kondo A, Yin Z, Guo Y, Tasset C, Sunday JS, and Takeuchi T. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prier exposure to methotrexate: Subpopulation analyses of a global phase 3 study (FINCH 3). Mod Rheum .32:pp.273-83, 2022.
  113. Tanaka Y, Matsubara T, Hashizume K, Amano N, and Takeuchi T. Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: Post-hoc analysis of a randmized, placebo-controlled, phase-4 study. Mod Rheum. 32:pp.500-7, 2022.
  114. Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae S-C, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Guo Y, Tasset C, Sundy JS, and Takeuchi T. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with rheumatoid arthritis who have an adequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH-1). Mod Rheum. 32:pp.263-72, 2022.

2021年度

  1. Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice.Rheumatology (Oxford). 2021 Nov 3;60(11):5247-5256.
  2. Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O’Callaghan AS, Nikiphorou E, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Cagnotto G, Nune A, Distler O, Chinoy H, Aggarwal V, Aggarwal R; COVAD Study Group. COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatol Int. 2022 Jan;42(1):23-29.
  3. Akiyama M, Takanashi S, Takeuchi T, Kaneko Y. Salivary gland involvement in ANCA-associated vasculitis.Autoimmun Rev. 2021 Nov;20(11):102940.
  4. Kaneko Y, Takeuchi T. An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine. 2021 Oct;146:155645.
  5. Takanashi S, Kaneko Y, Takeuchi T. Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Nov;80(11):1491-1493.
  6. Sun X, Li R, Cai Y, Al-Herz A, Lahiri M, Choudhury MR, Hidayat R, Suryana BPP, Kaneko Y, Fujio K, Van Hung N, Pandya S, Pang LK, Katchamart W, Sigdel KR, Paudyal B, Narongroeknawin P, Chevaisrakul P, Sun F, Lu Y, Ho C, Yeap SS, Li Z; APLAR RA SIG group. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg Health West Pac. 2021 Aug 12;15:100240.
  7. Kondo Y, Suzuki K, Inoue Y, Sakata K, Takahashi C, Kaneko Y, Takeuchi T. Safety and tolerability of ultrasound-guided synovial needle biopsy in Japanese arthritispatients. ModRheumatol. 2021Sep;31(5):960-965.
  8. Akiyama M, Kaneko Y. Comment on: Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease. Rheumatology (Oxford). 2021 Nov 3;60(11):e412-e413.
  9. Ota Y, Kaneko Y, Takeuchi T. Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases.ClinExpRheumatol. 2021NovDec;39(6):1324-1330.
  10. Hanaoka H, Ishigaki S, Takei H, Hiramoto K, Saito S, Kondo Y, Kikuchi J, Kaneko Y, Takeuchi T. Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension. Int J Rheum Dis. 2021 Nov;24(11):1419-1426.
  11. Kaneko Y. Interluekin-6 inhibitors for the treatment of adult-onset Still’s disease. Mod Rheumatol. 2022 Jan 5;32(1):12-15.
  12. Takahashi R, Yoshida T, Morimoto K, Kondo Y, Kikuchi J, Saito S, Ishigaki S, Kaneko Y, Takeuchi T, Itoh H, Oya M. Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports. Clin Med Insights Case Rep. 2021 Jul 27;14:11795476211036322.
  13. Inamo J, Kaneko Y, Kikuchi J, Takeuchi T. High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis. Clin Rheumatol. 2021 Sep;40(9):3615-3626.
  14. Furumai H, Nakazato Y, Machida H, Kato H, Nagai T, Sasaki H, Takada-Owada A, Kaneko Y, Ishida K. Cytological features and immunohistochemical findings related to lymphomatous effusion in an angioimmunoblastic T-cell lymphoma patient: Case report.Diagn Cytopathol. 2021 Aug;49(8):964-967.
  15. Akiyama M, Kaneko Y, Takeuchi T. Interleukin-4 as an emerging therapeutic target for IgG4-related disease. Ann Rheum Dis. 2022 Feb;81(2):e28.
  16. Kishimoto M, Ono K, Fukui S, Kawaai S, Deshpande GA, Yoshida K, Ichikawa N, Kaneko Y, Kawasaki T, Matsui K, Morita M, Tada K, Takizawa N, Tamura N, Taniguchi A, Taniguchi Y, Tsuji S, Okada M, Kobayashi S, Komagata Y, López-Medina C, Molto A, van der Heijde D, Dougados M, Tomita T, Kaname S. Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open. 2021 Sep;7(3):e001752.
  17. Shirai Y, Fukue R, Kaneko Y, Kuwana M. Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Diagnostics (Basel). 2021 Oct 28;11(11):2007.
  18. Nakazato Y, Machida H, Horii Y, Onozaki M, Ohikata K, Kaneko Y, Arai R, Niho S, Ishida K. Next-generation sequencing analyses using biopsy forceps and cytology brush rinse fluids for lung cancer genotyping: Report of five cases. Diagn Cytopathol. 2021 Oct;49(10):1148-1149..
  19. Sasaki T, Akiyama M, Kaneko Y, Takeuchi T. Immunoglobulin G4-related disease and idiopathic multicentric Castleman’s disease: confusable immune-mediated disorders.Rheumatology(Oxford). 2022Feb2;61(2):490-501.
  20. Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review.ModRheumatol. 2022Jan5;32(1):231-237.
  21. Kaneko Y, Takeuchi T. Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease. Expert Opin Biol Ther. 2022 Jan;22(1):79-85.
  22. Uchiyama S, Takanashi S, Takeno M, Gono T, Kaneko Y, Takeuchi T, Kuwana M. Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society?Mod Rheumatol. 2022 Feb 28;32(2):323-329.
  23. Ito H, Murata K, Sobue Y, Kojima T, Nishida K, Matsushita I, Kawahito Y, Kojima M, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Mori M, Morinobu A, Murashima A, Seto Y, Sugihara T, Tanaka E, Nakayama T, Harigai M. Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2022 Feb 28;32(2):296-306.
  24. Hanaoka H, Kikuchi J, Hiramoto K, Saito S, Kondo Y, Kaneko Y. Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. Clin Kidney J. 2022 Jan 31;15(7):1373-1378..
  25. Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Kaneko Y, Takeuchi T. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.Rheumatology (Oxford). 2022 Jan 7:keac002.
  26. Tanaka Y, Yamaguchi A, Miyamoto T, Tanimura K, Iwai H, Kaneko Y, Takeuchi T, Amano K, Iwamoto N, Kawakami A, Murakami M, Nishimoto N, Atsumi T, Sumida T, Ohmura K, Mimori T, Yamanaka H, Fujio K, Fujino Y, Saito K, Nakano K, Hirata S, Nakayamada S. Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology (Oxford). 2022 Feb 8:keac075.
  27. Kaneko Y, Ota T, Shibata K. Erratum to “Relationship between chopstick manipulation and cross-sectional shape in the developmental stages from infancy to early school age” [Appl. Ergon. 97 (2021) 103507]. Appl Ergon. 2022 May;101:103696.
  28. Kawahito Y, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M, Seto Y, Sugihara T, Tanaka E, Ito H, Kojima T, Matsushita I, Nishida K, Mori M, Murashima A, Yamanaka H, Nakayama T, Kojima M, Harigai M. Drug Treatment Algorithm and Recommendations from the 2020 update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis-Secondary Publication. Mod Rheumatol. 2022 Mar 16:roac017.
  29. Kojima M, Hasegawa M, Hirata S, Ito H, Kaneko Y, Kishimoto M, Kohno M, Kojima T, Matsushita I, Mori M, Morinobu A, Murashima A, Nishida K, Seto Y, Sobue Y, Sugihara T, Tanaka E, Nakayama T, Kawahito Y, Harigai M. Patients’ perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. Mod Rheumatol. 2022 Feb 28;32(2):307-312.
  30. Tanaka E, Kawahito Y, Kohno M, Hirata S, Kishimoto M, Kaneko Y, Tamai H, Seto Y, Morinobu A, Sugihara T, Murashima A, Kojima M, Mori M, Ito H, Kojima T, Sobue Y, Nishida K, Matsushita I, Nakayama T, Yamanaka H, Harigai M. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2022 Jan 5;32(1):74-86.
  31. Sobue Y, Kojima T, Ito H, Nishida K, Matsushita I, Kaneko Y, Kishimoto M, Kohno M, Sugihara T, Seto Y, Tanaka E, Nakayama T, Hirata S, Murashima A, Morinobu A, Mori M, Kojima M, Kawahito Y, Harigai M. Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2022 Jan 5;32(1):96-104.
  32. Sobue Y, Kojima M, Kojima T, Ito H, Nishida K, Matsushita I, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Murashima A, Morinobu A, Mori M, Nakayama T, Sugihara T, Seto Y, Tanaka E, Hasegawa M, Kawahito Y, Harigai M. Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. Mod Rheumatol. 2022 Jan 5;32(1):121-126.
  33. Kuramoto N, Saito S, Fujii T, Kaneko Y, Saito R, Tanaka M, Takada H, Nakano K, Saito K, Sugimoto N, Sasaki S, Harigai M, Suzuki Y. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case-control study. Mod Rheumatol. 2022 Jan 5;32(1):24-31.
  34. Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S, Kaneko Y, Nakano K, Saito K, Takada H, Sugimoto N, Sasaki S, Harigai M, Suzuki Y. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study.Mod Rheumatol. 2022 Jan 5;32(1):50-58.
  35. Taylor PC, Alten R, Álvaro Gracia JM, Kaneko Y, Walls C, Quebe A, Jia B, Bello N, Terres JR, Fleischmann R. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 2022 Mar;8(1):e001994..
  36. Tanemura S, Seki N, Tsujimoto H, Saito S, Kikuchi J, Sugahara K, Yoshimoto K, Suzuki K, Kaneko Y, Chiba K, Takeuchi T. Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells 2. IFN-α and IFN-λ1 cooperatively contribute to the expansion of Tph cells in systemic lupus erythematosus. Int Immunol. 2022 Jul 3:dxac032.
  37. Tsuboi H, Toko H, Honda F, Abe S, Takahashi H, Yagishita M, Hagiwara S, Ohyama A, Kondo Y, Nakano K, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Fujieda Y, Atsumi T, Suzuki Y, Kawano M, Nishina N, Kaneko Y, Takeuchi T, Kobayashi H, Takei M, Ogasawara M, Tamura N, Takasaki Y, Yokota K, Akiyama Y, Mimura T, Murakami K, Mimori T, Ohshima S, Azuma N, Sano H, Nishiyama S, Matsumoto I, Sumida T. Abatacept Ameliorates Both Glandular and Extraglandular Involvements in Patients With Sjögren’s Syndrome Associated with Rheumatoid Arthritis: Findings from an Open-Label, Multicenter, 1-Year, Prospective Study: the ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren’s Syndrome Endocrinopathy) and ROSE II trials. Mod Rheumatol. 2022 Feb 4:roac011.
  38. Takada H, Kaneko Y, Nakano K, Tanaka M, Fujii T, Saito K, Sugimoto N, Sasaki S, Saito S, Saito R, Kuramoto N, Harigai M, Suzuki Y. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study. Mod Rheumatol. 2022 Jan 5;32(1):32-40.
  39. Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, Suzuki Y. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Mod Rheumatol. 2022 Jan 5;32(1):41-49.
  40. Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-center, randomized controlled trial. Rheumatology (Oxford). 2022 Feb 18:keac101.
  41. Sugihara T, Kawahito Y, Morinobu A, Kaneko Y, Seto Y, Kojima T, Ito H, Kohno M, Nakayama T, Sobue Y, Nishida K, Matsushita I, Murashima A, Mori M, Tanaka E, Hirata S, Kishimoto M, Yamanaka H, Kojima M, Harigai M.Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2022 Feb 28;32(2):313-322.
  42. Ito H, Nishida K, Kojima T, Matsushita I, Kojima M, Hirata S, Kaneko Y, Kishimoto M, Kohno M, Mori M, Morinobu A, Murashima A, Seto Y, Sugihara T, Tanaka E, Nakayama T, Yamanaka H, Kawahito Y, Harigai M. Non-Drug and Surgical Treatment Algorithm and Recommendations for the 2020 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis – Secondary Publication. Mod Rheumatol. 2022 Mar 16:roac019.
  43. Tanemura S, Tsujimoto H, Seki N, Kojima S, Miyoshi F, Sugahara K, Yoshimoto K, Suzuki K, Kaneko Y, Chiba K, Takeuchi T. Role of interferons (IFNs) in differentiation of T peripheral helper (Tph) cells. 1: Type I IFNs promote differentiation of interleukin-21-producing Tph-like cells. Int Immunol. 2022 Jun 20:dxac026.
  44. Tanaka H, Asakura T, Kikuchi J, Ishii M, Namkoong H, Kaneko Y, Fukunaga K, Hasegawa N. Development of Rheumatoid Arthritis in Cavitary Mycobacterium avium Pulmonary Disease: A Case Report of Successful Treatment with CTLA4-Ig (Abatacept). Infect Drug Resist. 2022 Jan 11;15:91-97..
  45. Imai Y, Kondo Y, Ishigaki S, Nishina N, Ota Y, Hanaoka H, Kaneko Y, Takeuchi T. A case of eosinophilic granulomatosis with polyangiitis after prolonged intervals of an anti-interleukin-6 receptor antibody for rheumatoid arthritis. Mod Rheumatol Case Rep. 2022 Jan 7;6(1):83-86.
  46. Akiyama M, Suzuki K, Yoshimoto K, Yasuoka H, Kaneko Y, Takeuchi T. Peripheral TIGIT+ T Follicular Helper Cells That Produce High Levels of Interleukin-21via OX40 Represent Disease Activity in IgG4-Related Disease. Front Immunol. 2021 Apr 14;12:651357.
  47. Matsumoto K, Kurasawa T, Yoshimoto K, Suzuki K, Takeuchi T. Identification of neutrophil β2-integrin LFA-1 as a potential mechanistic biomarker in ANCA-associated vasculitis via microarray and validation analyses. Arthritis Res Ther. 2021 May6;23(1):136.
  48. Takeshita M, Suzuki K, Nakazawa M, Kamata H, Ishii M, Oyamada Y, Oshima H, Takeuchi T. Antigen-driven autoantibody production in lungs of autoimmune disease. J Autoimmunity .2021; 121,102661.
  49. Murata O, Suzuki K, Takeuchi T, Kudo A. Incidence and baseline characteristics of relapse or exacerbation in patients with pulmonary sarcoidosis in Japan. Sarcoidosis Vasculitis and Diffuse Lung Disease Journal. 2021;38(3):e2021026.
  50. Matsumoto K, Suzuki K, Yoshimoto K, Ishigaki S, Yoshida H, Magi M, Matsumoto Y, Kaneko Y, Takeuchi T. Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis Clinical & Translational Immunology. 2021 Jul 2;10(7):e1307.
  51. Inamo J, Suzuki K, Takeshita M, Kondo Y, Okuzono Y, Koga K, Kassai Y, Takiguchi M, Kurisu R, Yoshimura A, Takeuchi T. Molecular remission at T cell level in patients with rheumatoid arthritis. Sci Rep. 2021 Aug 17;11(1):16691.
  52. Murata O, Suzuki K, Takeuchi T, Maemondo M. The Risk Factors of Exacerbation in Interstitial Pneumonia With Autoimmune Features: A Single-Center Observational Cohort Study. Rheumatol Ther. 2021 Dec;8(4):1693-1710.
  53. Akiyama M, Kaneko Y, Saito S, Matsumoto K, Kondo Y, Hanaoka H, Otomo K, Oyama M, Matsubara S, Takeuchi T. A case of dropped head syndrome due to focal myositis that worsened with cellulitis and improved only by treatment of cellulitis. Mod Rheumatol Case Rep. 2021; 5:431-436.
  54. Hanaoka H, Kikuchi J, Kaneko Y, Seki N, Tsujimoto H, Chiba K, Takeuchi T. Proton Pump Inhibitor and Tacrolimus Uses are Associated with Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection. Front Pharmacol. 2021; 20:12:616719.
  55. Shiga K, Izumi K, Minato K, Sugio T, Yoshimura M, Kitazawa M, Hanashiro S, Cortright K, Kurokawa S, Momota Y, Sado M, Maeno T, Takebayashi T, Mimura M, Kishimoto T. Subjective well-being and month-long LF/HF ratio among deskworkers. PLoS One. 2021 Sep 7;16(9):e0257062.
  56. Hama S, Akiyama M, Shimada T, Higashida-Konishi M, Takei H, Izumi K, Oshima H, Okano Y. COVID-19 pneumonia can cause irreversible lung damage in dermatomyositis with pre-existing interstitial lung disease. Int J Rheum Dis. 2021 Sep;24(9):1221-1223.
  57. Izumi K, Minato K, Shiga K, Sugio T, Hanashiro S, Cortright K, Kudo S, Fujita T, Sado M, Maeno T, Takebayashi T, Mimura M, Kishimoto T. Unobtrusive Sensing Technology for Quantifying Stress and Well-Being Using Pulse, Speech, Body Motion, and Electrodermal Data in a Workplace Setting: Study Concept and Design. Front Psychiatry. 2021 Apr 28;12:611243.
  58. Izumi K, Murata O, Higashida-Konishi M, Kaneko Y, Oshima H, Takeuchi T. Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study. J Clin Med. 2021 Jun 30;10(13):2948.
  59. Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, Cho J, Lateef A, Hamijoyo L, Navarra SV, Zamora L, Sockalingam S, An Y, Li Z, Katsumata Y, Harigai M, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Basnayake BMDB, Chan M, Ng KPL, Tugnet N, Kumar S, Oon S, Goldblatt F, O’Neill S, Gibson KA, Ohkubo N, Tanaka Y, Bae SC, Lau CS, Nikpour M, Golder V, Morand EF; Asia-Pacific Lupus Collaboration. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther. 2022.24: 70.
  60. Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu YJ, Chen YH, Golder V, Lateef A, Cho J, Navarra SV, Zamora L, Hamijoyo L, Sockalingam S, An Y, Li Z, Montes R, Oon S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Chan M, Kikuchi J, Takeuchi T, Goldblatt F, O’Neill S, Bae SC, Lau CS, Hoi A, Karyekar CS, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration. Patterns of Medication Use in Systemic Lupus Erythematosus – A Multi-Centre Cohort Study. Arthritis Care Res (Hoboken). 2021 7. 1.
  61. Kandane-Rathnayake R, Louthrenoo W, Golder V, Luo SF, Wu YJ, Lateef A, Cho J, Li Z, An Y, Hamijoyo L, Navarra S, Zamora L, Katsumata Y, Harigai M, Sockalingam S, Chan M, Chen YH, O’Neill S, Goldblatt F, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Lau CS, Nikpour M, Morand E, Hoi A; Asia Pacific Lupus Collaboration. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. Rheumatology (Oxford). 2021.60: pp.5185-5193.
  62. Sakata K, Kikuchi J, Emoto K, Kotaki T, Ota Y, Nishina N, Hanaoka H, Otomo K, Suzuki K, Kaneko Y, Takeuchi T. Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review. Intern Med. 2021. 60: pp.2135-2143.
  63. Takanashi S, Kikuchi J, Sasaki T, Akiyama M, Yasuoka H, Yoshimoto K, Seki N, Sugahara K, Chiba K, Kaneko Y, Takeuchi T. Lymphadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker. Rheumatology (Oxford). 2021. 60: pp.967-975.
  64. Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, Kirino Y, Sugiyama Y, Tanino Y, Nunokawa T, Kaneko Y, Sato S, Asakawa K, Ukichi T, Kaieda S, Naniwa T, Okano Y, Kuwana M; the Multicenter Retrospective Cohort of Japanese Patients with Myositis-Associated ILD (JAMI) Investigators. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021.73: pp.677-686.
  65. Murata O, Suzuki K, Sugiura H, Kondo Y, Takeshita M, Koga K, Takiguchi M, Kurisu R, Kassai Y, Yasuoka H, Yamaoka K, Morita R, Yoshimura A, Takeuchi T. Thymus variants on imaging in patients with rheumatoid arthritis-clinical and immunological significance. Rheumatology (Oxford). 2021; 60(12):5595-5600.
  66. Kondo Y, Kaneko Y, Takei H, Tamai H, Kabata H, Suhara T, Yamamoto R, Nagata H, Ishii M, Sasaki J, Hasegawa N, Fukunaga K, Takeuchi T; Keio Donner Project. COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still’s disease. Clin Exp Rheumatol. 2021May-Jun;39(3):631-638.
  67. Fukushima T, Kabata H, Yamamoto R, Suhara T, Uwamino Y, Kondo Y, Masaki K, Kamata H, Nagata H, Homma K, Kaneko Y, Ishii M, Sasaki J, Morisaki H, Hasegawa N, Fukunaga K; Keio Donner Project Team. The real-time reverse transcription-polymerase chain reaction threshold cycle values for severe acute respiratory syndrome coronavirus 2 predict the prognosis of coronavirus disease 2019 pneumonia. Respir Investig. 2021; 59(3):360-363.
  68. Kondo Y, Kaneko Y, Oshige T, Fukui H, Saito S, Okayama M, Kamata H, Ishii M, Hasegawa N, Fukunaga K, Takeuchi T. Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus. Ann Rheum Dis. 2021 May; 80(5):e77
  69. Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review. Autoimmun Rev. 2021;20:102737.
  70. Takanashi S, Akiyama M, Nishina N, Kaneko Y, Takeuchi T. Characteristics and prognosis of IgG4-related skin disease: A case report and systematic literature review. Autoimmun Rev. 2021;20:102805.
  71. Akiyama M, Ohtsuki S, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Innate and Adaptive Immunity in Giant Cell Arteritis. Front Immunol. 2021;11:621098.
  72. Akiyama M, Kaneko Y. Recent advances in understanding the role of TIGIT+ follicular helper T cells in IgG4-related disease. Immuno. 2021;1:380-390.
  73. Higashida-Konishi M, Akiyama M (Corresponding), Hama S, Shimada T, Takei H, Izumi K, Oshima H, Okano Y. Acute encephalitis in primary Sjögren’s syndrome: a case report and literature review. Mod Rheumatol Case Rep. 2021;6:209-216.
  74. Takanashi S. Comment: Association Between the Prothrombin Time-International Normalized Ratio and Concomitant Use of Antibiotics in Warfarin Users: Focus on Type of Antibiotic and Susceptibility of Bacteroides fragilis to Antibiotics. Ann Pharmacother. 2022 Jan;56(1):108-109
  75. Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, Rokuda M, and van der Heijde D. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Mod Rheum (IF=2.862), online 2022.3.10
  76. Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, Matsumura R, Hayashi N, Abreu G, Tummla R, Morland EF, and Takeuchi T. The Efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis. Mod Rheum (IF=2.862), online 2022.4.
  77. Takeshita M, Nishina N, Moriyama S, Takahashi Y, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, and Takeuchi T for the Keio Donner project. Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. Clin Immunol (IF=10.190), 238:108999, 2022.
  78. Suematsu H, Kim K, Yamamoto T, Bang S-Y, Sakamoto Y, Shin J-M, Sugano N, Kim JS, Mukai M, Lee Y-K, Ohmura K, Park DJ, Takahashi D, Ahn G-Y, Karino K, Kwon Y-C, Miyamura T, Kim J, Nakamura J, Motomura G, Kuroda T, Niiro H, Miyamoto T, Takeuchi T, Ikari K, Amano K, Tada Y, Yamaji K, Shimizu M, Atsumi T, Seki T, Tanaka Y, Kubo T, Hisada R, Yoshioka T, Yamazaki M, Kabata T, Kajino T, Ohta Y, Okawa T, Naito Y, Kaneuji A, Yasunaga Y, Ohzono K, Tomizuka K, Koido M, Matsuda K, Okada Y, Suzuki A, Kin B-J, Kochi Y, Lee H-Y, Ikegawa S, Bae S-C, and Terao C. Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. Human Mol Genetics (IF=5.121), 31:1082-95, 2022.
  79. Winthrop K, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese M, Jiang D, Chen K, Bartok B, Jahreis K, Besuyen R, Burmester G-R, and Gottenberg J-E. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis (IF=27.973), 81:184-92, 2022.
  80. Taylor P, Takeuchi T, Burmester G, Duretz P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, and Winthrop K. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: Final results from long-term extension study and integrated database. Ann Rheum Dis (IF=27.973), 81:335-43, 2022.
  81. Takeuchi T, Hashimoto H, and Matsumoto M. The long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan. Mod Rheum (IF=2.862), 32:746-54, 2022.
  82. Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Bartok B, Pechonkina A, Kondo A, Yin Z, Guo Y, Tasset C, Sunday JS, and Takeuchi T. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prier exporsure to methotrexate: Subpopulation analyses of a global phase 3 study (FINCH 3). Mod Rheum (IF=2.862), 32:273-83, 2022.
  83. Takeuchi T, Nishikawa K, Yamada F, Ohshima S, Inoue M, Yoshioka Y, and Yamanaka H. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics. Mod Rheum (IF=2.862), 32:718-27, 2022.
  84. Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, and Rokuda M. A pooled analysis of severe infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Mod Rheum (IF=2.862), 32:708-17, 2022.
  85. Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, and Miyake D. Impact of age on the of efficacy and safety of the treatment of rheumatoid arthritis. Mod Rheum (IF=2.862), 32:696-707, 2022.
  86. Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae S-C, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Guo Y, Tasset C, Sundy JS, and Takeuchi T. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with rheumatoid arthritis who have an adequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH-1). Mod Rheum (IF=2.862), 32:263-72, 2022.
  87. Tanaka Y, Matsubara T, Hashizume K, Amano N, and Takeuchi T. Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: Post-hoc analysis of a randmized, placebo-controlled, phase-4 study. Mod Rheum (IF=2.862), 32:500-7, 2022.
  88. Takei H, Nishina N, Namkoong H, Suzuki K, Uwamino Y, Hasegawa N, and Takeuchi T. Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: A retrospective, single center-cohort study. Mod Rheum (IF=2.862), 32:434-40, 2022.
  89. Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, and Takeuchi T. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respiratory Medicine (IF=4.582),187:106574, 2021.
  90. Fujii T, Atsumi T, Okamoto N, Takahashi N, Tamura N, Nakajima A, Nakajima A, Matsuno H, Mukai I, Ishida A, Aizawa K, Kuwana M, Takagi M, and Takeuchi T. Post-marketing surveillance of meporizumab use in patients with eosinophilic granulomatosis with polyangiitis in Japan. Therapeutic Research (IF=0.41), 42:403-422, 2021.
  91. Tanaka Y, Takeuchi T, Izutsu H, Kaneko Y, Kato D, Fukuda M, Rokuda M, and Scultz NM. Patient- and physician-reported outcomes from two Phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. Arthritis Research and Therapy (IF=5.606), 23:221, 2021.
  92. Takeuchi T, Fleischmann R, Iikuni N, Shi H, Soma K, Paulissen J, Hirose T, and Smolen S. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc acalysis of data from ORAL-Strategy. Arthritis Research and Therapy (IF=5.606), 23:220, 2021.
  93. Tanaka Y, Takeuchi T, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heidje D. Effects of denosumab in Japanese patients with rheumatoid arthritis treated with conventional anti-rheumatic drugs:36-month extension of a phase III study. J Rheumatology (IF=5.346), 48:1163-71, 2021.
  94. Takeuchi T, Yoshida H, and Tanaka S. Role of Interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. Autoimmunity Reviews (IF=17.390), 20:102884, 2021.
  95. Kaneko Y and Takeuchi T. Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease. Exp Opin on Biol Ther (IF=5.589), 22:79-85, 2022.
  96. Genovese M, Durez P, Fleishmann R, Tanaka Y, Furst D, Yamanaka H, Korneva E, Vasyutin I, and Takeuchi T. Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. Eur J Rheum (IF=0.450), 8:120-9, 2021.
  97. Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Genovese MC, Kalunian K, Walker D, Gottenberg J-C, de Vlam K, Bartok B, Pechonkina A, Kondo A, Gao J, Guo Y, Tasset C, Sunday JS, and Tanaka Y. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: subgroup analyses of a global phase 3 study (FINCH 2). Mod Rheum (IF=2.862), 32:59-67, 2022.
  98. Honda H, Sakai R, Inoue E, Majima M, Konda N, Takada H, Kihara M, Yajima N, Nanki T, Yamamoto K, Takeuchi T, and Harigai M. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study. Mod Rheum (IF=2.862), 32:16-23, 2022.
  99. Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, and Takeuchi T. The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan. Drug Safety (IF=5.228), 44:711-22, 2021.
  100. Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Hisaki H, Hojo S, Kawano T, and Imai T. A phase 2 study of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying anti-rheumatic drugs. Mod Rheum (IF=2.862), 31:783-9, 2021.
  101. Takeshita M, Nishina N, Moriyama S, Takahashi Y, Uwamino Y, Nagata M, Aoki W, Masaki K, Ishii M, Saya H, Kondo Y, Suzuki K, Fukunaga K, Takeuchi T, and Keio Donner Project. Incomplete humoral response including neutralizing antibodies in asymptomatic and mild COVID-19 patients in Japan. Virology (IF=3.513), 555:35-43, 2021.
  102. Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y-W, Chen Y-H, Rokuda M, Izutsu H, Ushijima S, and Kaneko Y. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Rheumatology and Therapy (IF=4.081), 8:425-442, 2021.
  103. Yin X, Kim K, Suetsugu H, Bang S-Y, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng R-X, Otomo N, Laurynenka V, Kwon Y-C, Sheng Y, Sugano N, Hwang M Y, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung W T, Huang H, Takahashi D, Lee S-S, Wang M, Karino K, Shim S-C, Zheng X, Miyamura T, Kang Y M, Ye D, Nakamura J, Suh C-H, Tang Y, Motomura G, Park Y-B, Ding H, Kuroda T, Choe J-Y, Li C, Niiro H, Park Y, Shen C, Miyamoto T, Ahn G-Y, Fei W, Takeuchi T, Shin J-M, Li K, Kawaguchi Y, Lee Y-K, Wang Y, Amano K, Park D J, Yang W, Tada Y, Yamaji K, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y, Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head, Kottyan L C, Weirauch MT, Parameswaran S, Eswar S, Salim H, Chen X, Yamamoto K, Harley J B, Ohmura K, Kim T-H, Yang S, Yamamoto T, Kim B-J, Shen N, Ikegawa S, Lee H-S, Zhang X, Terao C, Cui Y, and Bae S-C. Meta-analysis of 208370 east Asian identifies 113 susceptibility loci for systemic lupus erythematosus. Ann Rheum Dis (IF=27.973), 80:632-40, 2021.
  104. Akiyama M, Kaneko Y, Sasaki T, and Takeuchi T. Comment on: HHV-8-negative multicentric Castleman disease with serological, histopathological and imaging features of igG4-related disease. Rheumatology (Oxford) (IF=7.046), 60: e76-77, 2021.
  105. Kajio N, Takeshita M, Suzuki K, Kaneda Y, Yamane H, Ikeura K, Sato H, Shimizu H, Tsunoda K, and Takeuchi T. Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling. Ann Rheum Dis (IF=27.973), 80:651-9, 2021.
  106. Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M, and Kato D. A pooled safety analysis of peficitinib (ASP015K) Asian patients with rheumatoid arthritis treated over a median of 2 years. Mod Rheum (IF=2.862), 31:543-55, 2021.
  107. Takeuchi T, Rischmeuller M, Blanco R, Xavier RM, Ueki Y, Atsumi T, Chen S, Friedman A, Pangan AL, Strand V, and van Vollenhoven RF. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: A sub-analysis of the Phase 3 SELECT-EARLY study. Mod Rheum (IF=2.862), 31:534-42, 2021.
  108. Nakazawa M, Suzuki K, Takechita M, Inamo J, Kamata H, Ishii M, Oyamada Y, Oshima H, and Takeuchi T. Distinct expression of coinhibitory molecules on alveolar T cells in patients with rheumatoid arthritis- and idiopathic inflammatory myopathies-associated interstitial lung disease. Arthritis & Rheumatology (IF=15.483), 73:576-86, 2021.
  109. Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, and Imai T. Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis with Inadequate Response to Methotrexate. Arthritis & Rheumatology (IF=15.483), 73:587-95, 2021.
  110. Inamo J, Kochi Y, and Takeuchi T. Is type 2 diabetes mellitus an inverse risk factor for the development of rheumatoid arthritis? J Human Genetics (IF=3.773), 66:219-223, 2021.
  111. Takeuchi T, Miyasaka N, Pedersen RD, Sugiyama N, and Hirose T. Radiographic and clinical effects of 10mg and 25mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis. Mod Rheum (IF=2.862), 31:319-25, 2021.
  112. Akiyama M, Kaneko Y, and Takeuchi T. Eosiophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: A potential mimicker of IgG4-reltaed disease. Ann Rheum Dis (IF=27.973), 81:e120, 2022.
  113. Matsumoto K, Yasuoka H, Yoshimoto K, Suzuki K, and Takeuchi T. Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis. Scientific Reports (IF=4.996), 11:222, 2021.
  114. Akiyama M, Kaneko Y, and Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systemic literature review. Autoimmunity Reviews (IF=17.390), 20:102737, 2021.
  115. Baer AN, Gottenberg J-E, St Claire EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, and Bootsma H. Efficacy and safety of abatacept in active primary Sjogren’s syndrome: results of a phase III, randomized, placebo-controlled trial. Ann Rheum Dis (IF=27.973), 80:339-48, 2021.
  116. Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleishmann R, Geissler K, McInnes IB, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos Z, Boehncke W-H, Emery P, Issacs JD, Kremer J, Lee EB, Maksymowych WP, Sholte-Voshaar M, Tam LS, Tanaka Y, van den Vosch F, Westhovens R, Xavier RM, and Smolen JS. Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors- A consensus statement. Ann Rheum Dis (IF=27.973), 80:71-87, 2021.
  117. Ushikubo M, Saito S, Kikuchi J, Takeshita M, Yoshimoto K, Yasuoka H, Yamaoka K, Seki N, Suzuki K, Oshima H, and Takeuchi T. Milk fat globule epidermal growth factor 8 (MFG-E8) on monocytes is a novel biomarker of disease activity in systemic lupus erythematosus. Lupus (IF=2.858), 30:61-9, 2021.
  118. Aletaha, D, Clifton B, Karpouzas G, Takeuchi T, Thorne JC, Bili A, Agarwal P, Hsu B, Rao R, Brown K, and Tanaka Y. Long-term Safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomized controlled trials (SIRROUND-LTE). RMD open (IF=5.806), 7:e001465, 2021.
  119. Takeuchi T, Tanaka Y, Higashitani C, Iwai M, Komatsu K, Akazawa R, and Lademacher C. A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in post-menopausal female patients with rheumatoid arthritis taking methotrexate. Mod Rheum (IF=2.862), 31:53-60, 2021.
  120. Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M, Pangan AL, Konishi Y, Meerwein M, and Tanaka Y. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE), Arthritis Research and Therapy (IF=5.606), 23:9, 2021.
  121. Takeuchi T, Soen S, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, Okubo N, Nitta T, and Tanaka Y. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Mod Rheum (IF=2.862), 31:34-41, 2021.
  122. Yamada H, Sasaki T, Matsumoto K, Suzuki K, Takeshita M, Tanemura S, Seki N, Tsujimoto H, and Takeuchi T. Distinct features between HLA-DR+ and HLA-DR- PD-1hi CXCR5- T peripheral helper cells in seropositive rheumatoid arthritis. Rheumatology (Oxford) (IF=7.046), 60:451-60, 2021.
  123. Takeuchi T, Wakasugi N, Uno S, and Makino H. Long-term safety and effectiveness of tacrolimus in lupus nephritis patients: 5-year interim post-marketing surveillance study in Japan (TRUST). J Rheumatology (IF=5.346), 48:74-81, 2021.

2020年度

  1. Kondo Y, Suzuki K, Saito S, Inoue Y, Kaneko Y, Sakata K, and Takeuchi T. Safety and tolerability of ultrasoundguided synovial needle biopsy in Japanese arthritis patients. Mod Rheum (IF=2.113) , online November 20,2020.
  2. Kajio N, Takeshita M, Suzuki K, Kaneda Y, Yamane H, Ikeura K, Sato H, Shimizu H, Tsunoda K, and Takeuchi T. Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling. Ann Rheum Dis (IF=16.102) , online November 18, 2020.
  3. Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M, and Kato D. A pooled safety analysis of peficitinib (ASP015K) Asian patients with rheumatoid arthritis treated over a median of 2 years. Modern Rheum (IF=2.113), online November 9, 2020.
  4. Baer AN, Gottenberg J-E, St Claire EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, and Bootsma H. Efficacy and safety of abatacept in active primary Sjogren’s syndrome: results fo a phase III, randomized, placebo-controlled trial. Ann Rheum Dis (IF=16.102) , online November 9, 2020.
  5. Takeuchi T, Rischmeuller M, Blanco R, Xavier RM, Ueki Y, Atsumi T, Chen S, Friedman A, Pangan AL, Strand V, and van Vollenhoven RF. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexatenaïve Japanese patients with rheumatoid arthritis: A sub-analysis of the Phase 3 SELECT-EARLY study. Mod Rheum (IF=2.113) , online November 8, 2020.
  6. Takanashi S, Kikuchi J, Sasaki T, Akiyama M, Yasuoka H, Yoshimoto K, Sugahara K, Kankeo Y, and Takeuchi T. Lymphoadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker. Rheumatology (Oxford) (IF=5.606), online November 7, 2020.
  7. Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleishmann R, Geissler K, McInnes IB, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos Z, Boehncke W-H, Emery P, Issacs JD, Kremer J, Lee EB, Maksymowych WP, Sholte-Voshaar M, Tam LS, Tanaka Y, van den Vosch F, Westhovens R, Xavier RM, and Smolen JS. Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors- A consensus statement. Ann Rheum Dis (IF=16.102) ,online November 6, 2020.
  8. Takeuchi T, Wakasugi N, Uno S, and Makino H. Long-term safety and effectiveness of tacrolimus in lupus nephritispatients: 5-year interim post-marketing surveillance study in Japan (TRUST). J Rheum (IF=3.350), online November 1, 2020.
  9. Tanaka Y, Kondo K, Ichibori A, Yanai Y, Susuta Y, Inoue S, and Takeuchi T. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: a multicenter, open-label exploratory study. Lupus (IF=2.251) , online October 28, 2020.
  10. Ushikubo M, Saito S, Kikuchi J, Takeshita M, Yoshimoto K, Yasuoka H, Yamaoka K, Seki N, Suzuki K, Oshima H, and Takeuchi T. Milk fat globule epidermal growth factor 8 (MFG-E8) on monocytes is a novel biomarker of disease activity in systemic lupus erythematosus. Lupus (IF=2.251), 30(1):61-69, 2021.
  11. Nakazawa M, Suzuki K, Takechita M, Inamo J, Kamata H, Ishii M, Oyamada Y, Oshima H, and Takeuchi T. Distinct expression of coinhibitory molecules on alveolar T cells in patients with rheumatoid arthritis- and idiopathic inflammatory myopathies-associated interstitial lung disease. Arthritis & Rheumatology (IF=9.586) ,online October 10, 2020.
  12. Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, and Imai T.Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis with Inadequate Response to Methotrexate. Arthritis & Rheumatology (IF=9.586) ,online October 10, 2020.
  13. Inamo J, Kochi Y, and Takeuchi T. Is type 2 diabetes mellitus an inverse risk factor for the development of rheumatoid arthritis? J Human Genetics (IF=2.831) , online September 8, 2020.
  14. Yamada H, Sasaki T, Matsumoto K, Suzuki K, Takeshita M, Tanemura S, Seki N, Tsujimoto H, and Takeuchi T. Distinct features between HLA-DR+ and HLA-DR- PD-1hi CXCR5- T peripheral helper cells in seropositive rheumatoid arthritis. Rheumatology (Oxford) (IF=5.606), online September 5, 2020.
  15. Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleishmann R, Bradley JD, Byers NL, Hyslop DL, Issa M, Nishikawa A, Rooney TP, Witt S, Dickson CL, Smolen JS, and Dougados M. Infections in the baricitinib clinical development program for patients with active rheumatoid arthritis. Ann Rheum Dis (IF=16.102) , online August 11, 2020.
  16. Sakata K, Yasuoka H, Yoshimoto K, and Takeuchi T. Decreased activation of ataxia teleangiectasia mutated (ATM) in monocytes frompatients with systemic sclerosis. Rheumatology (Oxford) (IF=5.606), online August 3, 2020.
  17. Takeuchi T, Miyasaka N, Pedersen RD, Sugiyama N, and Hirose T. Radiographic and clinical effects of 10mg and 25mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis. Mod Rheum (IF=2.113) , online July 31, 2020.
  18. Van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed M-E F, Chen S, Rischmueller M, Blanco R, Xavier RM, and Strand V. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial. Arthritis & Rheumatology (IF=9.586), online July 8, 2020.
  19. Akiyama M, Kaneko Y, and Takeuchi T.Eosiophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: A potential mimicker of IgG4-reltaed disease. Ann Rheum Dis (IF=16.102) , online June 26, 2020.
  20. Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othmann AA, Pangan AL, Asabe S, Kitamura S, Meerwein S, and Tanaka Y. Efficacy and Safety of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (SELECT-SUNRISE): A Placebo-controlled Phase 2b/3 Study. Rheumatology (Oxford) (IF=5.606), online April 11, 2020.
  21. Takeuchi T, Tanaka Y, Higashitani C, Iwai M, Komatsu K, Akazawa R, and Lademacher C. A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropinreleasing hormone antagonist, ASP1707, in post-menopausal female patients with rheumatoid arthritis taking methotrexate. Mod Rheum (IF=2.113) , online February 20, 2020.
  22. Takeuchi T, Soen S, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, Okubo N, Nitta T, and Tanaka Y. Predictors of new bone erosion inrheumatoid arthritis patients receiving conventional synthetic antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Mod Rheum (IF=2.113) , online January 9, 2020.
  23. Kerschbaumer A, Smolen J, Nash P, Dorner T, Dougados M, Fleischmann R, Geissler K, McInnes I, Takeuchi T, Trauner M, Winthrop K, de Wit M, Boehncke W-H, Falzon L, and van der Heijde D. Points to consider for the treatment of immune mediated inflammatory diseases with janus kinase inhibitors: a systematic literature research. RMD open , 6: e001374, 2020.
  24. Sakai R, Ito M, Yoshimoto K, Chikuma S, Kurasawa T, Kondo T, Suzuki K, Takeuchi T, Amano K, and Yoshimura A. Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4+ Treg axis during remission of crescentic glomerulonephritis. Clin Trans Immunol (IF=6.464) , 9: e1203, 2020.
  25. Takeuchi T, Tanaka Y, Erdman J, Kaneko Y, Saito M, Higashitani C, Smulders R, and Lademacher C. ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: Results from a phase 2a, randomized, double-blind, placebo-controlled trial. Arthritis Research and Therapy (IF=4.103) , 22:252, 2020.
  26. Cho J, Kandane-Rathnayake R, Louthrenoo W, Hoi A, Golder V, Chen Y-H, Luo SF, Wu Y-J J, Hamijoyo L, Lau CS, Navarra S, Zamora L, Tee M, Flora Jr A, Li Z-G, An Y, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Basnayake D, Goldblatt F, Chan M, Ng K, Bae S-C, Oon S, O’Neill S, Gibson K, Kumar S, Law A H N, Tugnet N, Tanaka Y, Nikpour M, Moreland E, and Lateef A. COVID-19 infection in patients with systemic lupus erythematosusu: Data from the Asia Pacific Lupus collaboration. Int J Rheim Dis (IF-1.980) , 23:1255-57, 2020.
  27. Hasegawa T, Kikuta J, Suda T, Yamashita E, Takeuchi T, Ishii M, and Seno S. Development of an intravital imaging system for the synovial tissue reveals the dynamics of CTLA-4 Ig in vivo. Scientific Rep (IF=3.998) ,10:13480, 2020.
  28. Tsukamoto M, Suzuki K, Tsunoda K, Ikeura K, Kameyama K, and Takeuchi T. The Value of Labial Salivary Gland Histopathology for Diagnosis of Sjögren’s syndrome in Patients with Anti-centromere Antibody Positivity. Int J Rheum Dis (IF-1.980), 23: 1024-29, 2020.
  29. Yamane M, Sato S, Shibata S, Hayano M, Yaguchi T, Kamijuku H, Ogawa M, Suzuki T, Mukai S, Shimmura S, Okano H, Takeuchi T, Kawakami Y, Ogawa y, and Tsubota K. Senescence-associated secretary phenotype promotes chronic ocular graft-vs-host disease in mice and humans. FASEB journal (IF=4.170) , 34:10778-800,2020.
  30. Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Tomomitsu T, Hirakawa A, and Soen S. Eldecalcidor is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). J Bone and Mineral Metabolism (IF=2.297) , 38:522-32, 2020.
  31. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, and Matsumoto T. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. J Bone and Mineral Metabolism (IF=2.297) ,38:511-21, 2020.
  32. Tanaka Y, Soen S, Ishiguro N, Yamanaka H, Yoneda T, Tanaka S, Ohira T, Nitta T, Okubo N, Genant H, van der Heijde D, and Takeuchi T. Identifying the preferable rheumatoid arthritis subgroups for the intervention with the anti-RNKL antibody denosumab to reduce progression of joint destruction. RMD Open , 6:e001249, 2020.
  33. Fleischmann R, Takeuchi T, Schiff M, Schlichting D, Xie L, Issa M, Stoykov I, Lisse J, Martinez-Osuna P, Rooney T, and Zerbini T. Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherpay or baricitinib plus methotrexate. Arthritis Care & Res (IF=4.056) , 72:1112-21,2020.
  34. Yoshimoto K, Suzuki K, Takei E, Ikeda Y, and Takeuchi T. Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren’s syndrome. Arthritis Research and Therapy (IF=4.103) , 22:157, 2020.
  35. Inamo J, Suzuki K, Takeshita M, Kassai Y, Takiguchi M, Kurisu R, Okuzono Y, Tasaki S, Yoshimura A, and Takeuchi T. Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren’s syndrome. Arthritis Research and Therapy (IF=4.103) , 22:153, 2020.
  36. Genovese MC, Smolen JS, Takeuchi T, Burmester G, Brinker D, Rooney TP, Zhong J, Maojun M, Saifan C, Cardoso A, Issa M, Wu W-S, and Winthrop KL. Safety profile of baricitinib for the treatment of rheumatoid arthritis over 3 years median treatment: An updated integrated safety analysis. Lancet Rheumatology , 2:e347-357, 2020.
  37. Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, and Takeuchi T. Longitudinal immune cell monitoring identified CD14++ CD16+ intermediate monocytes as a marker of relapse in patients with ANCAassociated vasculitis. Arthritis Research and Therapy (IF=4.103) , 22:145, 2020.
  38. Smolen JS, Landewé R, Bijlsma J, Burmester G, Dougados M, Kershbaumer A, McInnes IB, Sepriano A, van Vollenhoven R, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Bush MH, Buttgreit F, Caporali R, Cardiel MH, De Coke D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg J-E, Hetland ML, Huizinga T, Kouloumas M, Li Z, Mariette Z, Muller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, and van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis (IF=16.102) , 79: 685-99, 2020.
  39. Takanashi S, Kaneko Y, and Takeuchi T. CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. Ann Rheum Dis (IF=16.102) , 79:671-4, 2020.
  40. Yajima N, Tsujimoto Y, Fukuma S, Sada K, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, and Atsumi T. The development of quality indicators for systemic lupus erythematousus using electronic health data: modified RAND appropriateness approach. Mod Rheum (IF=2.113), 30:525-31, 2020.
  41. Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, and Takeuchi T. Serum amyloid A levels correlate with requirement of concomitant methotrexate in tocilizumab initiation: A post-hoc analysis of the SURPRISE study. Mod Rheum (IF=2.113) , 30:442-9, 2020.
  42. Sasaki T, Yajima T, Shimaoka T, Ogawa S, Saito T, Yamaoka K, Takeuchi T, and Kubo M. Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease. Int Immunol (IF=3.519) , 32:163-74, 2020.
  43. Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, and Takeuchi T. Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. Rheumatology (Oxford) (IF=5.606) , 59:545-53, 2020.
  44. Hanaoka H, Okazaki Y, Takeuchi T, and Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Research and Therapy (IF=4.103) , 22:88, 2020.
  45. Sugihara T, Hasegawa H, Uchida H, Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M, and JPVAS. Association factors of poor treamnet outcomes in patients with giant cellarteritis: clinical implication of large vessel lesions. Arthritis Research and Therapy (IF=4.103) , 22:72, 2020.
  46. Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y-W, Chen Y-H, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Nakashima Y, Shiomi T, and Yamada E. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean treatment with peficitinib) from a long term, openlabel extension study in Japan, Korea and Taiwan. Arthritis Research and Therapy (IF=4.103) , 22:47, 2020.
  47. Yokoyama-Kokuryo W, Yamazaki H, Takeuchi T, Amano K, Kikuchi J, Kondo T, Nakamura S, Sakai R, Hirano F, Nanki T, Koike R, and Harigai M. Identification of molecule associated with response to abatacept in patients with rheumatoid arthritis. Arthritis Research and Therapy (IF=4.103) , 22:46, 2020.
  48. Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Namanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. Int J Rheum Dis (IF-1.980) , 23:316-24, 2020.
  49. Takei H, Yasuoka H, Yoshimoto K, and Takeuchi T. Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells. Arthritis Research and Therapy (IF=4.103) , 22:20, 2020.
  50. Takeuchi T, Miyasaka N, Pedersen R, Sugiyama N, and Hirose T. Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis. Mod Rheum (IF=2.113) , 30:259-68, 2020.
  51. Akiyama M, Kaneko Y, and Takeuchi T. Does microbiome contribute to HLA-B52-positive Takayasu arteritis. Mod Rheum (IF=2.113) , 30:213-7, 2020.
  52. Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, Nagashima T, Hayashi N, Wang L, and Tummala R. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheum (IF=2.113) , 30:101-8, 2020.
  53. Takeuchi T, Tanaka Y, Matsumura R, Saito K, Yoshimura M, Amano K, Atsumi T, Suematsu E, Hayashi N, Wang L, and Tummala R. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheum (IF=2.113) , 30:93-100, 2020.
  54. Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, and Tanaka Y. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phase 2 and 3 trials. Mod Rheum (IF=2.113) , 30:36-43, 2020.
  55. Jinnin M, Ohta A, Ishihara S, Atsumi T, Fujimoto M, Kanda T, Kawaguchi Y, Kawakami A, Mimori A, Mimori T, Mimura T, Muro Y, Sano H, Shimizu J, Amano H, Takeuchi T, Tanaka Y, Yamamoto K, Sumida T, and Kohsaka H; The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare. The first external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Ann Rheum Dis (IF=16.102), 79:387-92, 2020.
  56. Yamada H, Kaneko Y, Tamai H, Takeuchi T. Biomarkers for disease flare in patients with adult-onset Still’s disease undergoing treatment with tocilizumab. Rheumatology (Oxford). 59(2):440-442, 2020.
  57. Sakata K, Kaneko Y, Yasuoka H, and Takeuchi T. Association of radiographic findings in hand X-ray with clinical features and autoantibodies in patients with systemic sclerosis. Clin Rheum (IF=2.394) , 39:113-9, 2020.
  58. Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atsumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi H, Horie N, and Sato N. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study. Ann Rheum Dis (IF=16.102) , 79:94-102, 2020.
  59. Takeshita M, Suzuki K, Kaneda Y, Yamane H, Ikeura K, Sato H, Kato S, Tsunoda K, Arase H, and Takeuchi T. Antigen-driven selection of antibodies against SSA, SSB, and the centromere “complex”, including a novel antigen, MIS12 complex, in the salivary glands. Ann Rheum Dis (IF=16.102) , 79:150-9, 2020.
  60. Kaneko Y, Nunokawa T, Taniguchi Y, Yamaguchi Y, Gono T, Masui K, Kawakami A, Kawaguchi Y, Sato S, Kuwana M; JAMI investigators. Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study. Rheumatology (Oxford). 59(1):112-119, 2020.
  61. Kaneko Y, Kawahito Y, Kojima M, Nakayama T, Hirata S, Kishimoto M, Endo H, Seto Y, Ito H, Nishida K, Matsushita I, Kojima T, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, Miyasaka N, Yamanaka H. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis – a systematic review and meta-analysis. Mod Rheumatol. 2020 [in press]
  62. Kaneko Y, Sato M, Cai Z, Sato M. Assessment of discordance of treatment satisfaction between patients with rheumatoid arthritis in low disease activity or in remission and their treating physicians: A cross-sectional survey. Mod Rheumatol. 2020 [in press]
  63. Pile K, Norager R, Skillecorn M, Gibson KA, Elderton S, Favorito W, Li Z, Mu R, Nakahara H, Kishimoto M, Hirata S, Kaneko Y, Lau CS, Tam LS, Chen YH, Chen P, Wahking B, Furtner D. Elevating the role of carers in rheumatoid arthritis management in the Asia-Pacific region. Int J Rheum Dis . 23(7): 898-910, 2020.
  64. Okamori S, Lee H, Kondo Y, Akiyama Y, Kabata H, Kaneko Y, Ishii M, Hasegawa N, Fukunaga K. COVID-19- associated rapidly progressive organizing pneumonia with fibrotic feature a report of two cases. Medicine (Baltimore) 2020 [in press]
  65. Kaneko Y. Efficacy and safety of peficitinib in rheumatoid arthritis. Mod Rheumatol. 30(5):773-778, 2020.
  66. Kida D, Takahashi N, Kaneko A, Hirano Y, Fujibayashi T, Kanayama Y, Hanabayashi M, Yabe Y, Takagi H, Oguchi T, Kato T, Funahashi K, Matsumoto T, Ando M, Kuwatsuka Y, Tanaka E, Yasuoka H, Kaneko Y, Hirata S, Murakami K, Sobue Y, Nishiume T, Suzuki M, Yokota Y, Terabe K, Asai S, Ishiguro N, Kojima T. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients. Sci Rep . 10(1):19717, 2020.
  67. Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, Suzuki Y. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Mod Rheumatol. 1-14, 2020.
  68. Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford) .59(9):2427-34, 2020.
  69. Sakai R, Ito M, Yoshimoto K, Chikuma S, Kurasawa T, Kondo T, Suzuki K, Takeuchi T, Amano K, Yoshimura A. Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4+ Treg axis during remission of crescentic glomerulonephritis. Clin Transl Immunology . 9(11):e1203, 2020.
  70. Hanaoka H, Nishimoto T, Okazaki Y, Takeuchi T, Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Res Ther. 22:88, 2020.
  71. Matsumoto K, Yasuoka H, Yoshimoto K, Suzuki K, Takeuchi T. Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis. Sci Rep . 11(1):222, 2021.
  72. Takeshita M, Nishina N, Moriyama S, Takahashi Y, Uwamino Y, Nagata M, Aoki W, Masaki K, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T; Keio Donner project. Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan. Virology. 555:35-43,2021.
  73. Monti S, Craven A, Klersy C, Montecucco C, Caporali R, Watts R, Merkel PA, Luqmani R; DCVAS Collaborators. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. Rheumatology (Oxford) . 60(2):617-628, 2021.
  74. Murata O, Suzuki K, Sugiura H, Kondo Y, Takeshita M, Koga K, Takiguchi M, Kurisu R, Kassai Y, Yasuoka H, Yamaoka K, Morita R, Yoshimura A, Takeuchi T. Thymus variants on imaging in patients with rheumatoid arthritis-Clinical and immunological significance. Rheumatology (Oxford) , 2021.
  75. Makhzoum JP, Grayson PC, Ponte C, Robson J, Suppiah R, Watts RA, Luqmani R, Merkel PA, Pagnoux C. DCVAS collaborators. Pulmonary Involvement in Primary Systemic Vasculitides. Rheumatology (Oxford) , 2021.
  76. Sakata K, Kikuchi J, Emoto K, Kotaki T, Ota Y, Nishina N, Hanaoka H, Otomo K, Suzuki K, Kaneko Y, Takeuchi T. Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review. Intern Med ,2021.
  77. Hanaoka H, Nishimoto T, Okazaki Y, Takeuchi T, Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Res Ther. 22:88, 2020.
  78. Kiyokawa T, Hanaoka H, Iida H, Ishimori K, Takakuwa Y, Okazaki T, Ozaki S, Kawahata K. High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis. Mod Rheumatol . 30:517-24, 2020.
  79. Otomo K, Takeuchi T. Osteitis condensans ilii in a patient with ulcerative colitis: a mimic of ankylosing spondylitis or non-radiographic axial spondyloarthritis. Mod Rheumatol Case Rep. 1-6, 2021.
  80. Akiyama M, Kaneko Y, Saito S, Matsumoto K, Kondo Y, Hanaoka H, Otomo K, Oyama M, Matsubara S, Takeuchi T. A case of dropped head syndrome due to focal myositis that worsened with cellulitis and improved only by treatment of cellulitis. Mod Rheumatol Case Rep. 1-6, 2021.
  81. Takahashi S, Otomo K, Kawakami Y, Nakamura M. Uveitis developing in tuberculous lymphadenitis-associated Behçet’s disease during anti-tuberculosis therapy. Respirol Case Rep . 8(6): e00617, 2020.
  82. Misako Higashida-Konishi, Keisuke Izumi, Satoshi Hama, Hiroshi Takei, Hisaji Oshima, Yutaka Okano. Comparing the Clinical and Laboratory Features of Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Seronegative Rheumatoid Arthritis. J Clin Med. 10(5), 1116, 2021.
  83. Misako Higashida-Konishi, Keisuke Izumi, Masako Tsukamoto, Hiroaki Ohya, Nozomi Takasugi, Satoshi Hama, Yutaro Hayashi, Mari Ushikubo, Kumiko Akiya, Araki Kazuhiro, Yutaka Okano, Hisaji Oshima. Anti-cyclic citrullinated peptide antibody in the cerebrospinal fluid in patients with rheumatoid arthritis who have central nervous system involvement. Clin Rheumatol. 39(8):2441-2448, 2020.
  84. Sayaka Takenaka, Takehisa Ogura, Hisaji Oshima, Keisuke Izumi, Ayako Hirata, Hideki Ito, Kennosuke Mizushina, Yuki Inoue, Takaharu Katagiri, Norihide Hayashi, Hideto Kameda. Development and exacerbation of pulmonary nontuberculous mycobacterial infection in patients with systemic autoimmune rheumatic diseases. Mod Rheumatol. 30(3):558-563, 2020.
  85. Keisuke Izumi, Kazumichi Minato, Kiko Shiga, Tatsuki Sugio, Sayaka Hanashiro, Kelley Cortright, Shun Kudo, Takanori Fujita, Mitsuhiro Sado, Takashi Maeno, Toru Takebayashi, Masaru Mimura, Taishiro Kishimoto. Quantification of stress and well-being using pulse, speech, and electrodermal data: Study concept and design. medRxiv , 2020.05.01.20082610, 2020.
  86. Nishina N, Sato S, Masui K, Gono T, and Kuwana M. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD open . e001202, 2020.
  87. Kaieda S, Gono T, Masui K, Nishina N, Sato S, and Kuwana M. A Multicenter Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI) investigators. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease. PLoS One . e0234523, 2020.
  88. Laniyati Hamijoyo, I Nyoman Suarjana, Andi Raga Ginting, Pande Ketut Kurniari, Perdana Aditya Rahman, Katsuya Suzuki, Jun Kikuchi, Shuntaro Saito. Pocket handbook in Indonesia (ISBN 978-979-3730-35-6)
  89. Guo Y, Kawaguchi A, Takeshita M, Sekiya T, Hirohama M, Yamashita A, Siomi H, Murano K. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. J Biol Chem . 2021.
  90. Kondo Y, Kaneko Y, Oshige T, Fukui H, Saito S, Okayama M, Kamata H, Ishii M, Hasegawa N, Fukunaga K, Takeuchi T. Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus. Ann Rheum Dis. 2021 May;80(5):e77. doi: 10.1136/annrheumdis-2020-218157. Epub PMID: 32759254, 2020.
  91. Akiyama Y, Horiuchi K, Kondo Y, Kabata H, Ishii M, Fukunaga K. A case of non-severe COVID-19 complicated by pulmonary embolism. Respirol Case Rep. 8(7):e00622. doi: 10.1002/rcr2.622. PMID: 32685167; PMCID: PMC7362677, 2020.
  92. Saito S, Okuyama A, Okada Y, Shibata A, Sakai R, Kurasawa T, Kondo T, Takei H, Amano K. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. Rheumatology (Oxford). 59(7):1617-1621, 2020.
  93. Kuramoto N, Saito S (co-first), Fujii T, Kaneko Y, Saito R, Tanaka M, Takada H, Nakano K, Saito K, Sugimoto N, Sasaki S, Harigai M, Suzuki Y. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case-control study. Mod Rheumatol. 1-16, 2021.
  94. Akiyama M, Kaneko Y, Takeuchi T. Etiology of IgG4-Related Pulmonary Hypertension. Cardiology. 145:263-266,2020.
  95. Akiyama M. Serum IgG4 level and IgG4 subclass of ANCA as disease biomarker for ANCA-associated vasculitis. Int J Rheum Dis . 23:126-127, 2020.
  96. Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum . 50:521-525, 2020.
  97. Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet’s disease: A systematic literature review. Semin Arthritis Rheum . 50:797-804, 2020.
  98. Akiyama M. Commentary on: Gabarrou G, Guilbeau-Frugier C, Blanc A, Telmon N, Savall F. Necessity for recognition of IgG4-related coronary arteritis and elucidating treatment strategy.J Forensic Sci 2018;63(2):611-3. https://doi.org/10.1111/1556-4029.13561. J Forensic Sci. 65:1795, 2020.
  99. Akiyama M, Kaneko Y, Takeuchi T. Lupus aortitis: a fatal, inflammatory cardiovascular complication in systemic lupus erythematosus. Lupus . 29:1652-1654, 2020.
  100. Akiyama M, Kaneko Y, Takeuchi T. Characteristics and prognosis of ANCA-positive retroperitoneal fibrosis: a systematic literature review. Autoimmun Rev. 19:102642, 2020.
  101. Akiyama M, Kaneko Y, Takeuchi T. Response to a Letter to the Editor entitled “Is Tocilizumab as efficient as steroids early in polymyalgia rheumatica?” Semin Arthritis Rheum . 50:890, 2020.
  102. Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. Ann Hematol . 99:2463-2475, 2020.
  103. Akiyama M. Recognition of rare, atypical manifestations is important for diagnosis and management of ANCA-associated vasculitis: comment on the article by Delaval L et al. Arthritis Rheumatol. 73:719, 2020.
  104. Akiyama M, Kaneko Y, Sasaki T, Takeuchi T. Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. Rheumatology (Oxford). 60:e73-e75, 2020.
  105. Wu B, Qiu J, Zhao TV, Wang Y, Maeda T, Goronzy IN, Akiyama M, Ohtsuki S, Jin K, Tian L, Goronzy JJ, Weyand CM. Succinyl-CoA Ligase Deficiency in Pro-inflammatory and Tissue-Invasive T Cells. Cell Metab. 32:967-980. e5, 2020.
  106. Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review. Autoimmun Rev. 20:102737, 2021.
  107. Akiyama M, Ohtsuki S, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Innate and Adaptive Immunity in Giant Cell Arteritis. Front Immunol. 11:621098, 2021.
  108. Higashida-Konishi M, Izumi K, Hama S, Takei H, Oshima H, Okano Y. Comparing the Clinical and Laboratory Features of Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Seronegative Rheumatoid Arthritis: Stage 1. J Clin Med. 10(2):340, 2021.
  109. Yuichiro Ota, Yuko Kaneko, Tsutomu Takeuchi. Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases. Clin Exp Rheumatol. 2020.
  110. Hasegawa T, Yamane T, Taguchi H. An Unusual Cause of Right Lower Abdominal Pain. Gastroenterology, Aug 21;S0016-5085(20)35071, 2020.
  111. Takanashi S. Correspondence on ‘Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis. annrheumdis-2020-219677,2020.
  112. Takanashi S, Hanaoka H, Ota Y, Kaneko Y, Takeuchi T. An Overlapping Case of IgG4-related Disease and Klinefelter Syndrome With Lupus-like Serological and Neurological Features: A Case Report and Literature Review. Intern Med. 59(20):2601-2609, 2020.
  113. Inamo J. T peripheral helper cells signature genes in patients with rheumatoid arthritis. Clin Rheumatol. 39:pp. 2019-2021, 2020.
  114. Inamo J. How should we overcome the threat by the pandemic of 2019-nCoV? Epidemic simulation using the SIRS model. Clin Rheumatol. 39:pp. 2471–2473, 2020.
  115. Inamo J. Distinct gene network in skin lesion of patients with diffuse cutaneous systemic sclerosis. Clin Rheumatol. 39:pp. 3143 – 3144, 2020.
  116. Inamo J. Association between celiac disease and systemic lupus erythematosus: a Mendelian randomization study. Rheumatology (Oxford). 59:pp. 2642-2644, 2020.
  117. Inamo J. Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis. Rheumatology (Oxford). 60:pp. 929-939, 2021.
  118. Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Ito K, Yamashita H, Hirakata M, Kawahata K, Kawakami A, Watanabe N, Atsumi T, Takasaki Y, and Miyasaka N Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis dermatomyositis: a single-arm clinical trial. Rheumatolog 59(5):1084-1093, 2020.

2019年度

  1. Takeuchi T, Tanaka Y, Higashitani C, Iwai M, Komatsu K, Akazawa R, and Lademacher C. A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in post-menopausal female patients with rheumatoid arthritis taking methotrexate. Mod Rheum. online February 20, 2020.
  2. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano THagino H, Hirakawa A, and Matsumoto T. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. J Bone and Mineral Metabolism. online January 22, 2020.
  3. Takeuchi T, Soen S, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, Okubo N, Nitta T, and Tanaka Y. Predictors of new bone erosion inrheumatoid arthritis patients receiving conventional synthetic antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Mod Rheum. online January 9, 2020.
  4. Yoshimoto K, Suzuki K, Takei E, Ikeda Y, and Takeuchi T. Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren’s syndrome.Arthritis Research and Therapy. 22:157, 2020.
  5. Inamo J, Suzuki K, Takeshita M, Kassai Y, Takiguchi M, Kurisu R, Okuzono Y, Tasaki S, Yoshimura A, and Takeuchi T. Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren’s syndrome. Arthritis Research and Therapy. 22:153, 2020.
  6. Genovese MC, Smolen JS, Takeuchi T, Burmester G, Brinker D, Rooney TP, Zhong J, Maojun M, Saifan C, Cardoso A, Issa M, Wu W-S, and Winthrop KL. Safety profile of baricitinib for the treatment of rheumatoid arthritis over 3 years median treatment: An updated integrated safety analysis. Lancet Rheumatology. 2:e347-357, 2020.
  7. Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, and Takeuchi T. Longitudinal immune cell monitoring identified CD14++ CD16+ intermediate monocytes as a marker of relapse in patients with ANCA-associated vasculitis. Arthritis Research and Therapy. 22:145.
  8. Akiyama M, Kaneko Y, and Takeuchi T. Effectiveness of tocilizumab in Bechet’s disease: A systemic literature review. Semin Arth Rheum. 50:797-804, 2020.
  9. Smolen JS, Landewé R, Bijlsma J, Burmester G, Dougados M, Kershbaumer A, McInnes IB, Sepriano A, van Vollenhoven R, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Bush MH, Buttgreit F, Caporali R, Cardiel MH, De Coke D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg J-E, Hetland ML, Huizinga T, Kouloumas M, Li Z, Mariette Z, Muller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, and van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 79: 685-99, 2020.
  10. Akiyama M, Kaneko Y, and Takeuchi T. Etiology of IgG4-related pulmonary hypertension. Cardiology. 145:263-6, 2020.
  11. Takanashi S, Kaneko Y, and Takeuchi T. CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. Ann Rheum Dis. 79:671-4, 2020.
  12. Choy E, de Benedetti F, Takeuchi T, Hashizume M, John MR, and Kishimoto T. Translating IL-6 biology into effective treatments. Nature Rev Rheum. 16:335-45, 2020.
  13. Yajima N, Tsujimoto Y, Fukuma S, Sada K, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, and Atsumi T. The development of quality indicators for systemic lupus erythematousus using electronic health data: modified RAND appropriateness approach. Mod Rheum. 30:525-31, 2020.
  14. Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, and Takeuchi T. Serum amyloid A levels correlate with requirement of concomitant methotrexate in tocilizumab initiation: A post-hoc analysis of the SURPRISE study. Mod Rheum. 30:442-9, 2020.
  15. Sasaki T, Yajima T, Shimaoka T, Ogawa S, Saito T, Yamaoka K, Takeuchi T, and Kubo M. Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease. Int Immunol. 32:163-74, 2020.
  16. Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, and Takeuchi T. Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. Rheumatology (Oxford). 59:545-53, 2020.
  17. Hanaoka H, Okazaki Y, Takeuchi T, and Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Research and Therapy. 22:88, 2020.
  18. Sugihara T, Hasegawa H, Uchida H, Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M, and JPVAS. Association factors of poor treamnet outcomes in patients with giant cellarteritis: clinical implication of large vessel lesions. Arthritis Research and Therapy. 22:72, 2020.
  19. Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y-W, Chen Y-H, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Nakashima Y, Shiomi T, and Yamada E. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean treatment with peficitinib) from a long term, open-label extension study in Japan, Korea and Taiwan. Arthritis Research and Therapy. 22:47, 2020.
  20. Yokoyama-Kokuryo W, Yamazaki H, Takeuchi T, Amano K, Kikuchi J, Kondo T, Nakamura S, Sakai R, Hirano F, Nanki T, Koike R, and Harigai M. Identification of molecule associated with response to abatacept in patients with rheumatoid arthritis. Arthritis Research and Therapy. 22:46, 2020.
  21. Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Namanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. Int J Rheum Dis. 23:316-24, 2020.
  22. Takei H, Yasuoka H, Yoshimoto K, and Takeuchi T. Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells. Arthritis Research and Therapy. 22:20, 2020.
  23. Takeuchi T, Miyasaka N, Pedersen R, Sugiyama N, and Hirose T. Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis. Mod Rheum. 30:259-68, 2020.
  24. Akiyama M, Kaneko Y, and Takeuchi T. Does microbiome contribute to HLA-B52-positive Takayasu arteritis. Mod Rheum. 30:213-7, 2020.
  25. Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, Nagashima T, Hayashi N, Wang L, and Tummala R. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheum. 30:101-8, 2020.
  26. Takeuchi T, Tanaka Y, Matsumura R, Saito K, Yoshimura M, Amano K, Atsumi T, Suematsu E, Hayashi N, Wang L, and Tummala R. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheum. 30:93-100, 2020.
  27. Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, and Tanaka Y. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phase 2 and 3 trials. Mod Rheum. 30:36-43, 2020.
  28. Jinnin M, Ohta A, Ishihara S, Atsumi T, Fujimoto M, Kanda T, Kawaguchi Y, Kawakami A, Mimori A, Mimori T, Mimura T, Muro Y, Sano H, Shimizu J, Amano H, Takeuchi T, Tanaka Y, Yamamoto K, Sumida T, and Kohsaka H. The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare. The first external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Ann Rheum Dis. 79:387-92, 2020.
  29. Yamada H, Kaneko Y, and Takeuchi T. Lactate dehydrogenase as a potential biomarker for relapse in patients with adult-onset Still’s disease undergoing treatment with tocilizumab. Rheumatology (Oxford). 59:440-2, 2020.
  30. Sakata K, Kaneko Y, Yasuoka H, and Takeuchi T. Association of radiographic findings in hand X-ray with clinical features and autoantibodies in patients with systemic sclerosis. Clin Rheum. 39:113-9, 2020.
  31. Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atsumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi H, Horie N, and Sato N. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patoentys with rheumatoid arthritis: the RRRR study. Ann Rheum Dis. 79:94-102, 2020.
  32. Takeshita M, Suzuki K, Kaneda Kaneda Y, Yamane H, Ikeura K, Sato H, Kato S, Tsunoda K, Arase H, and Takeuchi T. Antigen-driven selection of antibodies against SSA, SSB, and the centromere “complex”, including a novel antigen, MIS12 complex, in the salivary glands. Ann Rheum Dis. 79:150-9, 2020.
  33. Tsukamoto M, Suzuki K, Tsunoda K, Ikeura K, Kameyama K, Takeuchi T. Value of labial salivary gland histopathology for diagnosis of Sjögren’s syndrome in patients with anti-centromere antibody positivity. Int J Rheum Dis. 2020.
  34. Akiyama M, Kaneko Y, and Takeuchi T. Ground glass opacity with mixed consolidation on chest computed tomography reflects the severe condition of pneumocystis pneumonia in association with a poor prognosis in patients with connective tissue diseases. Intern Med. 58:3379-83, 2019.
  35. Inamo J, Kaneko Y, Ota Y, and Takeuchi T. Sub-types in eosinophilic granulomatosis with polyangiitis classified according to rheumatoid factor. Clin Rheum. 38:3493-99, 2019.
  36. Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, Ebina K, Hirao M, Okuzaki D, Yoshida Y, Hirao A, Kalinichenko V, Rachaudohuri P, Yamaoka K, Takeuchi T, and Ishii M. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nature Immunol. 20:1631-43, 2019.
  37. Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, and Takeuchi T. Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis. Arthritis Research and Therapy. 21:304, 2019.
  38. Fleischmann R, Takeuchi T, Schiff M, Schlichting D, Xie L, Issa M, Stoykov I, Lisse J, Martinez-Osuna P, Rooney T, and Zerbini T. Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherpay or baricitinib plus methotrexate. Arthris Care & Res. online June 24, 2019.
  39. Akiyama M, Kaneko Y, and Takeuchi T. Characteristics and prognosis of IgG4-related periaortitis/periarteritis: A systemic literature review. Autoimmunity reviews. 18:102354, 2019.
  40. Akiyama M, Suzuki K, Kaneko Y, and Takeuchi T. IgG4-related disease: A growing appreciation of follicular helper T cell expansion. Clin and translational gastroenterology. 10:e00076, 2019.
  41. Takeshita M, Suzuki K, Kondo Y, Morita R, Okuzono Y, Koga K, Kassai Y, Gamo K, Takiguchi M, Kurisu R, Mototani H, Ebisuno Y, Yoshimura A, and Takeuchi T. Multi-dimentional analysis identified arthritis-driving pathway in human T cells. Ann Rheum Dis. 78:1346-56, 2019.
  42. Matsumoto K, Kaneko Y, and Takeuchi T. Body mass index associates with disease relapse in patients with giant cell arteritis. Int J Rheum Dis. 22:1782-86, 2019.
  43. Yasuoka H, Tam YYA, Okazaki Y, Tamura Y, Matsuo K, Feghali-Bostwick C, Takeuchi T, and Kuwana M. Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: A potential role of M2 polarization. J Scleroderma and Related Dis. online, May 19, 2019.
  44. Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song S-W, Cheng Y-H, Wei J C-C, Lee S-H, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, and Yamada E. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 78:1320-32, 2019.
  45. Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Shiomi T, Yamada E, and van der Heijde D. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 78:1305-19, 2019.
  46. Genovese MC, Kalunian K, Walker D, Gottenberg G-C, de Vlam K, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, and Takeuchi T. Filgotinib in patients with bDMARD-refractory active rheumatoid arthritis: a randomized, placebo-controlled global phase 3 trial. JAMA. 322:315-25, 2019.
  47. Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, and van der Heijde. Effect of anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying anti-rhuematic drugs (DESIRABLE study): a randomized, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. 78:899-907, 2019.
  48. Tokuhira M, Saito S, Suzuki K, Higashi M, Momose S, Shimizu T, Mori T, Kimura Y, Amano K, Okamoto S, Takeuchi T, Tamaru Tamaru J, and Kizaki M. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders (cMTX-LPD). Leukemia & Lymphoma. 60:2508-15, 2019.
  49. Taylor P, Weinblatt M, Burmester G, Rooney T, Witt S, Walls C, Issa M, Salinas C, Saifan C, Zhang X, Cardoso A, Gonxalez-Gay M, Takeuchi T. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis & Rheumatology. 71:1042-55, 2019.
  50. Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyoizumi S, DeMasi R, Fukuma Y, Hirose T, Sugiyama N, Zwillich SH, and Tanaka Y. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post-hoc analysis of clinical trial data. Mod Rheum. 29:756-66, 2019.
  51. Takanashi S, Kaneko Y, and Takeuchi T. Effectiveness of tacrolimus on IgG4-related disease. Mod Rheum. 29:862-4, 2019.
  52. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Yoshizawa Y, Chinen I, Nakao T, and Koike T. Safety and effectiveness of abatacept in Japanese non-elderly and elderly patiernts with rheumatoid arthritis in an all-cases post-marketing surveillance. Mod Rheum. 29:747-55, 2019.
  53. van der Heijde, D., Strand, V.,Tanaka, Y.,Keystone, E.,Kremer, J., Zerbini, C.A.F., Cardiel, M.H., Cohen, S., Nash, P., Song, Y.-W., Tegzová, D., Gruben, D., Wallenstein, G., Connell, C.A. Email Author, Fleischmann, R., Hall, S., Nicholls, D., Rischmueller, M., Baker, M.F., Bessette, L., Cividino, A.A., Haraoui, B., Niall Jones, H., Keystone, E.C., Khraishi, M., Thorne, J., Birbara, C.A., Baraf, H.S.B., Bathon, J.M., Brodsky, A.L., Cush, J.J., Dikranian, A.H., Diri, E., Dura, P.A., Lohr, K.M., Fleischmann, R.M., Griffin, R.M., Halter, D.G., Hargrove, J.K.,Bouda, D.W., Reddy Pasya, S.K., Hill, G.L., Jackson, R.E., Kafka, S.P., Kaine, J.L., Katzenstein, P.L., Kempf, K.J., Kolba, K.S., Kremer, J.M., Longley, S., Mathews, S.D., Milton, A.C., Misischia, R.J., Moorman, H.A., Moreland, L.W., Niemer, M.W., Palmer, W.R., Sayers, M.E., Schuette, P.T., Shamim, T., Shergy, W.J., Sikes, D.H., Silverfield, J.C., Siva, C., Taborn, J.D., Walsh, B.T., Wells, A.F., Wolfe, S.M., Adhikari, P., Amano, K., Bae, S.-C., Chandrashekara, S., Chopra, A.K., Hsu, P.-N., Iwahashi, M., Kadel, J.K., Kawabe, Y., Koh, E.-M., Lan, J.-L., Lee, S.-K., Lin, H.-Y., Liou, L.-B., Liu, M.-F., Migita, K., Miyamoto, T., Miyasaka, N., Mori, S., Munakata, Y., Ohta, S., Park, W., Park, S.-H., Rao, U.R., Shim, S.C., Shobha, V., Takasaki, Y., Takeuchi T , Tanaka, Y., Tohma, S., Tsai, W.-C., Ueki, Y., Veeravalli, S.C.M., Wagh, S., Yamanaka, H., Yoo, B., Batalov, A., Bichoversuska, D., Dvorak, Z., Goranov, I., Hrytsenko, H.M., Kopackova, J., Mosterova, Z., Oparanov, B., Petrov, A., Pokrzywnicka-Gajek, I., Povoroznyuk, V.V., Rosa, J., Ruzga, Z., Settas, L., Stanislavchuk, M.A.,Tseluyko, V.I., Vitek, P., de Freitas Zerbini, C.A., Brenol, J.C.T., Cardiel-Rios, M.H., Escalante, W.J.O., Maldonado-Lopez, M.C., Jaller Raad, J.J., Hernandez, J.D.M., Jauregui, E.A., Keiserman, M.W., Melazzi, A.C.C., Pascual-Ramos, V., Pinto, L.T., Radominski, S.C., Ximenes, A.C., de Morales, S.V., the ORAL Scan Investigators. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: Clinical efficacy, radiographic and safety oucomes from a twenty-four month, phase III study. Arthritis and Rheumatology. 71:878-91, 2019.
  54. Tanaka Y, Mimori T, Yamanaka H, Nakajima R, Morita K, Kimura J, and Takeuchi T. Effectiveness and safety of initiating adalimumab plus ≧12mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK srudy post-marketing surveillance in Japan. Mod Rheum. 29:572-580, 2019.
  55. Inamo J, Kikuchi J, Suzuki K, Kaneko Y, Yasuoka H, Fujiwara H, Yamaoka K, and Takeuchi T. Reversible cerebral vasoconstriction syndrome triggered by tacrolimus mimicked neuropsychiatric involvement in systemic lupus erythematosus, Mod Rheum Case Reports. 3:119-123, 2019.
  56. Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, Zhu B, Quebe AK, Gaich CL, Zhang X, Dickson CL, Schlichting DE, Patel H, Durand F, and Emery P. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: Results from the RA-BEAM trial. J Clin Medicine. 8:831, 2019.
  57. Takanashi S, Nishina N, Nakazawa M, Kaneko Y, and Takeuchi T. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology (Oxford). 58:1034-39, 2019.
  58. Ishiguro N, Tanaka Y, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D, and Takeuchi T. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology (Oxford). 58:998-1005, 2019.
  59. Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B, and for the NEXUS study group. Efficacy and safety of namilumab, a human monoclonal antibody against granulocytemacrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Research and Therapy. 21:101, 2019.
  60. Kimura N, Suzuki K, and Takeuchi T. Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab. Inflammation and regeneration. 39:5, 2019.
  61. Tanaka Y, Takeuchi T, Yamanaka H, Nakano T, Akagi K, Ukyo Y, and Hsu B. Efficacy and safety of sirkumab Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosiss factor: subgroup analysis for a randomized, double-blind, multi-center, phase 3 study (SIRROUND-T). Mod Rheum. 29:306-13, 2019.
  62. Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo S-F, Wu Y-J J, Li Z, An Y, Lateef A, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O7Neill S, Goldblatt F, Hao Y, Zhang Z, Al-Saleh J, Khamashta M, Takeuchi T, Tanala Y, Bae S-C, Lau CS, Hoi A, Nikpour M, and Morand EF. Development of the asia pacific lupus collaboration cohort. Int J Rheum Dis. 22:425-33, 2019
  63. Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Camp JR, Cardillo TE, Ishii T, and Winthrop KL. Safety of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheum. 46:7-18, 2019.
  64. Inamo J, Kaneko Y, Sakata K, and Takeuchi T. Impact of subclinical synovitis in ankles and feet detected by ultrasonography in patients with rheumatoid arthritis. Int J Rheum Dis. 22:62-7, 2019.
  65. Kondo Y, Suzuki K, Inoue Y, Sakata K, Takahashi C, Takeshita M, Kassai Y, Miyazaki T, Morita R, Niki Y, Kaneko Y, Yasuoka H, Yamaoka K, Yoshimura A, and Takeuchi T. Significant association between joint ultrasonographic parameters and synobial inflammatory factors in rheumatoid arthritis. Arthritis Research and Therapy. 21:14, 2019.
  66. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney T, and Smolen JS. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: Results of a prospective study. Ann Rheum Dis. 78:171-8, 2019.
  67. Tsumakoto M, Suzuki K, and Takeuchi T. Ten-year observation of patients with primary Sjögren’s syndrome: initial presenting characteristics and the associated outcomes. Int J Rheum Dis. 22.929-33,2019.
  68. Tsukamoto M, Suzuki K, and Takeuchi T. Initial presenting determines clinical entity in patients with anti-centromere antibody positivity. Int J Rheum Dis (IF=1.980), 22:103-7, 2019.
  69. Matsunami M, Suzuki M, Haramoto Y, Fukui A, Inoue T, Yamaguchi K, Uchiyama I, Mori K, Tashiro K, Ito Y, Takeuchi T, Suzuki KT, Agata K, Shigenobu S, Hayashi T. A comprehensive reference transcriptome resource for the Iberian ribbed newt Pleurodeles waltl, an emerging model for developmental and regeneration biology. DNA Res. 1;26(3):217-229,2019.
  70. Kishimoto M, Yoshida K, Ichikawa N, Inoue H, Kaneko Y, Kawasaki T, Matsui K, Morita M, Suda M, Tada K, Takizawa N, Tamura N, Taniguchi A, Taniguchi Y, Tsuji S, Haji Y, Rokutanda R, Yanaoka H, Cheung PP, Gu J, Kim TH, Luo SF, Okada M, López Medina C, Molto A, Dougados M, Kobayashi S, van der Heijde D, Tomita T. Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. J Rheumatol.;46(8):896-903, 2019.
  71. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Hydroxychloroquine improves disease activity and allows reduction of corticosteroid dose regardless of background treatment in Japanese patients with systemic lupus erythematosus. Intern Med. 58: pp1257-1262, 2019.
  72. Takakuwa Y, Hanaoka H, Kiyokawa T, Iida H, Ishimori K, Uekusa T, Yamada H, Kawahata K. Adult-onset Still disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of hemophagocytic syndrome and relapse. Clin Exp Rheumatol. 34: pp23-7, 2019
  73. Iida H, Hanaoka H, Okada Y, Kiyokawa T, Takakuwa Y, Yamada H, Okazaki T, Ozaki S, Yamaguchi K, Nakajima Y, Kawahata K. A low perfusion-metabolic mismatch in 99mTl and 123I-BMIPP scintigraphy predicts poor prognosis in systemic sclerosis patients with asymptomatic cardiac involvement. Int J Rheum Dis. 22: pp1008-15, 2019.
  74. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Clin Rheumatol. 38: pp2785-91, 2019.
  75. Hayakawa M., Izumi K., Higashida-Konishi M, Ushikubo M, Tsukamoto M, Akiya K, Araki K, Oshima H. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. Rheumatol Int. 39:pp.161–166, 2019.
  76. Saito S, Okuyama A, Okada Y, Shibata A, Sakai R, Kurasawa T, Kondo T, Takei H, Amano K. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. Rheumatology (Oxford) 2019 Oct 26.
  77. Saito S, Takeuchi T. Immune Response in LPD During Methotrexate Administration (MTX-LPD) in Rheumatoid Arthritis Patients. Review. J Clin Exp Hematop 59(4):145-155,2019.
  78. Weyand CM, Watanabe R, Zhang H, Akiyama M, Berry GJ, Goronzy JJ. Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin Immunol. 206:pp.33-41, 2019.
  79. Akiyama M, Zeisbrich M, Ibrahim N, Ohtsuki S, Berry GJ, Hwang PH, Goronzy JJ, Weyand CM. Neutrophil Extracellular Traps Induce Tissue-Invasive Monocytes in Granulomatosis With Polyangiitis. Front Immunol. 10:2617, 2019.
  80. Hasegawa T, Kikuta J, Ishii M. Imaging the Bone-Immune Cell Interaction in Bone Destruction. Front Immunol. 26;10:596, 2019.
  81. Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Ito K, Yamashita H, Hirakata M, Kawahata K, Kawakami A, Watanabe N, Atsumi T, Takasaki Y, and Miyasaka N. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis dermatomyositis: a single-arm clinical trial. Rheumatolog 59:1084-1093, 2019
2018年
  1. Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, and van der Heijde. Effect of anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying anti-rhuematic drugs (DESIRABLE study): a randomized, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. in press.
  2. Akiyama M, Kaneko Y, and Takeuchi T. Does microbiome contribute to HLA-B52-positive Takayasu arteritis. Mod Rheum. in press.
  3. Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, Nagashima T, Hayashi N, Wang L, and Tummala R. safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheum. in press.
  4. Takeuchi T, Tanaka Y, Matsumura R, Saito K, Yoshimura M, Amano K, Atsumi T, Suematsu E, Hayashi N, Wang L, and Tummala R. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheum. in press.
  5. Tokuhira M, Saito S, Suzuki K, Higashi M, Momose S, Shimizu T, Mori T, Kimura Y, Amano K, Okamoto S, Takeuchi T, Tamaru Tamaru J, and Kizaki M. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders (cMTX-LPD). Leukemia & Lymphoma. online 2019.
  6. Takeuchi T, Miyasaka N, Pedersen R, Sugiyama N, and Hirose T. Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis. Mod Rheum. online March 29, 2019.
  7. Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, and Tanaka Y. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phase 2 and 3 trials. Mod Rheum. online February 20, 2019.
  8. Taylor P, Weinblatt M, Burmester G, Rooney T, Witt S, Walls C, Issa M, Salinas C, Saifan C, Zhang X, Cardoso A, Gonxalez-Gay M, Takeuchi T. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis & Rheumatology. online January 21, 2019.
  9. Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyoizumi S, DeMasi R, Fukuma Y, Hirose T, Sugiyama N, Zwillich SH, and Tanaka Y. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post-hoc analysis of clinical trial data. Mod Rheum. online January 11, 2019.
  10. Takanashi S, Nishina N, Nakazawa M, Kaneko Y, and Takeuchi T. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology (Oxford). online January 8, 2019.
  11. Takanashi S, Kaneko Y, and Takeuchi T. Effectiveness of tacrolimus on IgG4-related disease. Mod Rheum. online January 3, 2019.
  12. Ishiguro N, Tanaka Y, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D, and Takeuchi T. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology (Oxford). online January 2, 2019.
  13. Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B, and for the NEXUS study group. Efficacy and safety of namilumab, a human monoclonal antibody against granulocytemacrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Research and Therapy. 21:101, 2019.
  14. Kimura N, Suzuki K, and Takeuchi T. Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab. Inflammation and regeneration. 39:5, 2019.
  15. Tanaka Y, Takeuchi T, Harigai M, Yamanaka H, Nakano T, Akagi K, Ukyo Y, and Hsu B. Efficacy and safety of sirkumab Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor: subgroup analysis for a randomized, double-blind, multi-center, phase 3 study (SIRROUND-T). Mod Rheum. 29:306-13, 2019.
  16. Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo S-F, Wu Y-J J, Li Z, An Y, Lateef A, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O7Neill S, Goldblatt F, Hao Y, Zhang Z, Al-Saleh J, Khamashta M, Takeuchi T, Tanala Y, Bae S-C, Lau CS, Hoi A, Nikpour M, and Morand EF. Development of the asia pacific lupus collaboration cohort. Int J Rheum Dis. 22:425-33, 2019.
  17. Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Camp JR, Cardillo TE, Ishii T, and Winthrop KL. Safety of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheum. 46:7-18, 2019.
  18. Inamo J, Kaneko Y, Sakata K, and Takeuchi T. Impact of subclinical synovitis in ankles and feet detected by ultrasonography in patients with rheumatoid arthritis. Int J Rheum Dis. 22:62-7, 2019.
  19. Kondo Y, Suzuki K, Inoue Y, Sakata K, Takahashi C, Takeshita M, Kassai Y, Miyazaki T, Morita R, Niki Y, Kaneko Y, Yasuoka H, Yamaoka K, Yoshimura A, and Takeuchi T. Significant association between joint ultrasonographic parameters and synobial inflammatory factors in rheumatoid arthritis. Arthritis Research and Therapy. 21:14, 2019.
  20. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney T, and Smolen JS. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: Results of a prospective study. Ann Rheum Dis. 78:171-8, 2019.
  21. Takeuchi T, Smolen J, Choy EH, Aletaha D, McInnes I, and Jones SA. Considering new lessons about the use of IL-6 inhibitors in arthritis. Considerations in Medicine. 2:7-11, 2018.
  22. Tsukamoto M, Suzuki K, and Takeuchi T. Ten-year observation of patients with primary Sjögren’s syndrome: initial presenting characteristics and the associated outcomes. Int J Rheum Dis. online December 26, 2018.
  23. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Yoshizawa Y, Chinen I, Nakao T, and Koike T. Safety and effectiveness of abatacept in Japanese non-elderly and elderly patiernts with rheumatoid arthritis in an all-cases post-marketing surveillance. Mod Rheum. online October 25, 2018.
  24. Matsubara T, Inoue H, Nakajima T, Tanimura K, Sagawa A, Sato Y, Osano K, Nagano S, Ueki Y, Hanyu T, Hashizume K, Amano N, Tanaka Y, and Takeuchi T. Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. RMD open. 4:e000813, 2018.
  25. Tsukamoto M, Suzuki K, and Takeuchi T. Tsukamoto M, Suzuki K, and Takeuchi T. Initial presenting determines clinical entity in patients with anti-centromere antibody positivity. Int J Rheum Dis. online November 14, 2018.
  26. Thorne C, Takeuchi T, Karpouzas G, Sheng S, Fei K, and Hsu B. Investigating sirkumab for
    rheumatpid arthritis: 2-year results from the phase 3 SIRROUND-D study. RMD open. 4:e000731, 2018.
  27. Tsukamoto M, Suzuki K, and Takeuchi T. Clinical and immunological features of anti-centromere antibody-positive sjogren’s syndrome. Rheumatol Ther. 5:499-505, 2018.
  28. Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, and Takeuchi T. A randomised, double-blind, placebo-controlled phase III trial of tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment. Ann Rheum 1720-9, 2018.
  29. Tasaki S, Suzuki K, Kasai Y, Takeshita M, Murota A, Kondo Y, Ando T, Nakayama Y, Okuzono Y, Takiguchi M, Kurisu R, Miyazaki T, Yoshimoto K, Yasuoka H, Yamaoka K, Morita R, Yoshimura A, Toyoshiba H, and Takeuchi T. Multi-omics monitoring of drug response in rheumatoid arthritis: In pursuit of molecular remission. Nature communications. 9:2755, 2018.
  30. Akiyama M, Yasuoka H, Yoshimoto K, and Takeuchi T. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. Ann Rheum Dis. 77:1386-7, 2018.
  31. Akiyama M, Yasuoka H, Yoshimoto K, and Takeuchi T. Interleukin-4 contributes to the balance of subclasses toward IgG4 in IgG4 related disease. Cytokine. 110:416-9, 2018.
  32. Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka M, Yamanaka H, Yamamoto K, Takeuchi T, and the SURPRISE study group. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Ann Rheum Dis. 77:1268-75, 2018.
  33. Sasaki T, Akiyama M, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, and Takeuchi T. Risk factors of relapse following glucocorticoid tapering in IgG4-related diseases. Clin Exp Rheum. 36:S186-9, 2018.
  34. Inamo J, Kaneko Y, and Takeuchi T. Inflammatory tendosynovitis and enthesitis induced by immune checkpoint inhibitors. Clin Rheum. 27:1107-10, 2018.
  35. Takeuchi T, Tanaka Y, Yamanaka H, Harigai M, Nakano T, Akagi K, Ukyo Y, and Hsu B. Efficacy and safety of sirkumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. Mod Rheum. 28:941-9, 2018.
  36. Sumida T, Azuma N, Moriyama M, Takahashi, H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Takeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshihara T, Suzuki Y, Kawano M, Tomita M, and Tsuboi H. Clinical practice guideline for Sjogren’s syndrome 2017. Mod Rheum. 28:383-408, 2018.
  37. Murata O, Izumi K, Kaneko Y, Yasuoka H, Suzuki K, Matsubara S, Yamaoka K, and Takeuchi T. Microscopic polyangiitis diagnosed by muscle specimen: a case report and literature review. Mod Rheum Case Reports. 2:181-4, 2018.
  38. Kaneko Y, Takeuchi T, Cai Z, Sato M, Awakura K, Gaich C, Zhu B, Guo J, and Tanaka Y. Determinants of patient’s global assessment of disease activity and physician’s global assessment of disease activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. Mod Rheum. 28:96-8, 2018.
  39. Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Ukyo Y, Ishii Y, Yoshinari T, Baker D, and the GO-MONO study group. Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying anti-rheumatic drugs: Final results of the GO-MONO trial through week 120. Mod Rheum. 28:770-9, 2018.
  40. Dokoupllova E, Aleion J, Takeuchi T, Malavolta N, Wang Y, Rohrer S, and Richards N. Secukinumab after anti-TNF-α therapy; a phase 3 study in active rheumatoid arthritis. Scand J Rheum. 47:276-81, 2018.
  41. Tsukamoto M, Suzuki K, Seta N, and Takeuchi T. Increased circulating CD14brightCD16+ intermediate monocytes are regulated by TNF-α and IL-6 axis in accordance with disease activity in patients with rheumatoid arthritis. Clin Exp Rheum. 36:540-4, 2018.
  42. Matsumoto K, Akiyama M, Kajio N, Otomo K, Suzuki K, Nishina N< Kasuya K, Oishi N, Kameyama K, and Takeuchi T. Adolescent PR3-ANCA positibe hyper trophic pachymeningitis. Medicine (Baltimore). 97:17 (e0521), 2018.
  43. Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovsky J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, and Yamamoto K. Splicing variant of WDFY4 auguments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 77:602-11, 2018.
  44. Akiyama M and Takeuchi T. IgG4-related disease: Beyond glucocorticoids. Drugs and Aging. 35:275-87, 2018.
  45. Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T, Mori T, Okamoto S, Amano K, Tokuhira M, and Takeuchi T. Restoration of decreased T helper 1 CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Frontiers Immunol. 9:621, 2018.
  46. Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Hsu B, and Tanaka Y. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: A randomized phase 3 safety and efficacy study in Japanese patients. Arthritis Research and Therapy. 20:42, 2018.
  47. Tokuhira M, Saitoh S, Okuyama A, Suzuki K, Higashi M, Momose S, Shimizu T, Mori T, Anan-Nemoto M, Amano K, Okamoto S, Takeuchi T, Tamaru J, and Kizaki M. Clinicopathologic investing of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leukemia and Lymphoma. 59:1143-52, 2018.
  48. Nakazawa M, Kaneko Y, and Takeuchi T. Risk factors for the recurrence of interstitial lung disease in patientswith polymyositis and dermatomyositis: a retrospective cohort study. Clin Rheum. 35:765-71, 2018.
  49. Ishioka-Takei E, Yoshimoto K, Suzuki K, Nishikawa A, Yasuoka H, Yamaoka K, and Takeuchi T. Increased proportion of a CD38highIgD+ B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sjogren’s syndrome. Clin Immunol. 187:85-91, 2018.
  50. Akiyama M, Suzuki K, Yasuoka H, Kaneko Y, Yamaoka K, and Takeuchi T. Follicular helper T cells in the pathogensis of IgG4-related disease. Rheumatology (Oxford). 57:236-45, 2018.
  51. Takeuchi T, Okada K, Yoshida H and Yagi N. Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-year results. Mod Rheum. 28:85-94, 2018.
  52. Takeuchi T. Biomarkers as a treatment guide in rheumatoid arthritis. Clin Immunol.186:59-62, 2018.
  53. Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, Kawakubo M, Kitahara Y, Hojo S, Kawano T, and Imai T. Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-inpatient phase 1/2 study on rheumatoid arthritis. Mod Rheum. 28:58-65, 2018.
  54. Takeuchi T, Ishida K, Shiraki K, and Yoshiyasu T. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease modifying drugs (DMARDs): post-marketing surveillance in Japan. Mod Rheum. 28:48-57, 2018.
  55. Tanaka Y, Yamazaki K, Nakajima R, Komatsu S, Igarashi A, Tango T, Takeuchi T. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. Mod Rheum. 28:39-47, 2018.
  56. Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, and Takeuchi T. RANKL: atherapeutic target in bone destruction in Rheumatoid Arthritis. Mod Rheum. 28:9-16, 2018.
  57. Akiyama M, Sasaki T, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, and Takeuchi T. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity in IgG4-related disease and primary Sjogren’s syndrome. Clin Exp Rheum. 36:S157-64, 2018.
  58. Tanaka Y, Atsumi T, Amano K, Harigai M, Ishii T, Kawaguchi O, Rooney TP, Akashi N, and Takeuchi T. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analysis of four multinational phase 3 randomized trials. Mod Rheum. 28:583-91, 2018.
  59. Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Funakubo-Asanuma Y, Gorita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, and Sumida T. Evaluation of the alternative classification criteria of systemic lupus erythematosus established by systemic lupus international collaborating clinics (SLICC). Mod Rheum. 28:642-8, 2018.
  60. Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, and Kuwana M. Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circulation Journal. 82:546-54, 2018.
  61. Tokuhira M, Saito S, Okuyama A, Suzuki K, Higashi M, Momose S, Shimizu T, Mori T, Anan-Nemoto T, Amano K, Okamoto S, Takeuchi T, Tamaru JI, Kizaki M. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018 May;59(5):1143-1152.
  62. Murata O, Izumi K, Kaneko Y, Yasuoka H, Suzuki K, Matsubara S, Yamaoka K, Takeuchi T Microscopic polyangiitis diagnosed by muscle specimen: a case report and literature review, Modern Rheumatology Case Reports, 2018, 2:2, 181-184
  63. Nakazawa M, Suzuki K, Yasuoka H, Yamaoka K, Takeuchi T. Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies.Inflamm Regen. 19;38:20,2018
  64. Tanaka Y, Kameda H, Saito K, Kaneko Y, Tanaka E, Yasuda S, Tamura N, Fujio K, Fujii T, Kojima T, Anzai T, Hamada C, Fujino Y, Matsuda S, Kohsaka H. Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. Arthritis Res Ther. 20(1):151,2018.
  65. Guelfucci F, Kaneko Y, Mahlich J, Sruamsiri R. Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data. Rheumatol Ther. 5(1):171-183,2018.
  66. Ishida M, Kuroiwa Y, Yoshida E, Sato M, Krupa D, Henry N, Ikeda K, Kaneko Y. Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Mod Rheumatol. 28(5):789-799,2018.
  67. Otomo K, Maeda K, Yoshida N, Abu-Asab MS, Ichinose K, Nishino T, Kono M, Ferretti A, Bhargava R, Maruyama S, Bickerton S, Fahmy TM, Tsokos MG, Tsokos GC. CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. J Clin Invest. 128(8): 3445-3459, 2018.
  68. Takanashi S, Akiyama M, Suzuki K, Otomo K, Takeuchi T. IgG4-related fibrosing mediastinitis diagnosed with computed tomography-guided percutaneous needle biopsy: Two case reports and a review of the literature. Medicine (Baltimore). 97(22): e10935, 2018.
  69. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV. Arthritis Res Ther. 20: pp.86, 2018.
  70. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Takahiro Okazaki, Hidehiro Yamada, Shoichi Ozaki, Kawahata K. Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without the antiphospholipid syndrome. PLoS ONE. 13: pp. e0196172, 2018.
  71. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. A positive direct Coombs’ test in the absence of hemolytic anemia predicts high disease activity and poor renal response in systemic lupus erythematosus. Lupus. 27:pp. 2274-8, 2018.
  72. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clin Rheumatol. 38:pp. 585-90, 2019.
  73. Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor. Int J Rheum Dis. 22: pp. 468-72, 2019.
  74. Takakuwa Y, Hanaoka H, Kiyokawa T, Iida H, Fujimoto H, Yamasaki Y, Yamada H, Kawahata K. Low-dose rituximab as induction therapy for ANCA-associated vasculitis. Clin Rheumatol. 38; pp. 1217-23, 2019.
  75. Hayakawa M, Izumi K, Higashida-Konishi M, Ushikubo M, Tsukamoto M, Akiya K, Araki K, Oshima H. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. Rheumatol Int. 39(1):161-166, 2019.
  76. Kikuchi J, Kondo T, Shibata A, Sakai R, Okada Y, Chino K, Okuyama A, Kurasawa T, Takei H, Amano K. Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. Mod Rheumatol. 28: 444-451, 2018.
  77. Akiyama M. The call for considering follicular helper T cells in IgG4-related disease. J Allergy Clin Immunol. 2018;141:1958.
  78. Tamai H, Nishina N, Takeuchi T. Pulmonary Vein Vasculitis Presenting as Multiple Pulmonary Nodules in a Patient with Systemic Lupus Erythematosus. J Rheumatol. 46: pp.323-324, 2019.
  79. Watanuki S, Kikuchi T, Toyama T, Abe R, Nakayama H, Karigane D, Shimizu T, Kikuchi J, Matsumoto K, Yasuoka H, Kataoka M, Okamoto S, Mori T. Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment. Rinsho Ketsueki. 59(2):174-177,2018.
  80. Takanashi S, Nakazato T, Aisa Y, Ito C, Arakaki H, Osada Y, Hirano M, Mori T.The  prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.Ann Hematol. 97(9):1611-1618,2018.
  81. Nakazato T, Takanashi S, Hirano M, Ito C, Fujita Y, Osada Y, Aisa Y, Mori T. Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma. Ann Hematol. 97(8):1489-1491,2018.
  82. Ishigaki, S., Kuwae, M., Ishii, M., Asakura, T., Ueda, S., & Betsuyaku, T.:Black pleural effusion caused by pancreatic pseudocyst rupture. Clinical case reports. 7(2), 385. 2019.
  83. Ishigaki, S., Masaoka, T., Kameyama, H., Kawaida, M., Kameyama, K., Mori, T., & Kanai, T: Methotrexate-associated Lymphoproliferative Disorder of the Stomach Presumed to Be Mucosa-associated Lymphoid Tissue Lymphoma. Internal Medicine. 57(22), 3249-3254. 2018.
  84. Matsumoto K, Kaneko Y, Takeuchi T. Tendonitis on fingers in Behçet’s disease. Internal Medicine. 0650−17, 2018.
2017年
  1. Takeuchi T, Ishida K, Shiraki K, and Yoshiyasu T. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease modifying drugs (DMARDs): post-marketing surveillance in Japan. Mod Rheumatol. 28(1):pp.48-57, 2018.
  2. Takeuchi T, Miyasaka N, Inui T, Yano T, Yoshinari T, Abe T, and koike T. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in RA patients are associated with increased circulating TNF level, low drug levels, and reduced clinical response: a post-hoc analysis of the RISING study. Arthritis Res Ther. 19(1):pp.194, 2017.
  3. Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, Igarashi A, Tango T, Tanaka Y.Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. Adv Therapy. 34(3):pp.686-702, 2017.
  4. Takeuchi T, Okada K, Yoshida H and Yagi N. Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-year results. Mod Rheumatol. 28(1):pp.85-94, 2018.
  5. Takeuchi T, Thorme JC, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, and Tak P. Sirukumab for rheumatoid arthritis: the phase III, SIRROUND-D study. Ann Rheum Dis. 76(12):pp.2001-2008, 2017.
  6. Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Hsu B, and Tanaka Y. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: A randomized phase 3 safety and efficacy study in Japanese patients. Arthritis Res Ther. 20(1):pp.42, 2018.
  7. Takeuchi T. Biomarkers as a treatment guide in rheumatoid arthritis. Clin Immunol. 186:pp.59-62, 2018.
  8. Takeuchi T. Treatment of rheumatoid arthritis with biological agents – as a typical and common immune-mediated inflammatory disease. Proc Jpn Acad Ser B Phys Biol Sci. 93(8):pp.600-608, 2017.
  9. Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M. Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J. 82(2):pp.546-554, 2018.
  10. Kaneko Y, Takeuchi T, Cai Z, Sato M, Awakura K, Gaich C, Zhu B, Guo J, Tanaka Y. Determinants of Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. Mod Rheumatol. doi: 10.1080, 2018.
  11. Kaneko Y, Takeuchi T. Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis. Int Immunol. 29(11):pp.511-517, 2017.
  12. Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, Yamaoka K, and Takeuchi T. The association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD open. 3:e000363, 2017.
  13. Ishioka-Takei E, Yoshimoto K, Suzuki K, Nishikawa A, Yasuoka H, Yamaoka K, Takeuchi T. Increased proportion of a CD38highIgD+ B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sjögren’s syndrome. Clin Immunol. 187:pp.85-91, 2018.
  14. Kondo Y, Kaneko Y, Sugiura H, Matsumoto S, Nishina S, Jinzaki M, and Takeuchi T. Pre-treatment Interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging in rheumatoid arthritis patients. Rheumatology (Oxford). 56(7):pp.1089-1094, 2017.
  15. Saito S, Kaneko Y, Izumi K, Takeuchi T. Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. J Rheumatol. 44(5):pp.553-557, 2017.
  16. Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Tokuhira M, and Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford). 56(6):pp.940-6, 2017.
  17. Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Matsumoto Y, Yamaoka K, and Takeuchi T. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in rheumatoid arthritis patients. Arthritis Res Ther. 19(1):pp.231, 2017.
  18. Akiyama M, Kaneko Y, Takeuchi T. Comparison of the Clinical Characteristics of Pneumocystis Pneumonia between Patients with Rheumatoid Arthritis Being Treated with Biologics and Those Being Treated without Biologics. Biomed Res Int. 3710652, 2017.
  19. Akiyama M, Suzuki K, Yasuoka H, Kaneko Y, Yamaoka K, Takeuchi T. Follicular helper T cells in the pathogenesis of IgG4-related disease. Rheumatology (Oxford). 57(2):pp.236-245, 2018.
  20. Akiyama M, Yasuoka H, Takeuchi T. Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term tocilizumab. Ann Hematol. 96(12):pp.2117-2119, 2017.
  21. Hasegawa T, Kaneko Y, Izumi K, and Takeuchi T. Efficacy of denosumab combined with biologic agents on radiographic progression in rheumatoid arthritis. Joint Bone and Spine. 84(3):pp.379-380, 2017.
  22. Hasegawa T, Suzuki K, Kaneko Y, and Takeuchi T. Proteinuria selectivity index as a prognostic biomarker in lupus nephritis. Lupus. 26(6):pp.656-660, 2017.
  23. Sasaki T, Akiyama M, Kaneko Y, Mori T, Yasuoka H, Suzuki K, Yamaoka K, Okamoto S, and Takeuchi T. Distinct features of distinguishing-related IgG4 related disease from multicentric Castleman’s disease. RMD open. 3(1):e000432, 2017.
  24. Nakazawa M, Kaneko Y, and Takeuchi T. Risk factors for the recurrence of interstitial lung disease in patientswith polymyositis and dermatomyositis: a retrospective cohort study. Clin Rheumatol. 37(3):pp.765-771, 2018.
  25. Matsumoto K, Akiyama M, Kajio N, Otomo K, Suzuki K, Nishina N, Kasuya K, Oishi N, Kameyama K, Takeuchi T. Adolescent PR3-ANCA-positive hypertrophic pachymeningitis: A case report and review of the literature. Medicine (Baltimore). 97(17):e0521, 2018.
  26. Matsumoto K, Kikuchi J, Kaneko Y, Yasuoka H, Suzuki K, Tokuyama H, Kameyama K, Yamaoka K, Takeuchi T. Persistent fever and destructive arthritis caused by dialysis-related amyloidosis: a case report. Medicine (Baltimore). 97(1):e9359, 2018.
  27. Anan R, Akiyama M, Kaneko Y, Kikuchi J, Suzuki K, Matsubara S, Takeuchi T. Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: A case report and literature review. Medicine (Baltimore). 96(48):e8710, 2017.
  28. Takanashi S, Aisa Y, Ito C, Arakaki H, Osada Y, Amano Y, Hirano M, Nakazato T. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. Rheumatol Int. 37(10):pp.1629-1633, 2017.
  29. Kojima M, Nakayama T, Otani T, Hasegawa M, Kawahito Y, Kaneko Y, Kishimoto M, Hirata S, Seto Y, Endo H, Ito H, Kojima T, Nishida K, Matsushita I, Tsutani K, Igarashi A, Kamatani N, Miyasaka N, Yamanaka H. Integrating patients’ perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan. Mod Rheumatol. 27(6):pp.924-929, 2017.
  30. Aomori T, Tsuchiya A, Suzuki S, Jibiki A, Otsuka N, Ishioka E, Kaneko Y, Takeuchi T, Nakamura T: Suppression of antibody to infliximab by azathioprine in a patient with rheumatoid arthritis. Die Pharmazie. 72(2):pp.95-97, 2017.
  31. Asakura T, Arai D, Ishii M, Takei H, Sugiura H, Takeuchi T, Betsuyaku T. Pulmonary cryptococcosis developed from a nodule after treatment with infliximab for arthritis associated with ulcerative colitis. Annals of the American Thoracic Society. 14(4):pp.603-5, 2017.
  32. Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, and Koike T. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis. 76(8):pp.1348-56, 2017.
  33. Burmester G, Kaeley GS, Kavanaugh A, Gabay C, MacCarter D, Nash P, Takeuchi T, Goss S, Rodila R, Chen K, Kupper H, and Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD open. 3(2):e000465, 2017.
  34. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, A.F. Zerbini C, Gurbuz S, Dickson C, De Bono S, Schlichting D, Beattie S, Kuo W-L, Rooney T, Macias W, and Takeuchi T. Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Anti-rheumatic Drug Treatment. Arthritis and Rheum. 69(3):pp.506-17, 2017.
  35. Furuta S, Sugiyama T, Umibe T, Kaneko Y, Amano K, Kurasawa K, Nakagomi D, Hiraguri M, Hanaoka H, Sato Y, Ikeda K, Nakajima H; LoVAS Trial study investigators. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial. BMJ Open. 7(12):e018748, 2017.
  36. Fusama M, Nakahara H, van Eijk-Hustings Y, Oliver S, and Takeuchi T. Survey on attitudes regarding EULAR recommendations for the role of nurses involved in medical care of patients with chronic inflammatory arthritis in Japan. Mod Rheumatol. 27(5):pp.886-893, 2017.
  37. Hirano F, Yokoyama W, Yamazaki H, Amano K, Kawakami A, Hayashi T, Tamura N, Yasuda S, Dobashi H, Fujii T, Ito S, Kaneko Y, Matsui T, Okuda Y, Saito K, Suzuki F, Yoshimi R, Sakai R, Koike R, Kohsaka H, Miyasaka N, Harigai M; T2T Epidemiological Study Group. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. Mod Rheumatol. 27(5):pp.811-819, 2017.
  38. Ishiguro N, Atsumi, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Sakasone A, Takagi N, and Yamanaka H. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Mod Rheumatol. 27(2):pp.217-226, 2017.
  39. Ishizaki J, Takemori A, Suemori K, Matsumoto T, Akita Y, Sada K-E, Yuzawa Y, Amano K, Takasaki Y, Harigai M, Arimura Y, Makino H, Yasukawa M, Takemori N, Hasegawa H, Murakawa Y, Muso E, Komatsuda A, Ito S, Fujii T, Kawakami A, Nakaya I, Saito T, Ito T, Hirawa N, Yamamura M, Nakano M, Nitta K, Ogura M, Naniwa T, Ozaki S, Hirahashi J, Ogawa N, Hosoya T, Wada T, Horikoshi S, Kawaguchi Y, Hayashi T, Yoshida M, Watanabe T, Inaguma D, Tsuruya K, Homma N, Takeuchi T, Nakagawa N, Takeda S, Katabuchi R, Iwano M, Atsumi T, Fujimoto S, Banno S, Sugihara T, Kobayashi M, Yamagata K, Homma S, Dobashi H, Tsuboi N, Ishizu A, Sugiyama H. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther. 19(1):pp.218, 2017.
  40. Kim D, Kaneko Y, and Takeuchi T. Importance of obtaining remission for work productivity and activity of patients with rheumatoid arthritis. J Rheumatol. 44(8):pp.1112-7, 2017.
  41. Kubo S, Yamaoka K, Amano K, Nagano S, Tohma S, Suematsu E, Nagasawa H, Iwata K, Tanaka Y. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a prospective, multicenter, observational study. Rheumatology (Oxford). 56(8):pp.1293-1301, 2017.
  42. Miyagawa I, Nakayamada S, Nakano K, Yamagata K, Sakata K, Yamaoka K, Tanaka Y. Induction of regulatory T cells and its regulation with insulin-like growth factor/insulin-like growth factor binding protein-4 by human mesenchymal stem cells. J Immunol. 199(5):pp.1616-1625, 2017.
  43. Oba K, Horie N, Sato N, Saito K, Takeuchi T, Mimori T, Miyasaka N, Koike T, Tanaka Y. Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemp Clin Trials Commun. 8:pp.49-54, 2017.
  44. Osada Y, Arakaki H, Takanashi S, Ito C, Aisa Y, Nakazato T. Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients. Med Oncol. 34(4):pp.66, 2017
  45. Sakamoto Y, Yamamoto T, Sugano N, Takahashi D, Watanabe T, Atsumi T, Nakamura J, Hasegawa Y, Akashi K, Narita I, Miyamoto T, Takeuchi T, Ikari K, Amano K, Fujie A, Kubo T, Tada Y, Kaneuji A, Nakamura H, Miyamura T, Kabata T, Yamaji K, Okawa T, Sudo A, Ohzono K, Tanaka Y, Yasunaga Y, Matsuda S, Imai Y, Nakashima Y, Motomura G, Ikemura S, Yamaguchi R, Karasuyama K, Sonoda K, Nishii T, Sakai T, Takao M, Irie T, Asano T, Iwasaki N, Atsumi T, Tamaoki S, Nakanishi R, Tanabe S, Kishida S, Hagiwara S, Seki T, Tsukamoto H, Niiro H, Arinobu Y, Akahoshi M, Mitoma H, Ayano M, Kuroda T, Toyama Y, Funayama A, Hanaoka H, Yamaoka K, Kawaguchi Y, Yamanaka H, Hosozawa T, Momohara S, Chino K, Fujioka M, Ueshima K, Ishida M, Saito M, Hayashi S, Ikegami A, Ichiseki T, Mizokawa S, Ohta Y, Kajino Y, Sekiya F, Higuchi F, Hasegawa M, Miyamoto N, Miyazaki S, Yamaguchi T, Ando W, Saito K, Nakano K, Kuroda Y, Yamasaki T, Akiyama M, Kubo M, Kamatani Y, Iwamoto Y, Ikegawa S. Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. Sci Rep. 7(1):15035, 2017.
  46. Schiff M, Takeuchi T, Fleischmann R, Gaich C, DeLozier A, Schlichting D, Kuo W-L, Won J-E, Carmack T, Rooney T, Durez P, Shaikh S, Hidalgo RP, van Vollenhoven R, and Zerbini C. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther. 19(1):pp.208, 2017.
  47. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg J-E, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette Z, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, and van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 76(6):pp.960-977, 2017.
  48. Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, and Marshall L. Immnogenecity of biologics in chronic inflammatory diseases: A systemic review. BioDrugs. 31(4):pp.299-316, 2017.
  49. Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Takeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshihara T, Suzuki Y, Kawano M, Tomiita M, Tsuboi H. Clinical practice guideline for Sjögren’s syndrome 2017. Mod Rheumatol. 28(3):pp.383-408, 2018.
  50. Tahir H, Deodhar A, Genovese M, Takeuchi T, Aelion J, van den Bosch F, Haemmerie S, and Richards HB. Secukinumab in active rheumatoid arthritis after anti-TNFα therapy: A randomized, double-blind placebo-controlled phase 3 study. Rheumatol Ther. 4(2):pp.475-88, 2017.
  51. Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, and Takeuchi T. RANKL: atherapeutic target in bone destruction in Rheumatoid Arthritis. Mod Rheum. 28(1):pp.9-16, 2018.
  52. Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, Kawakubo M, Kitahara Y, Hojo S, Kawano T, and Imai T. Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-inpatient phase 1/2 study on rheumatoid arthritis. Mod Rheumatol. 28(1):pp.58-65, 2018.
  53. Tanaka Y, Takeuchi T, Akashi N, Takita Y, Kariyasu S, Kovacs B. Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. Mod Rheumatol. 27(2):pp.284-291, 2017.
  54. Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Kimura J, Agata N, and Takeuchi T. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Research and Therapy. 19(1):pp.56, 2017.
  55. Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, Lee SJ, and Nambu Y. Efficacy and safety of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 27(2):pp.237-245, 2017.
  56. Tanaka Y, Yamazaki K, Nakajima R, Komatsu S, Igarashi A, Tango T, Takeuchi T. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. Mod Rheumatol. 28(1):pp.39-47, 2018.
  57. Tasaki S, Suzuki K, Nishikawa A, Kassai Y, Takiguchi M, Kurisu R, Okuzono Y, Miyazaki T, Takeshita M, Yoshimoto K, Yasuoka H, Yamaoka K, Ikeura K, Tsunoda K, Morita R, Yoshimura A, Toyoshiba H, and Takeuchi T. Multi-omic disease signatures converge to cytotoxic CD8 T-cells in primary Sjögren’s syndrome. Ann Rheum Dis. 76(8):pp.1458-1466, 2017.
  58. Tokuhira M, Saito S, Okuyama A, Suzuki K, Higashi M, Momose S, Shimizu T, Mori T, Anan-Nemoto T, Amano K, Okamoto S, Takeuchi T, Tamaru JI, Kizaki M. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 59(5):pp.1143-1152, 2018.
  59. Tsuchiya A, Aomori T, Sakamoto M, Suzuki S, Jibiki A, Otsuka N, Ishioka E, Kaneko Y, Takeuchi T, Nakamura T: Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment. Pharmazie. 72(1):pp.22-28, 2017.
  60. Tsuboi H, Hagiwara S, Asashima H, Tahahashi H, Hirota T, Noma H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Nirata S, Mimori T, Matsumoto I, and Sumida T. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjogren’s syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis. 76(12):pp.1980-5, 2017.
  61. Tsukamoto M, Kameda H, Oshige T, Kaneko Y, Yoshimoto K, Suzuki K, and Takeuchi T. Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 27(5):pp.778-81, 2017.
  62. Tsukamoto M, Seta N, Yoshimoto K, Suzuki K, Yamaoka K, and Takeuchi T. CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther. 19(1):pp.28, 2017.
  63. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H, Chen C, Bananis E. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol. 69(10):pp.1960–1968, 2017.
  64. Yamazaki H, Hirano F, Takeuchi T, Amano K, Kikuchi J, Kihara M, Yokoyama W, Sugihara Y, Nagasaka K, Hagiyama H, Nonomura Y, Sakai R, Tanaka M, Koike R, Nanki T, Kohsaka H, Miyasaka N, and Harigai M. Simplified disease activity index remission at 6 month is an independent predictor of functional and structural remission at 12 months during abatacept treatment in patients with rheumatoid arthritis: prospective cohort study in Japan. Mod Rheumatol. 27(5):pp.787-794, 2017.
2016年
  1. Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, Takeuchi T. Polychondritis presenting with oculomotor and abducens nerve palsies as the initial manifestation. Mod Rheumatol. 26(5):pp.790-3, 2016.
  2. Akiyama M, Kaneko Y, Hayashi Y, Takeuchi T. IgG4-related disease involving vital organs diagnosed with lip biopsy: A case report and literature review. Medicine (Baltimore). 95(24):e3970, 2016.
  3. Akiyama M, Kaneko Y, Kondo H, Takeuchi T. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol. 35(11):pp.2829-2834, 2016.
  4. Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of Disease Activity with Acute Exacerbation of Interstitial Lung Disease during Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A retrospective, case control study. Rheumatol Int. 36(6):pp.881-9, 2016.
  5. Akiyama M, Suzuki K, Kassai Y, Miyazaki T, Morita R, Yoshimura A, Takeuchi T. Resolution of elevated circulating regulatory T cells by corticosteroids in patients with IgG4-related dacryoadenitis and sialoadenitis. Int J Rheum Dis. 19(4):pp.430-2, 2016.
  6. Akiyama M, Yasuoka H, Yamaoka K, Suzuki K, Kaneko Y, Kondo H, Kasai Y, Koga K, Miyazaki T, Morita R, Yoshimura A, and Takeuchi T. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. Arthritis Research and Therapy. 18:pp.167, 2016.
  7. Aomori T, Tsuchiya A, Suzuki S, Jibiki A, Otsuka N, Ishioka E, Kaneko Y, Takeuchi T, Nakamura T: Suppression of antibody to infliximab by azathioprine in a patient with rheumatoid arthritis. Die Pharmazie. Die Pharmazie. 72:pp.95-97, 2017.
  8. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, and Koike T. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 75:pp.75-83, 2016.
  9. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, A.F. Zerbini C, Gurbuz S, Dickson C, De Bono S, Schlichting D, Beattie S, Kuo W-L, Rooney T, Macias W, and Takeuchi T. Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Anti-rheumatic Drug Treatment. Arthritis Rheumatol. 69(3):pp.506-517, 2017.
  10. Hanaoka H, Kaneko Y, Suzuki S, Takada T, Hirakata M, Takeuchi T, and Kuwana M. Anti-signal recognition particle antibody in patients without inflammatory myopathy: a survey of 6180 patients with connective tissue diseases. Scan J Rheum. 45:pp.36-40, 2016.
  11. Hanaoka H, Kaneko Y, Suzuki S, Takada T, Hirakata M, Takeuchi T, Kuwana M. A unique case of polymyositis with anti-signal recognition particle antibody complicated by subacute interstitial lung disease and subluxing arthropathy, resembling anti-synthetase syndrome. Mod Rheumatol. 26(6):pp.979-980, 2016.
  12. Hanaoka H, Ota Y, Takeuchi T, and Kuwana M. Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis. Clin Rheum. 35:pp.495-500, 2016.
  13. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, and Koike T. Post marketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheum. 26:pp.491-8, 2016.
  14. Hasegawa T, Kaneko Y, Izumi K, Takeuchi T. Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. Jiont Bone Spine. 84(3):379-380, 2017.
  15. Hasegawa T, Suzuki K, Kaneko Y, Takeuchi T. Proteinuria selectivity index as a prognostic biomarker in lupus nephritis. Lupus. 26(6):pp.656-660, 2017.
  16. Hayashi S, Suzuki K, Yoshimoto K, Takeshita M, Kurasawa T, Yamaoka K. Takeuchi T. Early prognostic factors associated with efficacy of infliximab treatment for rheumatoid arthritis patients with inadequate response to methotrexate. Rheumatol Ther. 3(1):pp.155-166, 2016.
  17. Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K. Defranoux N. Tanaka Y. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Mod Rheumatol. 30:pp.1-7, 2016.
  18. Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, and Yamanaka H. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study. Mod Rheum. 27(2):pp.217-226. 2017.
  19. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, and Takeuchi T. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 75:pp.1917-23, 2016.
  20. Kikuchi J, Kaneko Y, Kasahara H, Emoto K, Kubo A, Okamoto S, Takeuchi T. Methotrexate-associated Intravascular large B-cell lymphoma in a patient with rheumatoid arthritis. Intern Med. 55(12):pp.1661-5, 2016.
  21. Kimura N, Suzuki K, Takeuchi T.Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients. Mod Rheumatol. 26:pp.676-80, 2016.
  22. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Takahashi Y, Mimori T, Hiramatsu K, Komatsu S, and Tanaka Y. Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post-Hoc Analysis of Japanese Patients (MELODY Study). Rheumatol Ther. 3:pp.129-141, 2016.
  23. Kuwana M, Shirai Y, and Takeuchi T. Elevated serum KL-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheum. online 2016.
  24. Lu Li, Yoshimoto K, Morita A, Kameda H, and Takeuchi T. Bendamustine increases IL-10 secretion from B cells via p38 MAP kinase activation. Int Immunopharm. 39:pp.273-9, 2016.
  25. Murota A, Kaneko Y, Yamaoka K, Takeuchi T. Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatology. 43(11):pp.1984-88, 2016.
  26. Murota A, Suzuki K, Kasai Y, Miyazaki T, Morita R, Kondo Y, Takeshita M, Niki Y, Yoshimura A, and Takeuchi T. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. Cytokine. 78:pp.87-93, 2016.
  27. Nishikawa A, Suzuki K, Kassai Y, Goto Y, Takiguchi M, Miyazaki T, Yoshimoto K, Yasuoka M, Yamaoka K, Morita R, Yoshimura A, Takeuchi T. Identification of Novel Serum Biomarkers associated with Disease Activity of Primary Sjögren’s Syndrome. Arthritis Res Ther. 18(1):pp.106, 2016.
  28. Saito S, Kaneko Y, Izumi K, Takeuchi T. Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. J Rheumatol. 44(5):pp.553-557, 2017.
  29. Sakai R, Kondo T, Kikuchi J, Shibata A, Chino K, Okuyama A, Takei H, Amano K. Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. Mod Rheumatol. 26:pp.900-907, 2016.
  30. Shihashi G, Kaneko Y, Suzuki S, Hanaoka H, Nakahara J, Takeuchi T, Suzuki N. Enlargement of thymoma triggers overlapping autoimmune diseases. Autoimmun Rev. 15(12):pp.1200-1201, 2016.
  31. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, and van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 75:pp.3-15, 2016.
  32. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg J-E, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette Z, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, and van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 76(6):pp.960-977, 2017.
  33. Sonomoto K, Yamaoka K, Kaneko H, Yamagata K, Sakata K, Zhang X, Kondo M, Zenke Y, Sabanai K, Nakayamada S, Sakai A, Tanaka Y. Spontaneous differentiation of human mesenchymal stem cells on poly-lactic-co-glycolic acid nano-fiber scaffold. PLoS One. 11(4):e0153231, 2016.
  34. Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, Yamaoka K, and Takeuchi T. The association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD open. 3(1):e000363, 2017.
  35. Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, Yamaoka K, Takeuchi T. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 3(1):e000363, 2017.
  36. Takei H, Hanaoka H, Kaneko Y, Yamaoka K, Sasaki A, Takeuchi T. Intriguing Findings of the Muscle on Magnetic Resonance Imaging in Polyarteritis Nodosa. Intern Med. 55:pp.3197-3200, 2016.
  37. Takeshita M, Kuno A, Suzuki K, Matsuda A, Shimazaki H, Nakagawa T, Otomo Y, Kabe Y, Suematsu M, Narimatsu H, and Takeuchi T. Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis. Arthritis Research and Therapy. 18:pp.112, 2016.
  38. Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, Igarashi A, Tango T, Tanaka Y.Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. Adv Therapy. 34:pp.686-702, 2017.
  39. Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, and van der Heijde. Effect of Denosumab on Japanese Patients with Rheumatoid Arthritis: A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate to Validate Inhibitory Effect on Bone Erosion (DRIVE). Ann Rheum Dis. 75:pp.983-90, 2016.
  40. Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, and Kaneko Y. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in moderate to severe rheumatoid arthritis patients in Japan: A 12-week, randomized, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 75:pp.1057-64, 2016.
  41. Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Cheng-Chung Wei J, Shao J, Togo O, and Mashimo H. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial. Mod Rheum. 26:pp.15-23, 2016.
  42. Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, tanaka Y, Eguchi K, Watabnabe A, Origasa H, Mobayashi M, Shoji T, Togo O, Miyasaka N, and Koike T. Post hoc analysis showing better clinical response of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Mod Rheum. 26:pp.473-80, 2016.
  43. Tanaka T, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Kimura J, Agata N, and Takeuchi T. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Research and Therapy. 19:pp.56, 2017.
  44. Tanaka Y, Takeuchi T, Akashi N, Takita Y, Kovacs B, and Kariyasu S. Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: subgroup analyses of the ILLUMINATE-1 study. Mod Rheum. 27(2):pp.284-291, 2017.
  45. Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, and Koike T. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematousus including lupus nephritis who are refractory to conventional therapy. Mod Rheum. 26:pp.80-86, 2016.
  46. Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Hiramatsu K, and Takeuchi T. Discontinuation of adalimumab in patients with early rheumatoid arthritis who are initially treated methotrexate alone or in combination with adalimumab: 1 year outcome of the HOPEFUL-2 study. RMD open. 2:e000186, 2016.
  47. Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, Lee SJ, and Nambu Y. Efficacy and safety of CT-P13 in Japanese patients with rheumatoid arthritisin an extension phase or after switching from infliximab. Mod Rheum. 27:pp.237-42, 2017.
  48. Thurmond R, Greenspan A, Radziszewsk W, Xu XL, Miao Y, Chen B, Ge TT, Zhou B, Baker DG, Pavlova D, Ritchlin C, Tanaka Y, Takeuchi T, and Smolen JS. Toreforant (JNJ-38518168), an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: results of two Phase 2 multicenter, randomized, double-blind, placebo-controlled parallel-group studies. J Rheum. 43(9):pp.1637-42, 2016.
  49. Tschiya A, Aomori T, Sakamoto M, Suzuki S, Jibiki A, Otsuka N, Ishioka E, Kaneko Y, Takeuchi T, Nakamura T: Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment. Die Pharmazie. 72:pp.22-28, 2017.
  50. Tsukamoto M, Seta N, Yoshimoto K, Suzuki K, Yamaoka K, and Takeuchi T. CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Research and Therapy. 19(1):pp.28, 2017.
  51. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, and Zwillich S. Tofacitinib, an oral JAK inhibitor, as monotherapy or background methotrexate in Japanese patients with rheumatoid arthritis: an open-label, long-tern extention study. Arthritis Care & Therapy. 18:pp.34, 2016.
  52. Yamaoka K, JAK inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 32:pp.29-33, 2016.
  53. Yamaoka K. Benefit-Risk Assessment of Tofacitinib in the Treatment of Rheumatoid Arthritis. Review Drug Safety. 39(9):pp.823-40, 2016.
  54. Zhao J, Kubo S, Nakayamada S, Shimajiri S, Zhang X, Yamaoka K, Tanaka Y. Association of Plasmacytoid Dendritic Cells with B Cell Infiltration in Minor Salivary Glands in Patients with Sjögren’s Syndrome. Mod Rheumatol. 26(5):pp.716-24, 2016.
  55. Tsukamoto M, Seta N, Yoshimoto K, Suzuki K, Yamaoka K, Takeuchi T.CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther. DOI: 10.1186/s13075-016-1216-6, 2017.>
2015年
  1. Yamanaka H, Ishiguro N, Tanaka Y, and Takeuchi T. Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. Mod Rheum. 25(1):pp.43-49, 2015.
  2. Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology. 54(4):pp.683-691, 2015.
  3. Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, and Kuwana M. Elevated pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol. 67(2):pp.498-507, 2015.
  4. Nishina N, Kaneko Y, Kameda H, and Takeuchi T. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: A retro-spective, single center study. Mod Rheumatol. 25(3):pp.401-4, 2015.
  5. Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, and Takeuchi T. Tocilizumab is clinically, functionally and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitrs. A single center retrospective cohort study (KEIO-TCZ study) at 52 week. Mod Rheumatol. 25(1):pp.31-37, 2015.
  6. Takeuchi T, Tanaka Y, Close D, Godwood A, Wu C-Y, and Saurigny D. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from phase IIa study. Mod Rheumatol. 25(1):pp.21-30, 2015.
  7. Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese study. Mod Rheumatol. 25(1):pp.11-20, 2015.
  8. Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, and Takeuchi T. Peripheral blood CD4+CD25+CD127low regulatory T  cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: Increase in regulatory T cells correlates with clinical response. Arthritis Res Ther.21;17:R10, 2015.
  9. Takeuchi T, Miyasaka N, Kawai S, Sugiyama N, Yuasa H, Yamashita N, Sugiyama N, Wagerle LC, Vlahos B, and Wajdula J. Pharmacokinetics, efficacy, safety profile of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials. Mod Rheumatol. 25(2):pp.173-186, 2015.
  10. Takeuchi T, Miyasaka M, Inui T, Yano T, Yoshinari T, Abe T, and Koike T. Prediction of clinical response after one year of infliximab therapy in rheumatoid arthritis based on disease activity at three months into therapy to tailor infliximab dose: post-hoc analysis of the RISING study. J Rheumatol. 42(4):pp.599-607, 2015.
  11. Hanaoka H, Kaneko Y, Kuwana M, and Takeuchi T. Early achievement of complete renal response predicts good long-term renal outcome and low systemic damage in newly diagnosed lupus nephritis class III and IV. Mod Rheumatol. 25(5):pp.714-8, 2015.
  12. Amano K, Matsubara T, Tanaka T, Inoue H, Iwahashi M, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, Karyekar CS, Takeuchi T, and Japan Abatacept Study Group. The long-term efficacy and safety of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Mod Rheumatol. 25(5):pp.665-71, 2015.
  13. Yang L, Fujimoto M, Murota H, Serada S, Fujimoto M, Honda H, Yamada K, Suzuki K, Nishikawa A, Hosono Y, Yoneda Y, Takehara K, Imura Y, Mimori T, Takeuchi T, Katayama I, and Naka T. Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud’s phenomenon. Rheumatology. 54(2):pp.349-358, 2015.
  14. Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, Lee SJ, and Nambu Y. Evaluation of the pharmacyetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 25(6):pp.817-24, 2015.
  15. Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y, Kondo H, Kasai Y, Miyazaki T, Morita R, Yoshimura A, and Takeuchi T. Number of circulating T follicular helper 2 cells correlates with IgG4 and IL-4 levels and plasmablast numbers in patients with IgG4-related disease. Arthritis Rheumatol. 67(9):pp.2476-81, 2015.
  16. Terao C, Ohmura K, Kochi Y, Ikari K, Okada Y, Shimizu M, Nishina N, Suzuki M, Myouzen M, Kawaguchi T, Takahashi M, Takasugi K, Murasawa A, Mizuki S, Iwahashi M, Funahashi K, Natsumeda M, Furu M, Hashimoto M, Ito H, Fujii T, Ezawa K, Matsubara T, Takeuchi T, Kubo M, Yamada R, Taniguchi A, Yamanaka H, Momohara S, Yamamoto K, Mimori T, and Matsuda F. Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. Arthritis Res Ther. 17:104, 2015.
  17. Takeshita M, Suzuki K, Kasai Y, Takiguchi M, Nakayama Y, OtomoY, Morita R, Miyazakai T, Yoshimura A, and Takeuchi T. Polarization diversity of human CD4+ stem cell memory T cells. Clin Immunol. 159(1):pp.107-17, 2015.
  18. Takeshita M, Suzuki K, Kikuchi J, Izumi K, Kurasawa T, Yoshimoto K, Amano K, and Takeuchi T. Infliximab and etanercept have distinct actions, but similar effects on cytokine profiles in rheumatoid arthritis. Cytokine. 75(2):pp.222-227, 2015.
  19. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, and Koike T. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 75(1):pp.75-83, 2015.
  20. Hanaoka H, Okazaki Y, Hashiguchi A, Yasuoka H, Takeuchi T, and Kuwana M. Overexpression of CXCR4 on Circulating B Cells in Patients with Active Systemic Lupus Erythematosus. Clin Exp Rheumatol. 33(6)pp.863-870, 2015.
  21. Weinblatt M, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Jilberstein M, Benerjee S, and Emery. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and inadequate response to methotrexate: Results from a phase IIb, randomized, double-blind, placebo/active controlled, dose-ranging multinational study. Arthritis Rheumatol. 67(10):pp.5291-600, 2015.
  22. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, and Koike T. Post marketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 26(4):pp.491-8, 2015.
  23. Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, and van der Heijde. Effect of Denosumab on Japanese Patients with Rheumatoid Arthritis: A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate to Validate Inhibitory Effect on Bone Erosion (DRIVE). Ann Rheum Dis. 75(6):pp.983-90, 2015.
  24. Izumi K, Kuda H, Ushikubo M, Kuwana M, Takeuchi T, and Oshima H. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD open. 27;1(1):e000162, 2015.
  25. Murota A, Suzuki K, Kasai Y, Miyazaki T, Morita R, Kondo Y, Takeshita M, Niki Y, Yoshimura A, and Takeuchi T. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. Cytokine. 78:pp.87-93, 2016.
  26. Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, and Koike T. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematousus including lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 26(1):pp.80-86, 2016.
  27. Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Cheng-Chung Wei J, Shao J, Togo O, and Mashimo H. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial. Mod Rheumatol. 26(1):pp.15-23, 2016.
  28. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, and van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 75(1):pp.3-15, 2016.
  29. Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, and Kaneko Y. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in moderate to severe rheumatoid arthritis patients in Japan: A 12-week, randomized, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 75(6):pp.1057-64, 2015.
  30. Izumi K, Kaneko K, Hashizume M, Yoshimoto K, and Takeuchi T. Baseline osteopontin levels predict the clinical effectiveness of tocilizumab, but not infliximab in biologic-naïve patients with rheumatoid arthritis: A single center prospective study at 1 year (The Keio-First Bio Cohort Study). PLoS One. 10(12): e0145468, 2015.
  31. Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, and Naka T. Leuicine-rich a2-glycoprotein as a potentiall biomarker for joint inflamemation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 67(8):pp.2056-60, 2015.
  32. Hayashi S, Suzuki K, Yoshimoto K, Takeshita M, Kurasawa T, Yamaoka K, and Takeuchi T. Early prognostic factors associated with the efficacy of infliximab treatment with for patients with rheumatoid arthritis with inadequate response to methotrexate. Rheumatol Ther. 2015.
  33. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, takeuchi T, Yamanaka H, Takahashi Y, Mimori T, Hiramatsu K, Komatsu S, and Tanaka Y. Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post-Hoc Analysis of Japanese Patients (MELODY Study). Rheumatol Ther. 3(1):pp129-141, 2015.
  34. Hanaoka H, Ota Y, Takeuchi T, Kuwana M. Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis. Clin Rheumatol. 35(2):pp.495-500, 2016.
  35. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, and Zwillich S. Tofacitinib, an oral JAK inhibitor, as monotherapy or background methotrexate in Japanese patients with rheumatoid arthritis: an open-label, long-tern extention study. Arthritis Res Ther. 18(1):pp.34, 2016.
  36. Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Hiramatsu K, and Takeuchi T. Discontinuation of adalimumab in patients with early rheumatoid arthritis who are initially treated methotrexate alone or in combination with adalimumab: 1 year outcome of the HOPEFUL-2 study. RMD ope., 2(1):e000186, 2016.
  37. Ogata A, Atsumi T, Fukuda T, Hirabayashi Y, Inaba M, Ishiguro N, Kai M, Kawabata D, Kida D, Kohsaka H, Matsumura R, Minota S, Mukai M, Sumida T, Takasugi K, Tamaki S, Takeuchi T, Ueda A, Yamamoto K, Yamanaka H, Yoshifuji H, Nomura A, and the MUSASHI investors. Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res. 67(10):pp.1354-62, 2015.
  38. Akiyama M, Kaneko Y, Yamaoka K, Kondo H, and Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int. 36(6):pp.881-9, 2016.
  39. Iwata S, Yamaoka K, Niiro H, Jabbarzadeh-Tabrizi S, Wang SP, Kondo M, Yoshikawa M, Akashi K, Tanaka Y. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. Lupus. 24(7):pp.695-704, 2015.
  40. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K. Discontinuation of adalimumab after achieving remission in patientswith established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 74(2):pp.389-95, 2015.
  41. Ishizaki J, Saito K, Nawata M, Mizuno Y, Tokunaga M, Sawamukai N, Tamura M, Hirata S, Yamaoka K, Hasegawa H, Tanaka Y. Low complements and high titer of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatology (Oxford). 54(3):pp.405-12, 2015.
  42. Hirata S, Li W, Defranoux N, Cavet G, Bolce R, Yamaoka K, Saito K, Tanaka Y. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Mod Rheumatol. 25(3):pp.344-9, 2015.
  43. Kondo M, Yamaoka K, Sonomoto K, Lin L, Nakano K, Tanaka Y. Contribution of the Interleukin-6/STAT-3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells. Arthritis Rheumatol. 67(5):pp.1250-60, 2015.
  44. Lin L, Yamagata K, Nakayamada S, Sawamukai N, Yamaoka K, Sakata K, Nakano K, Tanaka Y. Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. Biochem Biophys Res Commun. 463(3):pp.434-9, 2015 doi: 10.1016/j.bbrc.2015.05.094.
  45. Hirata S, Defranoux N, Hanami K, Yamaoka K, Saito K, Tanaka Y. Multi-biomarker disease activity score for monitoring rheumatoid arthritis. Review Current Biomarker Findings. 5:pp.69-78, 2015.
  46. Akiyama M, Kaneko Y, Yamaoka K, Hayashi Y, Yasuoka H, Suzuki K, Takeuchi T. Circulating T follicular helper 2 cell and plasmablast as biomarkers for detecting subclinical involvement of labial salivary glands by lip biopsy in IgG4-related disease. Clin Exp Rheumatol. 33(6):pp.949-50, 2015.
  47. Yazawa M, Nagashima H, Suzuki K, Kishi K. Rhinoplasty for Saddle Nose with Sarcoidosis. Surgical Science. pp.227-231, 2015.6.
  48. Akiyama M, Kaneko Y, Yamaoka K, Hayashi Y, Yasuoka H, Suzuki K, Takeuchi T. Subclinical labial salivary gland involvement in IgG4-related disease affected vital organs. Clin Exp Rheumatol. 33(6):pp.949-50, 2015.
  49. Namkoong H, Tasaka S, Akiyama M, Yagi K, Ishii M, Suzuki K, Kohno M, Hasegawa N, Takeuchi T, Betsuyaku T. Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. BMC Pulm Med. 23;15:126. D, 2015.
  50. Yasuoka H. Recent treatments of interstitiall lung disease with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med. 9(Suppl 1): pp.97-110, 2016.
  51. Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiyama H, Kohsaka H, Miyasaka N, Harigai M; for the PREVENT Study Group. Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study. J Rheumatol. 42(4):pp.614-22, 2015.
  52. Ito H, Kojima M, Nishida K, Matsushita I, Kojima T, Nakayama T, Endo H, Hirata S, Kaneko Y, Kawahito Y, Kishimoto M, Seto Y, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, Miyasaka N, Yamanaka H. Postoperative complications in patients with rheumatoid arthritis using a biological agent – a systematic review and meta-analysis-. Mod Rheumatol. 25(5):pp.672-8, 2015.
  53. Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, Takeuchi T. Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and a literature review. Intern Med. 54(9):pp.1131-4, 2015.
  54. Mitsunaga S, Hosomichi K, Okkudaira Y, Nakaoka H, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y, Oka A, Shiina T, Inoko H, Inoue I. Aggregation of rare/low frequency variants of the mitochondria respiratory chain-related proteins in rheumatoid arthritis patients. J Hum Genet. 60(8):pp.449-54, 2015.
  55. Hanaoka H, Kuwana M, Takeuchi T. Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes. Int J Rheum Dis. 18(7): pp768-75, 2015.
  56. Sasaki T, Nakamura W, Inokuma S, and Matsubara E. Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients. Clin Rheumatol. 35(2): pp.541-5, 2016.
2014年
  1. Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K, and Miyasaka M. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis. Mod Rheum. 24(1):pp.8-16, 2014.
  2. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and Tanaka Y. Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study. Ann Rheum Dis. 73(3):pp.536-543, 2014.
  3. Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, and Takeuchi T. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis. 73(5):pp.945-7, 2014.
  4. Kaneko Y, Hanaoka H, Hirakata M, Takeuchi T, and Kuwana M. Distinct arthropaties of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology. 53(6):pp.1120-24, 2014.
  5. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Drug free REmission/low disease activity after cessasion of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheum. 24(1):pp.17-25, 2014.
  6. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheum. 24(1):pp.26-32, 2014.
  7. Kaneko Y, Kuwana M, and Takeuchi T. Osteolytic change in distal interphalangeal joint and sacroiliac joints in subluxing arthropathy in anti-jo-1 antibody. Joint Bone & Spine. 80(5):pp.544-5, 2014.
  8. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yamaguchi H, and Yamanaka H. Characteristics related to good effectiveness and safety with tocilizumab: Post-marketing surveillance of 7901 rheumatoid arthritis patients in Japan. J Rheumatology. 41(1):pp.15-23, 2014.
  9. Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T, and kuwana M. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheum. 32(2):pp.211-7, 2014.
  10. Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, and Kameda H. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial. Mod Rheum. 24(4):pp.561-6, 2014.
  11. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheum. 24(5):pp.715-24, 2014.
  12. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheum. 24(4):pp.552-60, 2014.
  13. Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Mod Rheum. 24(5):pp.725-33, 2014.
  14. Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Mod Rheum. 24(5):pp.734-43, 2014.
  15. Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, and Takeuchi T. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheum. 24(5):pp.754-62, 2014.
  16. Yamanaka H, Ishiguro N, Takeuchi, T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, and Tanaka Y. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology. 53(5):pp.904-13, 2014.
  17. Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, Karyekar C, and Takeuchi T. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a phase II/III, randomized study. Mod Rheum. 24(6):pp.885-91, 2014.
  18. Mok CC, Yap DY, Navarra SV, Liu Z-H, Zao M-H, Lu L, Takeuchi T, Avihingsanon Y, Yu X-Q, Lapid EA, Lugue-Lizardo LR, Smethkul V, Shen N, Chen S-L, and Chan TM, for the Asian Lupus Nephritis Network. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology. 19(1):pp.11-20, 2014.
  19. Kaneko Y, Kuwana M, Kondo H, and Takeuchi T. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. J Rheumatology. 41(6):pp.1061-66, 2014.
  20. Takeuchi T, Matsubara T, Urata Y, Suematsu E, Ohta S, Honjyo S, Abe T, Yamamoto A, Miyasaka N, and the Japan Abatacept Study Group. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate conventional or biologic disease-modifying anti-rheumatic drugs. Mod Rheum. 24(5):pp.744-753, 2014.
  21. Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Namanaka H, and Miyasaka N. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective multi-center, observational study in Japan. Rheumatology. 54(4):pp.683-91, 2015.
  22. Inaba T, Hisatsune C, Sasaki Y, Sasaki Y, Ogawa Y, Ebisu E, Ogawa N, Matsui M, Takeuchi T, Mikoshiba K, and Tsubota T. Mice lacking inositol 1,4,5-triphospate receptors exhibit dry eye. Plos One. 9(6):e99205, 2014.
  23. Kaneko Y, Koike T, Oda H, Yamamoto K, Miyasaka N, Harigai M, Yamanaka H, Ishiguro N, Tanaka Y, and Takeuchi T. Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. Mod Rheum. 25(1):pp.43-9, 2015.
  24. Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, and Kuwana M. Elevated pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis. Arthritis & Rheumatology. 67(2):pp.498-507, 2015.
  25. Nishina N, Kaneko Y, Kameda H, and Takeuchi T. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: A retro-spective, single center study. Mod Rheum. 25(3):pp.401-4, 2015.
  26. Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, and Takeuchi T. Tocilizumab is clinically, functionally and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitrs. A single center retrospective cohort study (KEIO-TCZ study) at 52 week. Mod Rheum. 25(1):pp.31-37, 2015.
  27. Takeuchi T, Tanaka Y, Close D, Godwood A, Wu C-Y, and Saurigny D. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from phase IIa study. Mod Rheum. 25(1):pp.21-30, 2015.
  28. Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Mod Rheum. 25(1):pp.11-20, 2015.
  29. Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, and Takeuchi T. Peripheral blood CD4+CD25+CD127low regulatory T  cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: Increase in regulatory T cells correlates with clinical response. Arthritis Research & Therapy. 17(1):R10, 2015.
  30. Takeuchi T, Miyasaka N, Kawai S, Sugiyama N, Yuasa H, Yamashita N, Sugiyama N, Wagerle LC, Vlahos B, and Wajdula J. Pharmacokinetics, efficacy, safety profile of etanercept monotherap y in Japanese patients with rheumatoid arthritis: review of seven clinical trials. Mod Rheum. 25(2): pp.173-186, 2015.
  31. Takeuchi T, Miyasaka M, Inui T, Yano T, Yoshinari T, Abe T, and Koike T. Prediction of clinical response after one year of infliximab therapy in rheumatoid arthritis based on disease activity at three months into therapy to tailor infliximab dose: post-hoc analysis of the RISING study. J Rheumatology. 42(4):pp.599-607, 2015.
  32. Yang L, Fujimoto M, Murota H, Serada S, Fujimoto M, Honda H, Yamada K, Suzuki K, Nishikawa A, Hosono Y, Yoneda Y, Takehara K, Imura Y, Mimori T, Takeuchi T, Katayama I, and Naka T. Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud’s phenomenon. Rheumatology. 54(2):pp.349-58, 2015.
  33. Kaji K, Noreen F, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucus M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, and Kuwana M. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res. 66(4):pp.575-584, 2014.
  34. Saketkoo LA, Mittoo S, Frankel S, Lesage D, Sarver C, Phillips K, Strand V, Matteson EL, OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group, and Delphi Process Collaborators. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J. Rheumatol. 41(4):pp.792-798, 2014.
  35. Kaburaki J, and Kuwana M. How to detect early stage rheumatoid arthritis (RA) in persons undergoing Ningen Dock (health evaluation and promotion). Ningen Dock Int. 1(1):pp.24-33, 2014.
  36. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, Lesage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR and Dephi co-authors. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax. 69(5):pp.436-444, 2014.
  37. Shirai Y, Tamura Y, Yasuoka H, Satoh T, and Kuwana M. IgG4-related disease in pulmonary arterial hypertension on longterm epoprostenol treatment. Eur Respir J. 43(5):pp.1516-1519, 2014.
  38. Washio M, Fujii T, Kuwana M, Kawaguchi Y, Mimori A, Horiuchi T, Tada Y, Takahashi H, Mimori T, and Japan MCTD study group. Lifestyle and other related factors for the development of mixed connective tissue disease among Japanese females in comparison with systemic lupus erythematosus. Mod Rheumatol. 24(5):pp.788-792, 2014.
  39. Suzuki S, Yonekawa T, Kuwana M, Hayashi YK, Okazaki Y, Kawaguchi Y, Suzuki N, and Nishino I. Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopthies. J Neuroimmunol. 274(1-2):pp.202-208, 2014.
  40. Kuwana M. Dysregulated negative immune regulators in immune thrombocytopenia. ISBT Sci. Ser. 9:pp.217-222, 2014.
  41. Kuno T, Tamura Y, Kimura K, Ono T, Murata M, Kuwana M, Satoh T, and Fukuda K. Recurrent right atrial thrombosis due to Behçet’s disease. Can. J. Cardiol. 30(10):pp.1250.e1-3, 2014.
  42. Ito A, Nakamura Y, Saito K, Sho Y, Ishikawa K, Shimada H, Hatano Y, Okamoto O, Haranaka M, Ishii K, Nakamuro T, Kimoto K, Kuwana M, Hamaguchi Y, and Fujiwara S. Fatal case of clinically amyopathic dermatomyositis: cotton-wool spots as a sign of an aggressive subtype of dermatomyositis. J. Dermatol. 41(10):pp.943-944, 2014.
  43. Hanaoka H, Hashiguchi A, Konishi K, Ishii T, and Kuwana M. A rare association of Fabry’s disease and granulomatosis with polyangiitis: a potential pathogenic link. BMC Nephrol. 15(1):pp.157, 2014.
  44. Nishimoto T, Numajiri M, Nakazaki H, Okazaki Y, and Kuwana M. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia. Int. J. Hematol. 100(4):pp.341-344, 2014.
  45. Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, and Song YW. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis specific autoantibodies in dermatomyositis patients. Mod Rheumatol. 26(6):pp.945-948, 2014.
  46. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y. Analysis of various factors on the relapse of acute neurological attacks in Behcet’s disease. Mod Rheumatol. 24(6):pp.961-965, 2014.
  47. Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, and Yamanaka H. Cytokine profiles in polymyositis and dermatomyositis complicated with rapidly progressive or chronic interstitial lung disease. Rheumatology. 53(12):pp.2196-2203, 2014.
  48. Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, Suzuki T, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Ida H, Kakugawa T, Sakamoto N, Ishimatsu Y, Mukae H, Hamaguchi Y, Fujimoto M, Kuwana M, Origuchi T, Kohno S, and Kawakami A. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol. 25(1):pp.85-89, 2015.
  49. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behçet’s disease. J. Neurol. Sci. 349(1-2):pp.143-148, 2015.
  50. Salem D, Subang R, Okazaki Y, Laplante P, Levine JS, Kuwana M, and Rauch J. 2-glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantigens in multiple MHC class II haplotypes. J. Biol. Chem. 290(9):pp.5543-5555, 2015.
  51. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 73(12):pp.2192-8, 2014.
  52. Kubo S, Saito K, Hirata S, Fukuyo S, Yamaoka K, Sawamukai N, Nawata M, Iwata S, Mizuno Tanaka Y. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: A retrospective analysis of 6 months of abatacept treatment in routine practice. The ALTAIR study. Mod Rheumatol. 24(1):42-51, 2014.
  53. Fukuyo S, Saito K, Yamaoka K, Sawamukai N, Hirata S, Nawata M, Iwata S, Tanaka Y. Efficacy and safety of reducing duration of infliximab infusion. Mod Rheumatol. 24(2):275-80, 2014.
  54. Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol. 24(3):405-9, 2014.
  55. Yamaoka K, Tanaka Y. Targeting the JAKs in rheumatoid arthritis; focus on tofacitinib. Expert Opin Pharmacother. 15(1):103-13, 2014.
  56. Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: Relation to efficacy and infectious adverse events. Rheumatology (Oxford). 53(5):914-8, 2014.
  57. Fukuyo S, Yamaoka K, Sonomoto K, Tanaka Y. IL-6 accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3-dependent. Rheumatology (Oxford). 53(7):1282-90, 2014.
  58. Sonomoto K, Yamaoka K, Fukuyo S, Tanaka Y. The Role of Wnt5a/Ror2 signaling pathway in bone metabolism. Inflammation and Regeneration. 34:pp.103-108, 2014.
  59. Kubo S, Yamaoka K, Maeshima K, Tanaka Y. The possible mode of action of Tofacitinib, a JAK inhibitor. Inflammation and Regeneration. 34:pp.129-133, 2014.
  60. Sonomoto K, Yamaoka K, Tanaka Y. An approach to bone and cartilage repair of rheumatoid arthritis by mesenchymal stem cells. J UOEH. 36(2):pp.141-6, 2014
  61. Wang SP, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y. Tofacitinib a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 73(12):pp. 2213-5, 2014.
  62. Kondo M, Yamaoka K, Tanaka Y. Acquiring chondrocyte phenotype from human mesenchymal stem cells under inflammatory conditions. Int J Mol Sci. 15(11):pp.21270-85, 2014.
  63. Zhangmei, Yamaoka K, Sonomoto K, Kaneko H, Satake M, Yamamoto Y, Kondo M, Zhao J, Miyagawa I, Yamagata K, Fukuyo S, Okada Y, Tanaka Y. A novel delivering system of mesenchymal stem cells using Nano-fiber scaffold for treatment of rheumatic arthritis. PLoS One. 9(12):e114621. 2014.
  64. Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo K, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, HoshiD, Sato E, Yamanaka H. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumol. 24(3):pp.399-404, 2014.
  65. Kaneko Y, Takeuchi T. A paradigm shift in rheumatoid arthritis over the past decade. Internal Med. 53(17):pp.1895-903, 2014.
  66. Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, Takeuchi T. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol. 24(5):pp.754-762, 2014.
  67. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis. PLoS One. 9(2):pp.e87754, 2014.
  68. Hanaoka H,Hashiguchi A,Konishi K,Kuwana M,Takeuchi T. An unusual association between focal segmental sclerosis
and lupus nephritis:a distinct concept from lupus podocytopathy? CEN Case Reports. 4: pp.70-5, 2015.
2013年
  1. Takeuchi T, Harigaya M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Ohba T, Yoshinari T, Baker D, and the GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying anti-rheumatic drugs: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis. 72(9):pp.1488-95, 2013.
  2. Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, Yuasa H, and Vlahos B. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity and safety in Japanese subjects with rheumatoid arthritis. Mod Rheum. 23(4):pp.623-33, 2013.
  3. Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Hirata S, Mimori T, Matsumoto I, and Sumida T. Validation of different sets of criteria for the diagnosis of Sjogren’s syndrome in Japanese patients. Mod Rheum. 23(2):pp.219-225, 2013.
  4. Nakajima A, Saitoh K, Kojima T, Amano K, Yoshio T, Fukuda W, Inoue E, Taniguchi A, Momohara S, Minota S, Takeuchi T, Ishiguro N, Tanaka Y, and Yamanaka H. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Mod Rheum. 23(5):pp.945-52, 2013.
  5. Takeuchi T and Suzuki K. CD247 variants and single nucleotide polymorphisms observed in systemic lupus erythematosus patients. Rheumatology. 52(9):pp.1551-5, 2013.
  6. Nishina N, Kaneko Y, Kameda H, Kuwana M, and Takeuchi T. Reduction of plasma IL-6, but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clinical Rheum. 32(11):1661-6, 2013.
  7. Kaneko Y, Kondo H, Takeuchi T. American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol. 40(8):pp.1254-58, 2013.
  8. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Hirose T, Yoshinaga T, and Suzukawa M. Safety and effectiveness of 6 months etanercept monotherapy and combination therapy in Japanese patients with Rheumatoid Arthritis: Effect of concomitant disease-modifying anti-rheumatic drugs. J Rheumatology. 40(10):pp.1658-68, 2013.
  9. Kaneko Y, Kuwana M, Takeuchi T, and Oddis CV. Osteolytic change of distal interphalangeal joints and sacroiliac joints in subluxing arthropathy associated with anti-Jo-1 antibody.Joint Bone Spine. 80(5):pp.544-5, 2013.
  10. Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K, and Miyasaka M. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis. Mod Rheum. 24(1):pp.8-16, 2014.
  11. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and Tanaka Y. Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study. Ann Rheum Dis. 73(3):pp.536-543, 2014.
  12. Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, and Takeuchi T. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis. 73(5):pp.945-7, 2014.
  13. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Drug free REmission/low disease activity after cessasion of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheum. 24(1):pp.17-25, 2014.
  14. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheum. 24(1):pp.26-32, 2014.
  15. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yamaguchi H, and Yamanaka H. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatology. 41(1):pp.15-23, 2014.
  16. Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T, and Kuwana M. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheum. 32(2):pp.211-7, 2014.
  17. Yamanaka H, Ishiguro N, Takeuchi, T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, and Tanaka Y. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology. 53(5):pp.904-13, 2014.
  18. Mok CC, Yap DY, Navarra SV, Liu Z-H, Zao M-H, Lu L, Takeuchi T, Avihingsanon Y, Yu X-Q, Lapid EA, Lugue-Lizardo LR, Smethkul V, Shen N, Chen S-L, and Chan TM, for the Asian Lupus Nephritis Network. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology. 19(1):pp.11-20, 2014.
  19. Kaneko Y, Kuwana M, Kondo H, and Takeuchi T. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. J Rheumatology. 41(6):pp.1061-6, 2014.
  20. Azuma N, Nishioka A, Kuwana M, and Sano H. Relapsing polychodritis coexisting with immune thrombocytopenic purpura: an unusual association. Rheumatology. 52(4):pp.757-9, 2013.
  21. Hara S, Henmi T, Kawakami A, Fujikawa K, Mukae H, Ishimatsu Y, Sakamoto N, Kakugawa T, Kaji K, Fujimoto M, Kuwana M, Tsukada T, Satoh K, Motomura M, Tamai M, Nakamura H, Ida H, Hayashi T, Origuchi T, Eguchi K, and Kohno S. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatol Int. 33(4): pp.1059-64, 2013.
  22. Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M, Yamada H, Yamada R, Sato S, Takehara K, and Kuwana M. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 8(4): e60442, 2013.
  23. Suzuki S, Nishimoto T, Kohno M, Utsugisawa K, Nagane Y, Kuwana M, and Suzuki N. Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis. J. Neuroimmunol. 258(1-2):pp.61-6, 2013.
  24. Mitsunaga S, Hosomichi K, Okudaira Y, Nakaoka H, Kunii N, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y, Kashiwase K, Azuma F, Kulski JK, Inoue T, and Inoko H. Exome-sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2. J. Hum. Genet. 58(4):pp. 210-5, 2013.
  25. Sato S, Kuwana M, Fujita T, and Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod. Rheumatol. 23(3): pp.496-502, 2013.
  26. Masuda A, Yasuoka H, Satoh T, Okazaki Y, Yamaguchi Y, and Kuwana M. Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Res Ther. 15(4): R74, 2013.
  27. Chen Z, Cao M, Nieves Plana M, Liang J, Cai H, Kuwana M, and Sun L. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and meta-analysis. Arthritis Care Res. 65(8):pp.1316-24, 2013.
  28. Kuwana M, Watanabe H, Matsuoka N, and Sugiyama N. Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. BMJ Open. 3(8): e003113, 2013.
  29. Kawai M, Ogawa Y, Shimmura S, Oota S, Suzuki T, Kawamura N, Kuwana M, Kawakami Y, and Tsubota K. Expression and localization of aging markers in lacrimal gland of chronic graft-versus-host disease. Sci. Rep. 3: 2455, 2013.
  30. Satoh T, Miyazaki K, Shimohira A, Amano N, Okazaki Y, Nishimoto T, Akahoshi T, Munekata S, Kanoh Y, Ikeda Y, Higashihara M, Takahashi S, and Kuwana M. Fc receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia (letter). Blood. 122(11):pp.1991-2, 2013.
  31. Seta N, Okazaki Y, Miyazaki H, Kato T, and Kuwana M. Platelet-derived stromal cell-derived factor-1 is required for the transformation of circulating monocytes into multipotential cells. PLoS One. 8(9): e74246, 2013.
  32. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, and Takehara K. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. Mod. Rheumatol. 23(6):pp.1076-84, 2013.
  33. Shirai Y, Yasuoka H, Takeuchi T, Satoh T, and Kuwana M. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. Mod. Rheumatol. 23(6):pp.1211-20, 2013.
  34. Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J. Gastroenterol. 20(3):pp.714-23, 2014.
  35. Kuwana M, Okazaki Y, and Ikeda Y. Detection of circulating B cells producing anti-GPIb autoantibodies in patients with immune thrombocytopenia. PLoS One. 9(1): e86943, 2014.
  36. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, and Takehara K. Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. PLoS One. 9(2): e88150, 2014.
  37. Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, and Suzuki N. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur. J. Neurol. 21(2):pp.223-30, 2014.
  38. Kubo A, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, Dohi M, Tokuda H, Hashimoto S, Hattori N, Hanaoka M, Fukuda Y. Japanese Respiratory Society Committee for formulation of Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Invest. 51:pp.260-277, 2013.
  39. Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumatol. 24:pp.399-404, 2014.
  40. Aida-Yasuoka K, Peoples C, Yasuoka H, Hershberger P, Thiel K, Cauley JA, Medsger TA Jr, Feghali-Bostowick CA. Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis. Arthritis Res Ther.15:R10, 2013.
  41. Shirai Y, Tamura Y, Yasuoka H, Satoh T, Kuwana M. IgG4-related disease in pulmonary arterial hypertension on longterm epoprostenol treatment. Eur Respir J. 43(5):pp.1516-9, 2014.
  42. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis. PLOS one 9:e87754, 2014.
  43. Kurasawa T, Nagasawa H, Nishi E, Takei H, Okuyama A, Kondo T, Nishimura K, Sakai R, Shibata A, Chino K, Ogawa H, Ito T, Amano K, Kato H. Succeccful treatment of class Ⅳ+Ⅴ lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. Intern Med. 52(10):pp.1125-50(Epub 2013 May)
  44. Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii, T., Horita T, Saito, K., Okamoto A, Nishimoto N, Myouzen K, Kubo M, Hirakata M, Sumida T, Takasaki Y, Yamada R, Nakamura Y, Kamatani N, Yamamoto K. An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of *09:01 allele on disease phenotypes. Rheumatology (Oxford). 52(7):pp.1172-82, 2013.
  45. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M, Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K, Hisata S, Nukiwa T, Mimori T. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 14;9(1) :e85062, 2014.
2012年
  1. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and Tanaka Y. Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study. Ann Rheum Dis online January 11, 2013.
  2. Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H,Sano H,Tsubota K,Ogawa Y,Takamura E,Saito I,Inoue H,Nakamura S,Moriyama M,Takeuchi T,Tanaka Y, Hirata S, Mimori T, Matsumoto I, and Sumida T.Validation of different sets of criteria for the diagnosis of Sjogren’s syndrome in Japanese patients. Mod Rheum 23:pp.219-225, 2013.
  3. Takeuchi T and Suzuki K. CD247 variants single nucleotide polymorphisms observed in systemic lupus erythematosus. Rheumatology online March 22, 2013.
  4. Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjyo S, Abe T, Yamamoto A, Miyasaka N, and The Japan Abatacept Study Group. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with inadequate response to methotrexate. Mod Rheum 23:pp.226-235, 2013.
  5. Koike T, Harigaya M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, and Tanaka Y. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: post marketing surveillance report of the first 3,000 patients. Mod Rheum 22:pp.498-508, 2012.
  6. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, and Koike T. Inhibition of plasma IL-6 in addition to maintain efficacious trough level of infliximab was associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis, 71:pp.1583-85, 2012.
  7. Takeuchi T and Kameda H. What is the future of CCR5 antagonists? Arthritis Research and Therapy 14: R11, 2012.
  8. Takeuchi T, Suzuki K, Kondo T, Yoshimoto K, and Tsuzaka K. CD3  defects in systemic lupus erythematosus. Ann Rheum Dis 71:i78-i81, 2012.
  9. Harigai M, Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, and Miyasaka N. Discontiuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheum 22: pp.814-22, 2012.
  10. Nishi E, Kameda H, Ogawa H, Nagasawa H, Takei H, Okuyama A, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Sakai R, Ito T, Takeuchi T, and Amano K. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Mod Rheum 23:pp.97-103,2013
  11. Niki Y, Takeuchi T, Masanori Nakayama, Hayato Nagasawa, Takahiko Kurasawa, Harumoto Yamada, Toyama Y, and Takeshi Miyamoto. Clinical Significance of Cartilage Biomarkers for Monitoring Structural Joint Damage in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy. PLoS ONE 7:e37447, 2012.
  12. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Ito T, Kameda H, Takeuchi T, and Amano K. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports with literature review. Clin Rheum 31:pp.569-74, 2012.
  13. Takeuchi T, Harigaya M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Ohba T, Yoshinari T, Baker D, and the GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying anti-rheumatic drugs: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis online September 14, 2012.
  14. Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, Yuasa H, and Vlahos B. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity and safety in Japanese subjects with rheumatoid arthritis. Mod Rheum online September 26, 2012.
  15. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, and Takeuchi T, Japan Biological Agent Integrated Consortium (JBASIC).A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. Ann Rheum Dis 72:pp.310-2, 2012.
  16. Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momohara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, and Takeuchi T. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Mod Rheum, 22:pp.186-94, 2012.
  17. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, and Yamanaka H. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: Retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheum, 22:pp.327-338, 2012.
  18. Tanaka Y, Harigaya M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Ohba T, Yoshinari T, Baker D, and the GO-FORTH study group. Golimumab, a human anti-TNF- monoclonal antibody, injected subcutaneously every 4 weeks in Japanese patients with active rheumatoid arthritis in combination methotrexate: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-FORTH study through 24 weeks. Ann Rheum Dis, 71:pp.817-24, 2012.
  19. Kuwana M, and Okazaki Y. Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Ann Rheum Dis. 71(4): pp.617-620, 2012.
  20. Nishimoto T, Satoh T, Takeuchi T, Ikeda Y, and Kuwana M. Critical role of CD4+CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol. 40(4): pp.279-289, 2012.
  21. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, and Fujimoto M. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 71(5): pp.710-713, 2012.
  22. Mitsunaga S, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y, Narita A, Kashiwase K, Okudaira Y, Inoue T, Kulski JK, and Inoko H. Associations between six classical HLA loci and rheumatoid arthritis: a comprehensive analysis. Tissue Antigens. 80(1): pp.16-25, 2012.
  23. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y. Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 22(3): pp.405-413, 2012.
  24. Suzuki S, Hayashi Y, Kuwana M, Tsuburaya R, Suzuki N, and Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 69(6): pp.728-732, 2012.
  25. Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y, GB-0998 Study Group. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 22(3): pp.382-393, 2012.
  26. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S, Iwamoto N, Suzuki T, Nakashima Y, Tamai M, Arima K, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Ishimatsu Y, Mukae H, Kuwana M, Kohno S, Eguchi K, and Kawakami A. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with dermatomyositis. Rheumatology. 51(7): pp.1278-1284, 2012
  27. Nakajima A, Yoshino K, Soejima M, Kawaguchi Y, Satoh T, Kuwana M, and Yamanaka H. High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis. Rheumatol Int. 37(2): pp.2057-2061, 2012.
  28. Nishina N, Kaneko Y, Kuwana M, Hanaoka H, Kameda H, Mikami S, and Takeuchi T. IgG4-related disease without IgG4 over-expression: pathogenesis implications. Case Report Rheumatol. 2012: pp.754935, 2012.
  29. Sato S, Kuwana M, Fujita T, and Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 22(4): pp.625-629, 2012.
  30. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, Takagi K, Baba S, Okamoto Y, Ota Y, and Yamanaka H. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 51(9): pp.1563-1570, 2012.
  31. Satoh T, Tanaka Y, Okazaki Y, Kaburaki J, Ikeda Y, and Kuwana M. Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus. Rheumatology. 51(9): pp.1721-1728, 2012.
  32. Tamura Y, Ono T, Kuwana M, Inoue K, Takei M, Yamamoto T, Kawakami T, Fujita J, Kataoka M, Kimura K, Sano M, Daida H, Satoh T, and Fukuda K. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One. 7(9): pp.e45834, 2012.
  33. Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, and Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort. Rheumatology. 51(10): pp.1846-1854, 2012.
  34. Hanaoka H, Okazaki Y, Satoh T, Kaneko Y, Yasuoka H, Seta N, and Kuwana M. Circulating anti-double-stranded DNA antibody-secreting cells in patients with systemic lupus erythematosus: a novel biomarker for disease activity. Lupus. 21(12): pp.1284-1293, 2012.
  35. Cao H, Xia Q, Kang Y, Zhao X, Shi R, Lou J, Zhou M, Kuwana M, Ding X, and Zheng J. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-MDA5 antibody. Arthritis Care Res. 64(10): pp.1602-1610, 2012.
  36. Matsuura E, Ishiguro N, Katsumata Y, Urano W, Yamanaka H, Kondo M, Kuwana M, Kaji K, Hamaguchi Y, Fujimoto M, and Kawashima M. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-. Eur J Dermatol. 22(5): pp.668-671, 2012.
  37. Seta N, Okazaki Y, Izumi K, Miyazaki H, Kato T, and Kuwana M. Fibronectin binding is required for acquisition of mesenchymal/endothelial differentiation potential in human circulating monocytes. Clin Dev Immunol. 2012: pp.820827, 2012.
  38. Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, Ichida H, Katsumata Y, Hanaoka M, Ota Y, and Yamanaka H. Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 64(11): pp.3736-3740, 2012.
  39. Yasuoka H, and Kuwana M. Combined interstitial lung disease and pulmonary hypertension in systemic sclerosis: pathophysiology and management. CML-Pulmonary Hypertension. 3(4): pp.105-115, 2012.
  40. Horai Y, Isomoto E, Koga T, Okada A, Kawashiri S, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Kuwana M, and Kawakami A. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol. 23(1): pp.190-194, 2013.
  41. Yamaguchi Y, and Kuwana M. Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. Histol Histopathol. 28(2): pp.175-183, 2013.
  42. Terao C, Ohmura K, Kawaguchi Y, Nishimoto T, Kawasaki A, Takehara K, Furukawa H, Kochi Y, Ota Y, Ikari K, Sato S, Tohma S, Yamada R, Yamamoto K, Kubo M, Yamanaka H, Kuwana M, Tsuchiya N, Matsuda F, and Mimori T. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis Rheum. 65(2): pp.472-480, 2013.
  43. Nishimoto T, Satoh T, Simpson EK, Ni H, and Kuwana M. Predominant autoantibody response to GPIb/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia. J Thromb Haemost. 11(2): pp.369-372, 2013.
  44. Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momonara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, Takeuchi T. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Mod Rheumatol 2012;22:186-194.
  45. Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J-I, Itoyama S, Nagasawa H, Amano K, Kameda H, Takeuchi T, Mori S, Kizaki M. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 2012;53:616-623.
  46. Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, Dohi M, Koike T, Miyasaka N, Harigai M. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis – a report from the ad-hoc committee for safety of biological DAMRDs of the Japan College of Rheumatology. Mod Rheumatol 2013;23:297-303.
  47. Harigai M, Takamura A, Atsumi T, Dohi M, Hirata S, Kameda H, Nagasawa H, Seto Y, Koike T, Miyasaka N. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients – a report from the ad-hoc committee for safety of biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol 2013;23:284-296.
  48. Imura Y, Shirai Y, Nojima T, Nakashima R, Yamagata H, Miyachi K, Yoshifuji H, Kawabata D, Ohmura K, Usui T, Fujii T, Mimori T. NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Mod Rheumatol. 22(5):pp.685-94,2012
  49. Takei H, Nagasawa H, Sakai R, Nishimura K, Kurasawa T, Okuyama A, Nishi E, Shirai Y, Kondo T, Ogawa H, Ito T, Amano K. A case of multiple giant coronary aneurysms and abdominal aortic aneurysm coexisting with IgG4-related disease. Intern Med.51(8):pp.963-7,2012
  50. Nishimoto T, Kuwana M. CD4(+)CD25(+)Foxp3(+) Regulatory T Cells in the Pathophysiology of Immune Thrombocytopenia. Semin Hematol. 50 Suppl 1: pp.S43-9, 2013.
2011年
  1. Niki Y, Takeuchi T, Nakayama M, Nagasawa H, Kurasawa T, Yamada H, Toyama Y, and Miyamoto T. Clinical Significance of Cartilage Biomarkers for Monitoring Structural Joint Damage in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy. PLoS ONE 7:e37447, 2012
  2. Takeuchi T and Kameda H. What is the future of CCR5 antagonists? Arthritis Res Ther. 14: R11, 2012.
  3. Koike T, Harigaya M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, and Tanaka Y. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: post marketing surveillance report of the first 3,000 patients. Mod Rheum. on line Oct. 13, 2011.
  4. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Takai H, Hasegawa Y, Hatta K, Yamanaka H, Dohi M, Hashimoto S, Yamada H, Kawai S, Takeuchi T, Tateda K, and Goto H. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: Importance of pneumocyctis pneumonia in Japan revealed by a multicenter study. Intern Med. 50:pp.305-313, 2011.
  5. Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, and Miyasaka N. Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis patients with inadequate response to DMARDs - a multi-center, double blind, parallel-group trial. Mod Rheum. 21:pp.458-468, 2011.
  6. Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, Tsuzaka K, Ogawa Y, Tsubota K, Abe T, and Takeuchi T. Regulatory mechanism of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren’s syndrome. Arthritis Res Ther. 13:R170, 2011.
  7. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibfsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peya MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Moreno PS, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D, and the Treat to Target Taskforce. Treating Rheumatoid Arthritis to Target: multinational recommendatios assessment questionnaire. Ann Rheum Dis. on line Jul. 29, 2011.
  8. Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, and Miyasaka N. Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis patients with inadequate response to DMARDs – a multi-center, double blind, parallel-group trial. Mod Rheum. 21:pp.458-468, 2011.
  9. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Fruendlich B, and Suzukawa M. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with Rheumatoid Arthritis. Mod Rheum. 21:pp.343-351, 2011.
  10. Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med. 60:pp.75-81, 2011.
  11. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Satoh E, Saitao K, Kaneko Y, Fukuyo S, Kurasawa T,Hanami K, Kameda H, and Yamanaka H. Clinical, radiographic, and functional effectiveness of tocilizumab for rheumatoid arthritis patients -REACTION-52 weeks study. Rheumatology. 50:pp.1908-15, 2011.
  12. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, and Takeuchi T. Continuation of Methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with Rheumatoid Arthritis: 52-Week results from the JESMR Study. J Rheum. 38:pp.1585-92, 2011.
  13. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasana N, and Harigai M. Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors: a report from the registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety. J Rheum. on line Apr. 15, 2011.
  14. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, and Koike T. Significance of the baseline plasma TNF-alpha level in different doses of infliximab for patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.1208-15, 2011.
  15. Kaneko Y, Kuwana M, Kameda H, and Takeuchi T. Sensitivity and Specificity of 2010 Rheumatoid Arthritis Classification Criteria. Rheumatology. 50:pp.1268-74, 2011.
  16. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, and Takeuchi T. Decreased mRNA expression of two Foxp3 isoforms in peripheral blood mononuclear cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Immunopathol and Pharmacology. 24:pp.7-14, 2011.
  17. Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, and Yoshikawa H, and Nishimoto N. Humanized anti-interleukin 6 receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomakers, radiography, and BMI: data from the SAMURAI study. Mod Rheum. 21:pp.10-15, 2011.
  18. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, and Takeuchi T. Efficacy of tocilizumab for rheumatoid arthritis patients in daily practice in Japan –message from REACTION study. Mod Rheum. 21:pp.122-33, 2011.
  19. Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, and Takeuchi T. Fc gamma receptor IIIb polymorphism and usage of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.299-304, 2011.
  20. Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J-I, Itoyama S, Nagasawa H, Amano K, Kameda H, Takeuchi T, Mori S, Kizaki M. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 53:pp.616-623, 2012.
  21. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Ito T, Kameda H, Takeuchi T, Amano K. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 31:pp.569-574, 2012.
  22. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, and Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 158(4): pp.675-677, 2011.
  23. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Kodera M, Suga N, Higashi A, Ogusu K, Tsutusi K, Furusaki A, Tanabe H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, and Fujimoto M. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multi-centre, cross-sectional study. Arch Dermatol. 147(4): pp.391-398, 2011.
  24. Hoshino K, Satoh T, Kawaguchi Y, and Kuwana M. Association of Hepatocyte Growth Factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. Arthritis Rheum. 63(8): pp.2465-2472, 2011.
  25. Suzuki S, Utsugisawa K, Iwasa K, Satoh T, Nagane Y, Yoshikawa H, Kuwana M, and Suzuki N. Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis. J Neuroimmunol. 237(1-2): pp.87-92, 2011.
  26. Takahashi H, Kouno M, Nagao K, Wada N, Hata T, Nishimoto S, Iwakura Y, Yoshimura A, Yamada T, Kuwana M, Fujii H, Koyasu S, and Amagai M. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest. 121(9): pp.3677-3688, 2011.
  27. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, and Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 38(10): pp.973-979, 2011.
  28. Furuya Y, and Kuwana M. Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol. 38(10): pp.2186-2192, 2011.
  29. Noda S, Asano Y, Tamaki Z, Hirabayashi M, Yamamoto M, Takekoshi T, Hoashi T, Sugaya M, Morimoto R, Eto T, Kaji K, Fujimoto M, Kuwana M, and Sato S. Dermatomyositis with anti-OJ antibody. Rheumatol Int. 31(12): pp.1673-1675, 2011.
  30. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Muro Y, Ogawa F, Tanaka S, Takehara K, and Sato S. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicenter prospective observational study. Rheumatology. 51(1): pp.129-133, 2012.
  31. Seta N, and Kuwana M. Potential involvement of human circulating CD14+ monocytes in tissue repair and regeneration. Inflam Regen. 32(1): pp.1-7, 2012.
  32. Hattori H, Suzuki S, Okazaki Y, Suzuki N, and Kuwana M. Intracranial transplantation of monocyte-derived multipotential cells enhances recovery after ischemic stroke in rats. J Neurosci Res. 90(2): pp.479-488, 2012.
  33. Harigai M, Tanaka Y, Maisawa S, and The JA21963 Study Group. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study. J Rheumatol. 39(3): pp.486-495, 2012.
  34. Yamaguchi Y, Yasuoka H, Stolz DB, Feghali-Bostwick CA. Decreased caveolin-1 levels contribute to fibrois and deposition of extracellular IGFBP-5. J Cell Mol Med. 15:pp.957-969, 2011.
  35. Imura Y, Shirai Y, Nojima T, Nakashima R, Yamagata H, Miyachi K, Yoshifuji H, Kawabata D, Ohmura K, Usui T, Fujii T, Mimori T. NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Mod Rheumatol. 2012. [Epub ahead of print]
  36. Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, Ishii T, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saitio K, Kamachi M, Yamamoto K, et al. A Genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus erythematosus in Japanese. PloS Genetics 8(1):pp.1-10, 2012.
2010年
  1. Ogawa H, Kameda H, Amano K, and Takeuchi, T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 19:pp.162-169, 2010.
  2. Suzuki K, Tamaru J, Okuyama A, Kameda H, Amano K, Nagasawa H, Nishi, E, Yoshimoto K, Setoyama Y, Kaneko K, Osada H, Honda N, Sasaki Y, Itoyama S, Tsuzaka K, and Takeuchi T. IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation. Rheumatology. 49: pp.1789-1791, 2010.
  3. Suzuki K, Kameda H, Amano K, Nagasawa H, Takeii H, Nishi E, Okuyama A, Tsuzaka K, and Takeuchi T. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatology Int. on line, 2010 Feb 18.
  4. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Normalization of physical function by infliximab in RA patients: Factors associated with normal physical function. Clin Exp Rheum. 28:pp.365-372, 2010.
  5. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, and Koike T. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 69:pp.1286-1291, 2010.
  6. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Modern Rheum. 20:pp.337-342, 2010.
  7. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T; Japan Biological Agent Study Integrated Consortium (JBASIC). Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: A randomized trial. Mod Rheumatol 20: pp.531-538, 2010.
  8. Tsuzaka K, Itami Y, Takeuchi T, Shinozaki N, and Morishita T. ADAMTS5 is a biomarker for prediction of the response to Infliximab in patients with rheumatoid arthritis. J Rheum. 37:pp.1454-1460, 2010.
  9. Takeuchi T and Kameda H. The Japanese experiences with biologic therapies for Rheumatoid Arthritis. Nature Rev Rheum. 6:pp.644-652, 2010.
  10. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 21: pp.122-133, 2011.
  11. Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, and Takeuchi T. Fc gamma receptor IIIb polymorphism and usage of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.299-304, 2011.
  12. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, and Koike T. Baseline tumor necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.1208-1215, 2011.
  13. Yoshimoto K, Setoyama Y, Tsuzaka K, Abe T, and Takeuchi T. Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus. J Biomed Biotechnol. 2010;pii: 509021. Epub 2010 Sep 6.
  14. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, and Takeuchi T. Continuation of Methotrexate resulted in better clinical and radiographic outcomes than its discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. In press.
  15. Kaneko Y, Kuwana M, Kameda H, and Takeuchi T. Sensitivity and Specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology. In press.
  16. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasana N, and , Harigai M. Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors: a report from the registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety. J Rheumatol. In press.
  17. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, and Takeuchi T. Decreased mRNA expression of two Foxp3 isoforms in peripheral blood mononuclear cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Immunopathol and Pharmacology. 24:pp.7-14, 2011.
  18. Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, and Nishimoto N. Humanized anti-interleukin 6 receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomakers, radiography, and BMI: data from the SAMURAI study. Modern Rheum. 21:pp.10-15, 2011.
  19. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Satoh E, Saitao K, Kaneko Y, Fukuyo S, Kurasawa T,Hanami K, Kameda H, and Yamanaka H. Clinical, radiographic, and functional effectiveness of tocilizumab for rheumatoid arthritis patients -REACTION 52-week study. Rheumatology. In press.
  20. Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med. In press.
  21. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Taki H, Hasegawa Y, Hatta K, Yamanaka H, Dohi M, Hashimoto S, Yamada H, Kawai S, Takeuchi T, Tateda K, Goto H. Clinical and radiological features of acute-onset interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: Importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med. 50:pp.305-313, 2011.
  22. Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, Kuwana M, and Fukuda Y. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 49: pp.361-369, 2010.
  23. Kuwana M. Sensorineural hearing loss as a common manifestation in patients with mixed connective tissue disease. Int J Clin Rheumatol. 5: pp.165-167, 2010.
  24. Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, Ikezawa Z, and Kuwana M. Natural killer cells control a T helper 1 response in patients with Behçet’s disease. Arthritis Res Ther. 12: pp.R80, 2010.
  25. Seta N and Kuwana M. Derivation of multipotent progenitors from human circulating CD14+ monocytes. Exp Hematol. 38: pp.557-563, 2010.
  26. Furuya Y, Satoh T, and Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol. 2010: pp.720305, 2010.
  27. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, Tochimoto A, Baba S, Okamoto Y, Ota Y, and Yamanaka H. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 49: pp.1713-1719, 2010.
  28. Sato S, and Kuwana M. Clinically amyopathic dermatomyositis. Curr Opinion Rheumatol. 22: pp.639-643, 2010.
  29. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, and Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis: potential association with efficacy for interstitial lung disease. Rheumatology. 49: pp.2375-2380, 2010.
  30. Yamaguchi Y, Okazaki Y, Seta N, Satoh T, Takahashi K, Ikezawa Z, and Kuwana M. Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res Ther. 12: p.R205, 2010.
  31. Suzuki S, Utsugisawa K, Nagae Y, Satoh T, Kuwana M, and Suzuki N. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol. 230: pp.148-152, 2011.
  32. Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, Hara M, and Yamanaka H. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 21: pp.223-227, 2011.
  33. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, and Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 93: pp.329-335, 2011.
  34. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, and Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 158: pp.675-677, 2011.
  35. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Kodera M, Suga M, Higashi A, Ogusu K, Tsutusi K, Furusaki A, Tanabe H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, and Fujimoto M. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multi-centre, cross-sectional study. Arch Dermatol. 147: pp.391-398, 2011.
  36. Noda S, Asano Y, Tamaki Z, Hirabayashi M, Yamamoto M, Takekoshi T, Hoashi T, Sugaya M, Morimoto R, Eto T, Kaji K, Fujimoto M, Kuwana M, and Sato S. Dermatomyositis with anti-OJ antibody. Rheumatol Int. In press.
  37. Hara S, Henmi T, Kawakami A, Fujikawa K, Mukae H, Ishimatsu Y, Sakamoto N, Kakugawa T, Kaji K, Fujimoto M, Kuwana M, Tsukada T, Satoh K, Motomura M, Tamai M, Nakamura H, Ida H, Hayashi T, Origuchi T, Eguchi K, and Kohno S. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatol Int. In press.
  38. Yamaguchi Y, Yasuoka H, Stolz DB, Feghali-Bostwick CA. Decreased caveolin-1 levels contribute to fibrois and deposition of extracellular IGFBP-5. J Cell Mol Med. In press.
2009年
  1. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, and Kishimoto T. Study of Active controlled Tocilizumab monotherapy for Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate (SATORI):significantly reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheum 19:12-19, 2009.
  2. Suzuki K, Nagasawa H, Kameda H, Amano K, Kondo T, Itoyama S, Tanaka Y, Takeuchi T. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology 48:198-199, 2009.
  3. Suzuki K, Kameda H, Amano K, Nagasawa H, Sekiguchi H, Nishi E, Ogawa H, Tsuzaka K, and Takeuchi T. Single Center Prospective Study for Efficacy and Safety of Tacrolimus in Rheumatoid Arthritis. Rheumatology Int 29:431-6, 2009.
  4. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. Mod Rheum 19: 166-172, 2009.
  5. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Tanaka Y, Takeuchi T, and Miyasaka N. Pneumocystis pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis & Rheum 61:305-12, 2009.
  6. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, and Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin(IL)-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68: 1580-84, 2009.
  7. Sawada T, Inokuma S, Sato T, Ohtsuka T, Saeki Y, Takeuchi T, Matsuda T, Takemura T, and Sagawa A. Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 48:1069-72, 2009.
  8. Takeuchi T, Miyasaka N, Inoue K, Abe T, and Koike T. The Impact on Radiographic and Clinical Response of Infliximab Therapy Concomitant with Methotrexate in Patients with Rheumatoid Arthritis by the Trough Serum Level in the Dose Escalating Study: the RISING Study. Mod Rheumatology 19:478-87, 2009.
  9. Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T , Yoshikawa H, and Nishimoto N. A combination of biochemical markers of cartilages and markers of cartilage and bone turnover, radiographic image and body mass index to predict progression of joint destruction in patients with rheumatoid Arthritis treated with Disease modifying Anti-Rheumatic Drugs. Mod Rheum 19: 273-282, 2009.
  10. Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, Nagasawa H, Suzuki K, Matsubara K, and Takeuchi T. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Research Comm 387: 261-265, 2009.
  11. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, and Suzukawa M. Post-marketing surveillance of the safety and efficacy of etanercept in Japan. J Rheum 36:898-906, 2009.
  12. Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Ohtsuka T, Saeki Y, Takeuchi T, and Sawada T. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rhematology 48:1265-8, 2009.
  13. Ogawa H, Kameda H, Amano K, and Takeuchi, T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 19:162-169, 2010.
  14. Suzuki K, Tamaru J, Okuyama A, Kameda H, Amano K, Nagasawa H, Nishi, E, Yoshimoto K, Setoyama Y, Kaneko K, Osada H,Honda N, Yasaki Y, Itoyama S, Tsuzaka K, and Takeuchi T. IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialo-adenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation. Rheumatology, in press.
  15. Suzuki K, Kameda H, Amano K, Nagasawa H, Takeii H, Nishi E, Okuyama A, Tsuzaka K, and Takeuchi T. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatolog 29:431-436, 2009.
  16. Kameda H, Amano K, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Suzuki K,Takeuchi T. Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. Intern Med. 48(22): 1931-8, 2009.
  17. Tsuzaka K, Itami Y, Takeuchi T, Shinozaki N, Morishita T. ADAMTS5 is a biomarker for prediction of the response to Infliximab in patients with rheumatoid arthritis. J Rheumatol 37:1454-1560, 2010.
  18. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Normalization of physical function by infliximab in RA patients: Factors associated with normal physical function. Clin Exp Rheum 28:365-72, 2010.
  19. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, and Koike T. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by remicade in RA) study. Ann Rheum Dis 69:1286-91, 2010.
  20. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Mod Rheum, in press.
  21. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T, and Japan Biological Agent Integrated Consortium (J-BASIC). The comparison of efficacy and safety between continuation and discontinuation of methotrexate (MTX) at the commencement of etanercept in patients with active rheumatoid arthritis despite MTX therapy: 24-week results from the JESMR study. Modern Rheumatology, in press.
  22. Yamanaka H, Tanaka Y, Hoshi D, Inoue E, Saito K, Amano K, Kameda H, and Takeuchi T. Efficacy of tocilizumab for rheumatoid arthritis patients in daily practice in Japan –message from REACTION study, in press.
  23. Keiko Yoshimoto, Yumiko Setoyama, Kensei Tsuzaka, Tohru Abe, Tsutomu Takeuchi: Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T Cells of patients with systemic lupus erythematosus.Journal of Biomedicine and Biotechnology (submitted)
  24. Satoh T, Pandey JP, Okazaki Y, Asahi A, Kawakami Y, Ikeda Y, and Kuwana M. Single nucleotide polymorphism of interleukin-1β associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens. 73(4): 353-357, 2009.
  25. Takada T, Hirakata M, Suwa A, Kaneko Y, Kuwana M, Ishihara T, Ikeda Y. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod. Rheumatol. 19(2): 156-164, 2009.
  26. Kawaguchi Y, Nakamura Y, Matsumoto I, Nishimaki E, Satoh T, Kuwana M, Sumida T, and Hara M. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann. Rheum. Dis. 68(5): 710-714, 2009.
  27. Nagata E, Hattori H, Kato M, Ogasawara S, Suzuki S, Shibata M, Shimizu T, Hamada J, Osada T, Takaoka R, Kuwana M, Tsunoda T, Aiso S, Takizawa S, Suzuki N, and Takagi S. Identification of biomarkers associated with migraine with aura. Neurosci. Res. 64(1): 104-110, 2009.
  28. Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, Aramaki T, Ichinose K, Tamai M, Kamachi M, Nakamura H, Ida H, Origuchi T, Ishimoto H, Mukae H, Kuwana M, Kohno S, Takehara K, Sato S, and Eguchi K. Association of distinctive clinical subsets with myositis-specific autoantibodies toward anti-155/140kD polypeptides, anti-140kD polypeptides, and anti-aminoacyl tRNA synthetases in patients with dermatomyositis of Japanese population: a single-center, cross-sectional study. Scand. J. Rheumatol. 38(4): 263-267, 2009.
  29. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, and Crowther M. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 94(6): 850-856, 2009.
  30. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, and Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60(7): 2193-2200, 2009.
  31. Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucus M, Medsger TA Jr, and Feghali-Bostwick CA. Anti-U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 61(7): 958-965, 2009.
  32. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, and Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb. Haemost. 102(2): 371-378, 2009.
  33. Yoshida H, Ishida H, Yoshihara T, Oyamada T, Kuwana M, Imamura T, and Morimoto A. Complication of Evans’ syndrome in an infant with hereditary spherocytosis: a case report. J. Hematol. Oncol. 2: 40, 2009.
  34. Kuwana M, Okazaki Y, and Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod. Rheumatol. 19(5): 530-535, 2009.
  35. Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, Kuwana M, and Suzuki N. Autoimmune targets to heart and skeletal muscles in myasthenia gravis. Arch. Neurol. 66(11): 1334-1338, 2009.
  36. Kawaguchi Y, Ota Y, Kawamoto M, Ito I, Tsuchiya N, Sugiura T, Katsumata Y, Soejima M, Sato S, Hasegawa M, Fujimoto M, Takehara K, Kuwana M, Yamanaka H, and Hara M. Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. Ann. Rheum. Dis. 2009; 68(12): 1921-1924.
  37. Seta N, Kobayashi S, Hashimoto H, and Kuwana M. Characterization of autoreactive T-cell clones to myeloperoxidase in patients with microscopic polyangiitis and healthy individuals. Clin. Exp. Rheumatol. 27(5): 826-829, 2009.
  38. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, and Kuwana M. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology. 48(12): 1570-1574, 2009.
  39. Kaneko Y, Suwa A, Hirakata M, Ikeda Y, and Kuwana M. Clinical associations with autoantibody reactivities to individual components of U1 small nuclear ribonucleoprotein. Lupus. 19(3): 307-312, 2010.
  40. Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, Kuwana M, and, Fukuda Y. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern. Med. 49(5): 361-369, 2010.
  41. Kuwana M. Sensorineural hearing loss as a common manifestation in patients with mixed connective tissue disease. Int. J. Clin. Rheumatol. 5(2): 165-167, 2010.
  42. Suwa A, Hirakata M, Kaneko Y, Sato S, Suzuki Y, Kuwana M. Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: case report. Clin Rheumatol. 28(2):227-229, 2009.
  43. Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, Ikezawa Z, and Kuwana M. Natural killer cells control a T helper 1 response in patients with Behçet’s disease. Arthritis Res. Ther. In press.
  44. Seta N and Kuwana M. Derivation of multipotent progenitors from human circulating CD14+ monocytes. Exp. Hematol. In press.
  45. Kuwana M, Okazaki Y, and Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J. Thromb. Haemost. 7(2): 322-329, 2009.
  46. Hironari Hanaoka, Yuka Okazaki, Takashi Satoh, Yuko Kaneko, Hidekata Yasuoka, Noriyuki Seta and Masataka Kuwana.Emergence of anti-double strand DNA (dsDNA) antibody-secreting cells into peripheral blood predicts disease flare in patients with systemic lupus erythematosus(SLE). Arthritis Rheum, 60:S340, 2009.
  47. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, and Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis: potential association with efficacy for interstitial lung disease. Rheumatology. In revision.
  48. Tokuhira M, Hanzawa K, Watanabe R, Sekiguchi Y, Nemoto T, Toyozumi Y, Tamaru-J-I, Itiyama S, Suzuki K, Kameda H, Mori S, Kizaki M. Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis. J Hematol Oncol 2:27,2009.
  49. Yamaguchi Y, Okazaki Y, Seta N, Satoh T, Takahashi K, Ikezawa Z, and Kuwana M. Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. J. Invest. Dermatol. Submitted for publication.
  50. Sato H, Yanagimachi E, Arai H, Okazaki Y, and Kuwana M. Mycobacterium avium infection of the lung complicated by chronic immune thrombocytopenic purpura. Chest. Submitted for publication.
  51. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am J Respir Cell Mol Biol, 41:179-88, 2009.
  52. Yasuoka H, Hsu E, Ruiz X, Steinman RA, Choi AMK, Feghali-Bostwick CA. The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and Egr-1-dependent and –independent mechanisms. Am J Pathol, 175:605-15. 2009.
  53. Veraldi KL, Gibson BT, Yasuoka H, Myerburg MM, Kelly EA, Balzar S, Jarjour NN, Pilewski JM, Wenzel SE, Feghali-Bostwick CA. Role of Insulin-like Growth Factor Binding Protein-3 in Allergic Airway Remodeling. Am J Respir Crit Care Med. 180:611-7, 2009.